EP0776218A2 - Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil - Google Patents

Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil

Info

Publication number
EP0776218A2
EP0776218A2 EP95916103A EP95916103A EP0776218A2 EP 0776218 A2 EP0776218 A2 EP 0776218A2 EP 95916103 A EP95916103 A EP 95916103A EP 95916103 A EP95916103 A EP 95916103A EP 0776218 A2 EP0776218 A2 EP 0776218A2
Authority
EP
European Patent Office
Prior art keywords
fgf
conjugate
dna
protein
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95916103A
Other languages
German (de)
English (en)
Inventor
Barbara A. Sosnowski
J.Andrew Baird
L.L. Houston
Michael P. Nova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selective Genetics Inc
Original Assignee
Selective Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selective Genetics Inc filed Critical Selective Genetics Inc
Priority to EP01125266A priority Critical patent/EP1188448A3/fr
Publication of EP0776218A2 publication Critical patent/EP0776218A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates generally to the treatment of diseases, and more specifically, to the preparation and use of heparin-binding growth factor conjugates to alter the function, gene expression, or viability of a cell in a therapeutic manner.
  • Glaucoma which is the leading cause of blindness in the United States, is a group of diseases characterized by progressive atrophy of the optic nerve head leading to visual field loss, and, ultimately, blindness. Glaucoma is generally associated with elevated intraocular pressure, which is an important risk factor for visual field loss because it causes further damage to optic nerve fibers.
  • Glaucoma There are several types of glaucoma, including open and closed angle glaucoma. The most prevalent type is primary open angle glaucoma in which the aqueous humor has free access to the irridocorneal angle, but aqueous humor drainage is impaired. In contrast, in closed angle glaucoma, the irridocorneal angle is closed by the peripheral iris. The angle block can usually be corrected by surgery.
  • glaucoma Less prevalent types of glaucoma include secondary glaucomas related to inflammation, trauma and hemorrhage.
  • the aqueous humor keeps the eyeball inflated, supplies the nutritional needs of the vascular lens and cornea and washes away metabolites and toxic substances within the eye.
  • Aqueous humor enters posterior chamber by three means: (1) active secretion by nonpigmented epithelial cells of the ciliary process; (2) ultrafiltration of blood plasma; and (3) diffusion.
  • Newly formed aqueous humor flows from the posterial chamber around the lens and through the pupil into the anterior chamber; aqueous humor leaves the eye by passive bulk flow at the irridocorneal angle and uveoscleral outflow.
  • Intraocular pressure is a function of the difference between the rate at which aqueous humor enters and leaves eye.
  • glaucoma filtering operations particularly trabeculectomy. These operations involve creation of a fistula between the subconjunctival space and the anterior chamber. In order for the surgery to be effective, the fistula must remain substantially unobstructed. However, these drainage or filtering procedures often fail by virtue of their closure of the passageway resulting from the healing of the very wound created for gaining access to the surgical site.
  • One technique for corneal reshaping involves the use of a pulsed laser photoablation apparatus to ablate very thin layers of corneal tissue with greater precision than can typically be achieved with mechanical means (see, Trokel et al., Am. J. Ophthalmol. 96:710-715, 1983).
  • laser corneal reprofiling operations also referred to as photorefractive keratectomy ("PRK”) or laser refractive keratoplasties (LRK)
  • PRK photorefractive keratectomy
  • LRK laser refractive keratoplasties
  • Ptergyii are triangular fibrovascular growths on the surface of the eye that originate in the bulbar conjunctiva. They grow progressively over the cornea reducing vision by causing irregular astigmatism. In more severe stages, they grow across the visual axis causing blindness.
  • Ultraviolet radiation exposure of mammalian eyes has been associated with the growth of the eye disease pterygia and the promotion of the conversion of pinguecula to pterygia (American Academy of Ophthalmology, Basic and Clinical Science Course, Cornea Section 4, Retina Vitress 1987-1988 Edition, pp. 72-73). Pterygii are often treated by surgical removal, but they are difficult to manage because of a 40%-50% recurrence rate.
  • Recurrence is presently treated by radiation, mitomycin C drops and conjunctival autografting. Because radiation and mitomycin can cause scleral melting and loss of the eye, and autografting is expensive, delicate and often ineffective, there is a need to develop alternative treatments to prevent recurrence of pterygii. In order to prevent recurrence of pterygii, to ensure the success of glaucoma filtering surgeries and to prevent corneal hazing following excimer laser surgeries of the eye, there is, thus, a need to develop methods and compositions for safe and effective treatments.
  • HGPRT hypoxanthine-guanine phosphoribosyl transferase
  • cystic fibrosis and Duchenne muscular dystrophy for which the respective defective genes have recently been identified
  • Tay sachs disease and hemoglobin disorders, such as ⁇ -thalassemia.
  • genetic therapy has been proposed as a means to deliver therapeutic products, such as tumor necrosis factor (TNF) for the treatment of cancers and CD4 receptor protein for the treatment of AIDS (see, e.g., PCT International Application No. WO 90/01870).
  • TNF tumor necrosis factor
  • CD4 receptor protein for the treatment of AIDS
  • Genetic therapy involves introducing DNA into at least some cells of a host organism in a manner such that the products encoded by the DNA are expressed in the host.
  • the DNA may be integrated into the genome of the host cells or it may be maintained and replicated as part of an episomal element.
  • the DNA may encode products that replace or supplement the product of a defective or absent gene, a gene expressed at low levels, or therapeutic products that are effective for treating a disease.
  • the DNA is typically operatively linked to a promoter and other transcriptional and translational regulatory elements that are recognized by host cell effector molecules, such as RNA polymerase II so that it can be expressed in the host cell.
  • the DNA may also mediate or encode RNA or protein products that mediate expression of a host cell gene or biochemical process. Expression of the DNA can thereby be fine-tuned to the needs of the afflicted host.
  • Genetic therapy is presently effected by removing selected target cells, from an afflicted individual, introducing DNA that encodes a therapeutically effective product into the cells and returning the modified cells to the individual.
  • recombinant viral vectors which are derived from viruses that infect eukaryotic cells, provide the most promising means for introducing DNA into cells.
  • a virus upon infection of a eukaryotic host, a virus commandeers the transcriptional and translational machinery of the host cell.
  • viral regulatory signals such as promoters, particularly those recognized early in infection, tend to be highly efficient so that any DNA that is in operative linkage with such promoters and regulatory signals is efficiently expressed at high levels.
  • Eukaryotic viruses have, therefore, been used as vectors for cloning and expression of DNA in eukaryotic cells.
  • Heparin-binding growth factors In ocular disorders and in gene therapy, specificity of delivery of a cytotoxic agent or nucleic acid will enhance the effectiveness of the therapy by minimizing damage to normal cells or inappropriate and undesirable expression of products in nontarget cells.
  • Growth factors such as FGF, which specifically bind to receptors on target cells, have been conjugated directly to saporin-6 to produce the mitotoxin FGF-SAP (see, e.g., U.S. Patent No. 5,191,067 to Lappi et al.; and Lappi et al., Biochem. and Biophys. Res. Comm. 160:917-923, 1989).
  • cytotoxic conjugates for treatment of ocular disorders
  • the relatively low ratio of therapeutic to toxic dosage is the relatively low ratio of therapeutic to toxic dosage.
  • a receptor such as the FGF receptor
  • the conjugate Upon binding to a receptor, such as the FGF receptor, it is believed that the conjugate is internalized via a pathway that directs a portion of the conjugate to the endosome, where, if cleaved, the targeted agent can be released into the cytoplasm.
  • the conjugate is then trafficked to the lysosome, where it is degraded.
  • conjugates so that, upon, internalization, a larger percentage of internalized conjugate is directed to the endosome or is cleaved in the endosome, whereby the effect of the linked agent may be realized. Since the cleavage is generally necessary for the linked agent to exert its effects, it would be desirable to increase the percentage of internalized conjugates that are cleaved upon internalization. It would also be desirable to render the conjugate more selective for the targeted cells, so that more of the conjugate or cleaved targeted agent reaches the cytoplasm of targeted cells, such as tumor cells, than the cytoplasm of non-targeted cells, so that lower concentrations may be administered.
  • the present invention exploits the use of heparin-binding growth factor conjugates which have increased specificity and deliver higher amounts of agents, such as cytotoxins and nucleic acids to targeted cells, while providing other related advantages.
  • conjugates and compositions containing preparations of conjugates contain a polypeptide that is reactive with an FGF receptor (also referred to herein as an FGF protein), such as bFGF, linked to a targeted agent.
  • FGF receptor also referred to herein as an FGF protein
  • the compositions are substantially monogenous.
  • Conjugates and preparations of conjugates with enhanced specificity and/or activity are also provided. The specificity, activity, and/or intracellular availability of conjugates of FGF and a targeted agent has been altered by including a linker or modifying the linkage between the FGF portion of the conjugate and the targeted moiety and/or by modifying the FGF portion of the conjugate, and, also, where advantageous modifying the targeted agent.
  • FGF-(L) q -targeted agent in which FGF refers to a polypeptide that is reactive with an FGF receptor (also referred to herein as an FGF protein), such as bFGF, L refers to a linker, q is 1 or more, generally 1 to 4, and the targeted agent is any agent, such as a cytotoxic agent or a nucleic acid, or a drug, such as methotrexate, intended for internalization by a cell that expresses an FGF receptor.
  • FGF refers to a polypeptide that is reactive with an FGF receptor (also referred to herein as an FGF protein), such as bFGF
  • L refers to a linker
  • q is 1 or more, generally 1 to 4
  • the targeted agent is any agent, such as a cytotoxic agent or a nucleic acid, or a drug, such as methotrexate, intended for internalization by a cell that expresses an FGF receptor.
  • More than one linker may be present; as many linkers as desired may be present as long as the resulting conjugate retains the requisite ability to bind to an FGF receptor and internalize the linked agent, which upon internalization retains its activity.
  • the FGF may be linked through it N- terminus, C-terminus or elsewhere in the polypeptide to the targeted agent or linker.
  • Polypeptides that are reactive with an FGF receptor include any molecule that reacts with FGF receptors on cells that bear FGF receptors and results in internalization of the linked targeted agent.
  • Particularly preferred polypeptides that are reactive with an FGF receptor include members of the FGF family of polypeptides, muteins of these polypetides, and chimeric or hybrid molecules that contain portions of any of these family members. Any member of the FGF family or any portion thereof that binds to FGF receptors and internalizes a linked agent may be used.
  • the linker is selected to increase the specificity, toxicity, solubility, serum stability, and/or intracellular availability targeted moiety. More preferred linkers are those that can be incorporated in fusion proteins and expressed in a host cell, such as E. coli. Such linkers include: enzyme substrates, such as cathepsin B substrate, cathepsin D substrate, trypsin substrate, thrombin substrate, subtilisin substrate, factor Xa substrate, and enterokinase substrate; linkers that increase solubility, flexibility, and/or intracellular cleavability, such as (gly m ser) n and (ser m gly) n , in which n is 1 to 6, preferably 1 to 4, more preferably 2 to 4, and m is 1 to 6, preferably 1 to 4, more preferably 2 to 4.
  • linkers are those, such as cathepsin D substrate, that are preferentially cleaved in the endosome or cytoplasm following internalization of the conjugate linker; other such linkers, such as (gly m ser) n and (ser m gly) n , increase the serum stability and/or solubility of the conjugate or the availability of the region joining the FGF and targeted agent for cleavage.
  • linkers may be included in order to take advantage of desired properties of each linker.
  • linkers include, acid cleavable linkers, such as bismaleimideothoxy propane, acid labile-transferrin conjugates and adipic acid diihydrazide, that would be cleaved in more acidic intracellular compartments; photocleavable cross linkers that are cleaved by visible or UV light.
  • acid cleavable linkers such as bismaleimideothoxy propane, acid labile-transferrin conjugates and adipic acid diihydrazide, that would be cleaved in more acidic intracellular compartments
  • photocleavable cross linkers that are cleaved by visible or UV light.
  • photocleavable linkers are of particular interest.
  • the targeted agents or moieties include any molecule that, when internalized, alter the metabolism or gene expression in the cell.
  • agents include cytotoxic agents, such as ribosome inactivating proteins, nucleic acids and nucleic acids encoding cytotoxins, that result in inhibition of growth or cell death.
  • agents also include antisense RNA, DNA, and truncated proteins that alter gene expression via interactions with the DNA, or co-suppression or other mechanism.
  • the conjugates herein may also be used to deliver DNA and thereby serve as agents for gene therapy or to deliver agents that, upon, transcription and/or translation thereof, result in cell death.
  • Cytotoxic agents include, but are not limited to, ribosome inactivating proteins, inhibitors of DNA, RNA and/or protein synthesis, including antisense nucleic acids, and other metabolic inhibitors.
  • the cytotoxic agent is a ribosome- inactivating protein (RIP), such as, for example, saporin, although other cytotoxic agents can also be advantageously used.
  • RIP ribosome- inactivating protein
  • substantially all of the conjugates in a preparation contain the same ratio of the polypeptide that is reactive with an FGF receptor to targeted agent. Such preparations are referred to as monogenous preparations. In preferred embodiments, all of the conjugates contain the same ratio of molecule of FGF protein and targeted agent per mole of conjugate so that the resulting preparation is a substantially monogenous.
  • cytotoxic agents such as a RIPs, including SAP
  • FGF polypeptides and monogenous preparation of cytotoxic conjugates that contains a defined molar ratio of each of the constituents. These methods include chemical conjugation methods and methods that rely on recombinant production of the conjugates.
  • the resulting conjugates provided herein can be used in pharmaceutical compositions to treat FGF-mediated pathophysiological conditions by specifically targeting to cells having FGF receptors and inhibiting proliferation of or causing death of the cells.
  • pathophysiological conditions include, for example, tumor development, restenosis, Dupuytren's Contracture, certain complications of diabetes such as proliferative diabetic retinopathies, rheumatoid arthritis, and certain ophthalmic disorders, such as secondary lens clouding following extracapsular cataract surgery and corneal clouding following laser surgery, such as photorefractive kerectomy (PRK), and dermatological disorders, such as psoriasis and Karposi's sarcoma.
  • Treatment is effected by administering a therapeutically effective amount of the FGF conjugate in a physiologically acceptable excipient.
  • the conjugate can be used to target cytotoxic agents into cells having FGF receptors, and to inhibit the proliferation of such cells.
  • compositions for the treatment of complications following laser surgery and glaucoma surgery and for prevention and treatment of pterygii are provided.
  • the methods entail contacting the affected portion of the eye with a composition containing conjugates of a polypeptide that is reactive with an fibroblast growth factor (FGF) receptor (also referred to herein as an FGF protein or FGF polypeptide) and a targeted cytotoxic agent.
  • FGF fibroblast growth factor
  • Pharmaceutical compositions for use in the methods herein are also provided.
  • the resulting conjugates provided herein also can be used in pharmaceutical compositions to deliver nucleic acids to cells in order to alter the transcription translation of a particular gene product, to bind to a selected site on an intracellular protein or an extracellular protein, via an autocrine mechanism, or to effect genetic therapy.
  • Methods for genetic therapy are also provided. The methods entail linking a nucleic acid encoding a therapeutic agent or encoding a gene that replaces a defective gene or provides an absent gene to a protein reactive with an FGF receptor and administering the resulting conjugate.
  • Conjugates of a heparin-binding growth factor protein and a nucleic acid binding domain bound to a nucleic acid molecule are provided.
  • the nucleic acid binding domain may be bound to a specific sequence or bind nonspecifically.
  • the growth factor is a member of the FGF, VEGF, or HBEGF family or fragment thereof.
  • the nucleic acid molecule preferably encodes a protein capable of killing a cell or rendering the cell susceptible to killing.
  • the conjugate linkage may contain a linker that increases the serum stability or intracellular availability of the nucleic acid binding domain.
  • a preferred embodiment is FGF conjugated to poly-L-lysine and the nucleic acid encodes saporin.
  • corneaal haze or “clouding” refers to the clouding of the cornea that results from exposure of the cornea to laser radiation during eye surgery, particularly LRK.
  • the haze or clouding appears to result from fibroblastic keratocyte proliferation in the subepithelial zone following photoablation of the cornea.
  • cytotoxic agent refers to a molecule capable of inhibiting cell function.
  • the agent may inhibit proliferation or may be toxic to cells.
  • the term includes agents whose toxic effects are mediated only when transported into the cell and also those whose toxic effect is mediated at the cell surface.
  • a variety of cytotoxic agents can be used and include those that inhibit protein synthesis and those that inhibit expression of certain genes essential for cellular growth or survival. Cytotoxic agents include those that result in cell death and those that inhibit cell growth, proliferation and/or differentiation.
  • Cytotoxic agents include saporin, the ricins, abrin and other RIPs, Pseudomonas exotoxin, inhibitors of DNA, RNA or protein synthesis or other metabolic inhibitors that are known to those of skill in this art.
  • Saporin is preferred, but other suitable RIPs and toxins include, but are not limited to, ricin, ricin A chain, maize RIP, gelonin, diphtheria toxin, diphtheria toxin A chain, trichosanthin, tritin, pokeweed antiviral protein (PAP), mirabilis antiviral protein (MAP), Dianthins 32 and 30, abrin, monordin, bryodin, shiga, a catalytic inhibitor of protein biosynthesis from cucumber seeds (see, e.g., WO 93/24620, pseudomonas endotoxin and others known to those of skill in this art.
  • RIP is used herein to broadly include such cytotoxins, as well as other cytotoxic molecules that inhibit cellular metabolic process, including transcription, translation, biosynthetic or degradative pathways, DNA synthesis and other such process, or that kill cells.
  • saporin (abbreviated herein as SAP) refers to polypeptides having amino acid sequences found in the natural plant host Saponaria qfficinalis, as well as modified sequences, having amino acid substitutions, deletions, insertions or additions, which still express substantial ribosome-inactivating activity. Purified preparations of saporin are frequently observed to include several molecular isoforms of the protein. It is understood that differences in amino acid sequences can occur in saporin from different species as well as between saporin molecules from individual organisms of the same species.
  • N-terminal extension refers to a peptide region that is linked to the amino terminus of a biologically active portion of a cytotoxic agent, such as a saporin polypeptide, or another protein, such as a DNA binding domain. N-terminal extensions having as few as 2 amino acids, and up to many amino acids, are provided. The upper limit is determined empirically. The length of the N-terminal extension is not important as long as the resulting conjugate or fusion protein binds to cell surface receptors and is internalized. (See WO 93/25688, the disclosure of which is incorporated in its entirety herein.)
  • a "linker” is an N-terminal extension that links the heparin-binding growth factor or fragment thereof and the targeted moiety, a second protein or nucleic acid.
  • the linkers provided herein confer specificity, enhance intracellular availability, serum stability and/or solubility on the conjugate.
  • the linkers provided herein confer specificity on the cytotoxic conjugate by, for example, conferring specificity for certain proteases, particularly proteases that are present in only certain subcellular compartments or that are present at higher levels in tumor cells than normal cells.
  • the linkers may also include sorting signals that direct the conjugate to particular intracellular loci or compartments.
  • the linkers may also serve as spacers to reduce steric hindrance between the growth factor and other protein or linked nucleic acid.
  • a modification that is effected substantially near the N-terminus of a cytotoxic agent, such as saporin, is generally effected within the first about ten residues of the protein.
  • Such modifications include the addition or deletion of residues, such as the addition of a cysteine to facilitate conjugation between the polypeptide reactive with an FGF receptor or fragment of the polypeptide and the cytotoxic moiety portion to form cytotoxic agents that contain a defined molar ratio, preferably a ratio of 1 : 1 , of cytotoxic agent and polypeptide reactive with an FGF receptor or fragment of the polypeptide.
  • a "mitotoxin” is a cytotoxic molecule targeted to specific cells by a mitogen.
  • ligand refers to any polypeptide that is capable of binding to a cell-surface protein and is capable of facilitating the internalization of a ligand- containing fusion protein into the cell.
  • ligands include growth factors, antibodies or fragments thereof, hormones, and other types of proteins.
  • polypeptide reactive with an FGF receptor refers to any polypeptide that specifically interacts with an FGF receptor, preferably the high- affinity FGF receptor, and that is transported into the cell by virtue of its interaction with the FGF receptor. Polypeptides reactive with an FGF receptor are also referred to herein as FGF proteins.
  • FGF proteins include members of the FGF family of peptides, including FGF-1 through FGF-9, chimeras or hybrids of any of FGF-1 through FGF-9, or FGFs that have deletions (see, e.g., Published International Application No. WO 90/02800 and national stage applications and patents based thereon) or insertions of amino acids, as long as the resulting peptide or protein specifically interacts with an FGF receptor and is internalized by virtue of this interaction.
  • FGF refers to polypeptides having amino acid sequences of native FGF proteins, as well as modified sequences, having amino acid substitutions, deletions, insertions or additions in the native protein but retaining the ability to bind to FGF receptors and to be internalized.
  • polypeptides include, but are not limited to, FGF-1 - FGF-9.
  • bFGF should be generally understood to refer to polypeptides having substantially the same amino acid sequences and receptor-targeting activity as that of bovine bFGF or human bFGF. It is understood that differences in amino acid sequences can occur among FGFs of different species as well as among FGFs from individual organisms or species.
  • FGFs are also intended to encompass proteins isolated from natural sources as well as those made synthetically, as by recombinant means or possibly by chemical synthesis.
  • FGF also encompasses muteins of FGF that possess the ability to target to FGF-receptor expressing cells.
  • Such muteins include, but are not limited to, those produced by replacing one or more of the cysteines with serine as herein or that have any other amino acids deleted or replaced as long as the resulting protein has the ability to bind to FGF-receptor bearing cells and internalized the linked targeted agent.
  • such muteins will have conservative amino acid changes, such as those set forth below in Table 1.
  • DNA encoding such muteins will, unless modified by replacement of degenerate codons, hybridize under conditions of at least low stringency to DNA encoding bFGF (SEQ ID NOS. 12 and 13) or DNA encoding any of the FGFs set forth in SEQ ID. NOS. 24-32.
  • DNA encoding an FGF peptide or polypeptide reactive with an FGF receptor refers to any of the DNA fragments set forth herein as coding such peptide and to any such DNA fragments known to those of skill in the art. Any such DNA molecule may be isolated from a human cell library using any of the preceding DNA fragments as a probe.
  • FGF receptors refer to receptors that specifically interact with a member of the FGF family of proteins and transport it into the cell. Included among these are the receptors described in International Application No. WO 91/00916, which is based on U.S. Patent Application Serial No. 07/377,033; International Application No. WO 92/00999, which is based on U.S. Patent Application Serial No. 07/549,587; International Application No. WO 90/05522; and International Application No. WO 92/12948; see, also, Imamura, Biochem. Biophys. Res. Comm. 755:583-590, 1988; Partanen et al., EMBO J. 70:1347-1354, 1991; and Moscatelli, J. Cell. Physiol. 737:123-130, 1987.
  • VEGF refers to any polypeptide that specifically, either as a monomer or dimer, interacts with a VEGF receptor and is transported into the cell by virtue of its interaction with the receptor.
  • VEGF refers to peptides having amino acid sequences of native VEGF polypeptide monomers, as well as modified VEGF polypeptides, having amino acid substitutions, deletions, insertions or additions in the native protein, but when dimerized, retaining the ability to bind to a VEGF receptor and to be internalized in a cell bearing such receptor.
  • polypeptides include, but are not limited to human VEGF121, human VEGF165.
  • VEGF 189 human VEGF 189, human VEGF206, bovine VEGF 120, bovine VEGF 164, bovine VEGF188, bovine VEGF205- and homodimers and heterodimers of any VEGF monomer or monomers. It is understood that differences in amino acid sequences can occur among VEGFs of different species as well as among VEGFs from individual organisms or species and that such minor allelic variations or variations among species are intended to be encompassed by reference to VEGF herein.
  • VEGFs are intended to encompass proteins isolated from natural sources as well as those made synthetically, as by recombinant means or possibly by chemical synthesis.
  • VEGF also encompasses muteins of VEGF that possess the ability to target a linked targeted agent to VEGF-receptor bearing cells.
  • Such muteins include, but are not limited to, those produced by replacing one or more of the cysteines with serine as herein or those that have any other amino acids deleted or replaced, with the proviso that the resulting protein has the ability, either as a monomer or as a dimer, to bind to VEGF-receptor bearing cells and to be internalized upon such binding or to internalize a linked targeted agent.
  • muteins will have conservative amino acid changes, such as those set forth below in Table 1.
  • DNA encoding such muteins will, unless modified by replacement of degenerate codons, hybridize under conditions of at least low stringency to DNA encoding a VEGF (SEQ ID NOS. 87-90) or an exon thereof (SEQ ID NOS. 78-86).
  • a portion of a VEGF refers to a fragment or piece of VEGF that is sufficient, either alone or as a dimer with another fragment or a VEGF monomer, to bind to a receptor to which VEGF dimers bind and internalize a linked targeted agent.
  • DNA encoding a VEGF peptide or "polypeptide” refers to any of the DNA fragments set forth herein as coding such peptides, to any such DNA fragments known to those of skill in the art, any DNA fragment that encodes a VEGF that binds to a VEGF receptor and is internalized thereby and may be isolated from a human cell library using any of the preceding DNA fragments as a probe or any DNA fragment that encodes any of the VEGF peptides set forth in SEQ ID NOS. 87-90 and any DNA fragment that may be produced from any of the preceding DNA fragments by substitution of degenerate codons.
  • VEGF-mediated pathophysiological condition refers to a deleterious condition characterized by or caused by proliferation of cells that are sensitive to VEGF mitogenic stimulation.
  • VEGF receptors refer to receptors that specifically interact with a naturally-occurring member of the VEGF family of proteins and transport it into a cell bearing such receptors. Included among these are the fins-like tyrosine kinase receptor (FLT) and the kinase insert domain-containing receptor (KDR) (see, e.g., International Application WO 92/14748, which is based on U.S. Applications Serial No. 08/657,236, de Vries et al., Science 255:989-91, 1992; Terman et al., Biochem. Biophys. Res. Commun. 757:1579-1586, 1992; Kendall et al., Proc. Natl. Acad. Sci. USA 90: 10705-10709, 1993; and Peters et al., Proc. Natl. Acad. Sci. USA 90:8915-8919, 1993).
  • FLT fins-like tyrosine kinase receptor
  • heparin-binding epidermal growth factor-like growth factor (HBEGF) polypeptides refer to any polypeptide that specifically interacts with a HBEGF receptor, a receptor to which native human HBEGF polypeptide binds and which transports the HBEGF intracellularly, that has a heparin-binding domain, and that is transported into the cell by virtue of its interaction with the receptor.
  • HBEGF refers to polypeptides having amino acid sequences of a native HBEGF polypeptide, as well as variants, having amino acid substitutions, deletions, insertions or additions in the native protein but retaining the ability to bind to a HBEGF receptor and to be internalized in a cell bearing such receptor.
  • HBEGF polypeptides peptides include, but are not limited to human HBEGF (SEQ ID NO. 92), monkey HBEGF (SEQ ID NO. 94) and rat HBEGF (SEQ ID NO. 95).
  • HBEGF polypeptides include those having SEQ ID NOS. 91-95, N-terminally or C-terminally shortened versions thereof, including mature HBEGFs, and also including, modified versions of HBEGF thereof that retain the ability to bind to HBEGF receptors and internalize linked targeted agents.
  • HBEGFs are intended to encompass HBEGF polypeptides isolated from natural sources as well as those made synthetically, as by recombinant means or by chemical synthesis. This term also encompasses the precursor forms, such as those set forth in SEQ ID NOS. 91, 92 and 94-96 and mature forms, such as that set forth in SEQ ID NO. 93. HBEGF also encompasses muteins of HBEGF that possess the ability to target a targeted agent, such as a cytotoxic agent, including but not limited to ribosome- inactivating proteins, such as saporin, light activated porphyrin, and antisense nucleic acids, to HBEGF-receptor expressing cells.
  • a targeted agent such as a cytotoxic agent, including but not limited to ribosome- inactivating proteins, such as saporin, light activated porphyrin, and antisense nucleic acids, to HBEGF-receptor expressing cells.
  • Such muteins include, but are not limited to, those produced by replacing one or more of the cysteines with serine as described hereinafter or that have any other amino acids deleted or replaced as long as the resulting protein has the ability to bind to HBEGF-receptor bearing cells and internalize the linked targeted agent.
  • such muteins will have conservative amino acid changes, such as those set forth below in Table 1.
  • DNA encoding such muteins will, unless modified by replacement of degenerate codons, hybridize under conditions of at least low stringency to DNA encoding native HBEGF (e.g., SEQ ID NO. 91) and encode an HBEGF polypeptide, as defined herein.
  • mature HBEGF refers to processed HBEGFs. It has been found that various isoforms of mature HBEGF have variable N-termini, and include, but are not limited to, those having N-termini corresponding to amino acid positions 63, 73, 74, 77 and 82 of the precursor protein (see, e.g., SEQ ID NOS. 91-93, see, also, SEQ ID NOS. 94 and 95).
  • a "portion of a HBEGF” refers to a fragment or piece of HBEGF that is sufficient to bind to a receptor to which native HBEGF binds and internalize a linked targeted agent.
  • an "amino acid residue of HBEGF” is non-essential if a HBEGF polypeptide that has been modified by deletion of the residue possesses substantially the same ability to bind to a HBEGF receptor and internalize a linked agent that the unmodified HBEGF has.
  • DNA encoding an HBEGF peptide or polypeptide refers to any DNA fragment encoding an HBEGF, as defined above.
  • Exemplary DNA fragments include: any such DNA fragments known to those of skill in the art; any DNA fragment that encodes an HBEGF that binds to an HBEGF receptor and is internalized thereby and may be isolated from a human cell library using any of the preceding DNA fragments as a probe; and any DNA fragment that encodes any of the HBEGF polypeptides set forth in SEQ ID NOS. 92-95.
  • Such DNA sequences encoding HBEGF fragments are available from publicly accessible databases, such as: DNA July 1993 release from DNASTAR, Inc. Madison, WI, and GENBANK Accession Nos.
  • DNA encoding HBEGF polypeptides will, unless modified by replacement of degenerate codons, hybridize under conditions of at least low stringency to DNA encoding a native HBEGF (e.g., SEQ ID NO. 91).
  • any DNA fragment that may be produced from any of the preceding DNA fragments by substitution of degenerate codons is also contemplated for use herein. It is understood that since the complete amino acid sequence of HBEGF polypeptides, and DNA fragments encoding such peptides, are available to those of skill in this art, it is routine to substitute degenerate codons and produce any of the possible DNA fragments that encode such HBEGF polypeptides. It is also generally possible to synthesize DNA encoding such peptides based on the amino acid sequence.
  • HBEGF receptor refers to receptors that specifically interact with members of the HBEGF family of proteins and that are able to transport HBEGF into the cell, e.g., by receptor-mediated endocytosis.
  • HBEGF polypeptides interact with the high affinity EGF receptors (EGF-R) on bovine aortic smooth muscle cells and A431 epidermoid carcinoma cells (see Higashiyama et al., Science 257:936-939, 1991; Higashiyama et al., J. Biol. Chem. 267:6205-6212, 1992).
  • EGF-receptors are also HBEGF-Rs.
  • the EGF-Rs described herein include those encoded by the erbB gene family.
  • Heparin-binding growth factor refers to any member of a family of heparin- binding growth factor proteins, in which at least one member of the family binds heparin.
  • Preferred growth factors in this regard include FGF, VEGF, and HBEGF.
  • Such growth factors encompass isoforms, peptide fragments derived from a family member, splice variants, and single or multiple exons, some forms of which may not bind heparin.
  • NABD Nucleic acid binding domain
  • a targeted agent such as a cytotoxic agent
  • a targeted agent means to direct it to a cell that expresses a selected receptor by linking the agent to a polypeptide reactive with an FGF receptor or other heparin-binding growth factor to produce a conjugate.
  • the conjugate Upon binding to the receptor the conjugate is internalized by the cell and the conjugate is trafficked through the cell via the endosomal compartment, where cleavage of the conjugate can occur.
  • conjugates are preparations of conjugates in which each conjugate has the same, generally 1:1, though not necessarily, molar ratio of targeting molecule to targeted agent.
  • Monogenous conjugates are substantially identical in that they possess indistinguishable chemical and physical properties and generally preparations of such conjugates contain only one species of conjugate. It is, of course understood, that some variability among the species may be present and will be tolerated to the extent that the activity of each member of the conjugate is substantially the same.
  • saporin that is expressed in bacterial hosts as provided herein may contain a mixture of species that differ at their N- terminus. Such recombinantly produced saporin, however, is suitable for use to produce chemically conjugated conjugates by the methods herein.
  • the resulting preparation is monogenous as defined herein in that each conjugate contains the same molar ratio of FGF protein to targeted agent, but each conjugate is not necessarily identical, but is substantially identical in that each conjugate has substantially the same biological activity.
  • a “homogeneous population” or composition of conjugates means that the constituent members of the population or composition are monogenous and further do not form aggregates.
  • secretion signal refers to a peptide region within the precursor protein that directs secretion of the precursor protein from the cytoplasm of the host into the periplasmic space or into the extracellular growth medium. Such signals may be either at the amino terminus or carboxyl terminus of the precursor protein. The preferred secretion signal is linked to the amino terminus of the N-terminal extension region.
  • NTS nuclear translocation or targeting sequence
  • Examples of NTS are set forth in Table I, below. Comparison with known NTSs, and if necessary testing of candidate sequences, should permit those of skill in the art to readily identify other amino acid sequences that function as NTSs.
  • a heterologous NTS refers to an NTS that is different from the NTS that occurs in the wild-type peptide, polypeptide, or protein.
  • the NTS may be derived from another polypeptide, it may be synthesized, or it may be derived from another region in the same polypeptide.
  • nucleic acids describe any nucleic acids used in the context of the invention that modify gene transcription or translation. This term also includes nucleic acids and methods that provide nucleic acids that bind to sites on proteins and to receptors. It includes, but is not limited to, the following types of nucleic acids: nucleic acids encoding a protein, antisense mRNA, DNA intended to form triplex molecules, extracellular protein binding oligonucleotides, and small nucleotide molecules.
  • Antisense nucleic acids are single-stranded nucleic acids construct that specifically bind to mRNA by way of complementary sequences, thereby preventing translation of the mRNA (see, e.g., U.S. Patent No.
  • Antisense nucleic also include double-stranded cyclic oligonucleotides, such as hammerhead or dumbbell oligonucleotides, which have been shown to specifically inhibit RNA synthesis (see, e.g., Clusel et al., Nucl. Acids Res. 27:3405-3411, 1993).
  • Triplex molecules refer to single DNA strands that target duplex DNA, forming colinear triplexes by binding to the major groove, and thereby prevent or alter transcription (see, e.g., U.S. Patent No. 5,176,996 to Hogan et al.). Triplex DNA has been designed that bind tightly and specifically to selected DNA sites.
  • a ribozyme is an enzyme that is made of RNA and primarily acts on RNA substrates.
  • ribozymes refer to RNA constructs that specifically cleave messenger RNA (see, e.g., U.S. Patent Nos. 5,180,818, 5,116,742 and 5,093,246 to Cech et al.) and in particular refers to ribozymes that are designed to target RNA molecules for cleavage and that thereby in some manner inhibit or interfere with cell growth or with expression of a targeted mRNA or protein.
  • Extracellular protein binding oligonucleotides refer to oligonucleotides that specifically bind to proteins
  • Nucleic acids may be composed of the well-known deoxyribonucleotides and ribonucleotides composed of the bases: adenosine, cytosine, guanine, thymidine, and uridine.
  • various other nucleotide derivatives and non-phosphate backbones or phosphate-derivative backbones may be used.
  • PO oligonucleotides normal phosphodiester oligonucleotides
  • X 0. (see structure, below); type I)
  • several resistant types of oligonucleotides have been developed.
  • oligonucleotides include types II-IV oligonucleotides: in which B is a nucleotide base; and X is OEt in phosphotriester (type II), X is Me in methylphosphonate (type III; referred to as MP oligos); and X is S in phosphorothioate (referred to as PS oligos; U.S. Patent No. 5,218,088 to Gorenstein et al. describes a method for preparation of PS oligos).
  • MP and PS oligonucleotides have been the focus of most investigation. Nucleic acids may be single or double stranded and may be chimeric, that is composed of both DNA and RNA.
  • a "therapeutic nucleic acid” refers to a nucleic acid that is used to effect genetic therapy by serving as a replacement for a defective gene, by encoding a therapeutic product, such as TNF, or by encoding a cytotoxic molecule, especially an enzyme, such as saporin.
  • the therapeutic nucleic acid may encode all or a portion of a gene, and may function by recombining with DNA already present in a cell, thereby replacing a defective portion of a gene. It may also encode a portion of a protein and exert its effect by virtue of co-suppression of a gene product.
  • expression vector includes vectors capable of expressing DNA fragments that are in operative linkage with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments.
  • an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA.
  • Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or may integrate into the host cell genome.
  • a "promoter region” refers to the portion of DNA of a gene that controls transcription of DNA to which it is operatively linked.
  • a portion of the promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation.
  • the promoter region includes cis- or trans-acting sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. Promoters, depending upon the nature of the regulation, may be constitutive or regulated. Preferred promoters for use herein are tightly regulated such that, absent induction, the DNA encoding the polypeptide is not expressed.
  • a "transcription terminator region” has either (a) a subsegment that encodes a polyadenylation signal and polyadenylation site in the transcript, and/or (b) a subsegment that provides a transcription termination signal that terminates transcription by the polymerase that recognizes the selected promoter.
  • Transcription terminators are optional components of the expression systems herein, but are employed in preferred embodiments.
  • transfection refers to the taking up of DNA or RNA by a host cell. Transformation refers to this process performed in a manner such that the DNA is replicable, either as an extrachromosomal element or as part of the chromosomal DNA of the host. Methods and means for effecting transfection and transformation are well known to those of skill in this art (see, e.g., Wigler et al., Proc. Natl. Acad. Sci. USA 76:1373-1376, 1979; Cohen et al., Proc. Natl. Acad. Sci. USA 69:2110, 1972).
  • FGF-mediated pathophysiological condition refers to a deleterious condition characterized by or caused by proliferation of cells that are sensitive to bFGF mitogenic stimulation.
  • Basic FGF-mediated pathophysiological conditions include, but are not limited to, certain tumors, rheumatoid arthritis, restenosis, Dupuytren's Contracture and certain complications of diabetes, such as proliferative retinopathy.
  • substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis and which are sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance.
  • Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art.
  • a substantially chemically pure compound may, however, be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound.
  • hybridize under conditions of a specified stringency is used to describe the stability of hybrids formed between two single-stranded nucleic acid fragments and refers to the conditions of ionic strength and temperature at which such hybrids are washed, following annealing under conditions of stringency less than or equal to that of the washing step.
  • high, medium and low stringency encompass the following conditions or equivalent conditions thereto: 1) high stringency: 0.1 x SSPE or SSC, 0.1% SDS, 65°C 2) medium stringency: 0.2 x SSPE or SSC, 0.1% SDS, 50°C
  • culture means a propagation of cells in a medium conducive to their growth, and all sub-cultures thereof.
  • subculture refers to a culture of cells grown from cells of another culture (source culture), or any subculture of the source culture, regardless of the number of subculturings that have been performed between the subculture of interest and the source culture.
  • an "effective amount" of a compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce the symptoms associated with the disease. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective. The amount may cure the disease but, typically, is administered in order to ameliorate the symptoms of the disease. Repeated administration may be required to achieve the desired amelioration of symptoms.
  • esters or other derivatives of the conjugates include any salts, esters or derivatives that may be readily prepared by those of skill in this art using known methods for such derivatization and that produce compounds that may be administered to animals or humans without substantial toxic effects and that either are pharmaceutically active or are prodrugs.
  • treatment means any manner in which the symptoms of a conditions, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein. Amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.
  • an "ophthalmically effective amount” is that amount which, in the composition administered and by the technique administered, provides an amount of therapeutic agent to the involved eye tissues sufficient to prevent or reduce corneal haze following excimer laser surgery, prevent closure of a trabeculectomy or prevent or substantially slow the recurrence of pterygii.
  • biological activity refers to the in vivo activities of a compoimd or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures.
  • the biological activity of a cytotoxic agent, such as saporin or an antisense nucleic acid refers to the ability of such agent to interfere with the metabolism of the cell by inhibiting protein synthesis, DNA synthesis, or the activities of particular proteins and regulatory molecules.
  • the biological activity of a RIP refers to its ability to inhibit protein synthesis by inactivation of ribosomes either in vivo or in vitro or to inhibit the growth of or kill cells upon internalization of the RIP by the cells.
  • Such biological or cytotoxic activity may be assayed by any method known to those of skill in the art including, but not limited to, the in vitro assays that measure protein synthesis and in vivo assays that assess cytotoxicity by measuring the effect of a test compound on cell proliferation or on protein synthesis.
  • ED 50 refers to the concentration at which 50% of the cells are killed following a 72-hour incubation with a cytotoxic conjugate, such as FGF-SAP.
  • ID 50 refers to the concentration of a cytotoxic conjugate required to inhibit protein synthesis in treated cells by 50% compared to protein synthesis in the absence of the protein.
  • the conjugates that are provided herein contain a heparin-binding growth factor protein linked via a linker to a targeted agent, such as a cytotoxic agent, DNA binding domain or nucleic acid.
  • a targeted agent such as a cytotoxic agent, DNA binding domain or nucleic acid.
  • the linking is effected either chemically, by recombinant expression of a fusion protein in instances when the targeted agent is a protein, and by combinations of chemical and recombinant expression.
  • the conjugate Upon binding to an appropriate receptor, the conjugate is internalized by the cell and the conjugate is trafficked through the cell via the endosomal compartment, where at least a portion of it is cleaved.
  • linkers such as the cathepsin D linkers, provided herein are designed to increase the portion of conjugate that is cleaved in the endosome of targeted cells, such as tumor cells, and to thereby increase the amount of targeted agent that is delivered to the cytoplasm and/or nucleus.
  • Others of the linkers provided herein are designed to increase the serum stability and/or solubility of the conjugate and thereby increase the amount of targeted agent delivered to the targeted cell. In preferred embodiments, several linkers will be combined to take advantage of the desired properties of each.
  • FGF fibroblast growth factor
  • FGF-9 acidic FGF
  • bFGF basic FGF
  • int-2 see, e.g., Moore et al., EMBO J. 5:919-924, 1986
  • hst-1/K-FGF see, e.g., Sakamoto et al., Proc. Natl. Acad. Sci.
  • FGF-8 see, e.g., Tanaka et al., Proc Natl. Acad. Sci. U.S.A. 89:8528-8532, 1992
  • FGF-9 see, Miyamoto et al., Mol. Cell. Biol. 13 :4251 -4259, 1993
  • Acidic and basic FGF which were the first members of the FGF family that were characterized, are about 55% identical at the amino acid level and are highly conserved among species.
  • Basic FGF has a molecular weight of approximately 16 kD, is basic and temperature sensitive and has a high isoelectric point.
  • Acidic FGF has an acidic isoelectric point.
  • the other members of the FGF family have subsequently been identified on the basis of amino acid sequence homologies with aFGF and bFGF and common physical and biological properties, including the ability to bind to one or more FGF receptors.
  • Basic FGF, int-2, hst-1/K-FGF, FGF-5, hst-2/FGF-6 and FGF-8 are oncogenes.
  • bFGF is expressed in melanomas
  • int-2 is expressed in mammary tumor virus
  • hst-1/K-FGF is expressed in angiogenic tumors.
  • Acidic FGF, bFGF, KGF and FGF-9 are expressed in normal cells and tissues.
  • FGFs exhibit a mitogenic effect on a wide variety of mesenchymal, endocrine and neural cells. They are also important in differentiation and development. Of particular interest is their stimulatory effect on collateral vascularization and angiogenesis. Such effects have stimulated considerable interest in FGFs as therapeutic agents, for example, as pharmaceuticals for wound healing, neovascularization, nerve regeneration and cartilage repair. In addition to potentially useful proliferative effects, FGF-induced mitogenic stimulation may, in some instances, be detrimental. For example, cell proliferation and angiogenesis are an integral aspect of tumor growth.
  • Members of the FGF family, including bFGF are thought to play a pathophysiological role, for example, in tumor development, rheumatoid arthritis, proliferative diabetic retinopathies and other complications of diabetes.
  • FGFs are mediated by high affinity receptor tyrosine kinases on the cell surface membranes or FGF-responsive cells (see, e.g., Imamura et al., Biochem. Biophys. Res. Comm. 755:583-590, 1988; Huang et al., J. Biol. Chem. 267:9568-9571, 1986, which are incorporated herein by reference).
  • Lower affinity receptors also play a role in mediating FGF activities.
  • the high affinity receptor proteins which are single chain polypeptides with molecular weights ranging from 110 to 150 kD, depending on cell type, constitute a family of structurally related FGF receptors.
  • VEGFs Vascular endothelial growth factors
  • VEGFs were identified by their ability to directly stimulate endothelial cell growth, but do not appear to have mitogenic effects on other types of cells. VEGFs also cause a rapid and reversible increase in blood vessel permeability.
  • the members of this family have been referred to variously as vascular endothelial growth factor (VEGF), vascular permeability factor (VPF) and vasculotropin (see, e.g., Plouet et al., EMBO J. 5:3801-3806, 1989) and are collectively referred to as VEGF.
  • VEGF vascular endothelial growth factor
  • VPF vascular permeability factor
  • vasculotropin see, e.g., Plouet et al., EMBO J. 5:3801-3806, 1989
  • VEGF was originally isolated from a guinea pig heptocarcinoma cell line, line 10, (see, e.g., U.S. Patent No. 4,456,550 to Dvorak et al.) and has subsequently been identified in humans and in normal cells. It is a glycoprotein that binds to specific cell surface receptors and is expressed during normal development and in certain normal adult organs. Purified VEGF is a basic, heparin-binding, homodimeric glycoprotein, which is heat-stable, acid-stable and may be inactivated by reducing agents. VEGF family members arise from a single gene organized as eight exons and spanning approximately 14 kb in the human genome.
  • VEGF vascular endothelial growth factor
  • VEGF 165- Transcripts encoding VEGFj21 and VEGF 189 are detectable in most cells and tissues that express the VEGF gene.
  • VEGF2O6 is less abundant and has been identified only in a human fetal liver cDNA library.
  • VEGF 121 is a weakly acidic polypeptide that lacks the heparin binding domain and, consequently, does not bind to heparin.
  • VEGF 1 9 and VEGF206 are more basic than VEGF 165 and bind to heparin with greater affinity. Although not every identified VEGF isoform binds heparin, all isoforms are considered to be heparin-binding growth factors within the context of this invention.
  • the secreted isoforms, VEGF121 and VEGF 5 are preferred VEGF proteins.
  • the longer isoforms, VEGF 89 and VEGF206' are almost completely bound to the extracellular matrix and need to be released by an agent, such as suramin, heparin or heparinase, and plasmin.
  • Other preferred VEGF proteins contain various combinations of VEGF exons, such that the protein still binds VEGF receptor and is internalized. It is not necessary that a VEGF protein used in the context of this invention either retain any of its in vivo biological activities, such as stimulating endothelial cell growth, or bind heparin.
  • VEGF protein or fragment thereof bind the VEGF receptor and be internalized into the cell bearing the receptor.
  • VEGF it may be desirable in certain contexts for VEGF to manifest certain of its biological activities.
  • VEGF is used as a carrier for DNA encoding a molecule useful in wound healing, it would be desirable that VEGF exhibit vessel permeability activity and promotion of fibroblast migration and angiogenesis. It will be apparent from the teachings provided within which of the activities of VEGF are desirable to maintain.
  • VEGF promotes an array of responses in endothelium, including blood vessel hyperpermeability, endothelial cell growth, angiogenesis, and enhanced glucose transport.
  • VEGF stimulates the growth of endothelial cells from a variety of sources (including brain capillaries, fetal and adult aortas, and umbilical veins) at low concentrations, but is reported to have no effect on the growth of vascular smooth muscle cells, adrenal cortex cells, keratinocytes, lens epithelial cells, or BHK-21 fibroblasts.
  • VEGF also is a potent polypeptide regulator of blood vessel function; it causes a rapid but transient increase in microvascular permeability without causing endothelial cell damage or mast cell degranulation, and its action is not blocked by antihistamines. VEGF has also been reported to induce monocyte migration and activation.
  • VEGF has been implicated as a tumor angiogenesis factor in some human gliomas.
  • Kaposi's sarcoma cells cultured from AIDS patients also express and secrete high levels of VEGF.
  • monoclonal antibodies that inhibit VEGF-induced angiogenesis exert an inhibitory effect on the growth of human rhabdomyosarcoma, glioblastoma multiforme, or leiomyosarcoma cell lines in nude mice.
  • VEGF appears to have a role in wound healing.
  • wound healing as in tumor stroma generation, VEGF probably exerts the dual functions of maintaining increased vessel permeability so that plasma proteins, such as fibrinogen extravasate, clot to form provisional matrix, and induce the migration of fibroblasts and new blood vessels; and stimulating endothelial cell division, thereby enhancing angiogenesis directly.
  • VEGF is also expressed in healing wounds by some of the macrophages that populate the developing granulation tissue.
  • VEGF may have a role in certain types of chronic inflammation. Enhanced vascular permeability is one of the earliest events in the inflammatory response. VEGF has been detected in some non-cancerous human effusions and VEGF mRNA in activated macrophages suggests a role for VEGF in forms of inflammation characterized by macrophage infiltration, such as delayed hypersensitivity and chronic inflammation. Also, VEGF is a chemoattractant for monocytes and VEGF has been shown to enhance the activity of the inflammatory mediator tumor necrosis factor (TNF).
  • TNF tumor necrosis factor
  • VEGF may also play a role in the pathogenesis of the angiogenic disease rheumatoid arthritis as high levels of VEGF are found in the synovial fluid of rheumatoid arthritis patients.
  • Quiescent and proliferating endothelial cells display high-affinity binding to VEGF, and endothelial cell responses to VEGF appear to be mediated by high affinity cell surface receptors. Expression of either receptor on nonendothelial cells, however, does not confer upon such cells the ability to proliferate in response to VEGF.
  • Two tyrosine kinases have been identified as VEGF receptors.
  • the first, known as fins-like tyrosine kinase or FLT is a receptor tyrosine kinase that is specific for VEGF.
  • FLT receptor tyrosine kinase
  • expression of FLT mRNA is localized to the endothelium and to populations of cells that give rise to endothelium.
  • the second receptor KDR (human kinase insert domain-containing receptor), and its mouse homologue FLK-1 are closely related to FLT.
  • the KDR/FLK-1 receptor is expressed in endothelium during the fetal growth stage, during earlier embryonic development, and in adult tissues.
  • FLT and KDR are membrane-spanning receptors that each contain seven immunoglobulin-like domains in the extracellular ligand-binding region, a single transmembrane-spanning sequence, and a cytoplasmic tyrosine kinase sequence that is interrupted by a "kinase insert" domain.
  • RNA encoding FLT and KDR have been identified in tumor blood vessels, and, as such, these receptors are likely to be relevant for VEGF-endothelial cell interactions in tumors.
  • FLT mRNA is expressed by endothelial cells of blood vessels supplying glioblastomas.
  • FLT and KDR mRNAs are upregulated in tumor blood vessels in invasive human colon adenocarcinoma, but not in the blood vessels of adjacent normal tissues.
  • VEGF vascular endothelial growth factor
  • disorders characterized by inadequate tissue perfusion such as obstructive atherosclerosis and diabetes, diabetic retinopathy and other angiogenesis in the posterior eye, and prevention of restenosis following percutaneous transluminal angioplasty are candidates for use of VEGF as a therapeutic agent.
  • Inhibition of VEGF activity may serve as a means to inhibit pathological vessel formation and, thereby, is of considerable interest in a variety of clinical applications, particularly oncology.
  • subfragments of VEGF which bind receptor but do not stimulate vessel formation are ideal candidates for carrying DNA molecules encoding cytotoxins to tumor cells.
  • HBEGF heparin-binding EGF-like growth factor
  • HBEGFs exhibit a mitogenic effect on a wide variety of cells including BALB/c 3T3 fibroblast cells and smooth muscle cells, but unlike VEGFs, are not mitogenic for endothelial cells (Higashiyama et al., Science 257:936-939, 1991). HBEGF appears to be a more potent mitogen for smooth muscle cells than either EGF or TGF- ⁇ , although all three factors bind to EGF receptors. Of particular interest, HBEGF has a stimulatory effect on collateral vascularization and angiogenesis. In some instances, however, HBEGF-induced mitogenic stimulation may be detrimental. For example, cell proliferation and angiogenesis are an integral aspect of tumor growth. Members of the HBEGF family are thought to play a pathophysiological role, for example, in a variety of tumors, such as bladder carcinomas, breast tumors and non-small cell lung tumors.
  • HBEGF isolated from U-937 cells is heterogeneous in structure and contains at least 86 amino acids and two sites of O-linked glycosyl groups (Higashiyama et al., J. Biol. Chem. 267:6205-6212, 1992).
  • the carboxyl-terminal half of the secreted HBEGF shares approximately 35% sequence identity with human EGF, including six cysteines spaced in the pattern characteristic of members of the EGF protein family.
  • the amino-terminal portion of the mature factor is characterized by stretches of hydrophilic residues and has no structural equivalent in EGF.
  • HBEGF heparin-binding sequences of HBEGF reside primarily in a twenty one-amino acid stretch upstream of and slightly overlapping the EGF-like domain.
  • HBEGFs The effects of HBEGFs are mediated by EGF receptor tyrosine kinases expressed on cell surfaces of HBEGF-responsive cells (see, e.g., U.S. Patent Nos. 5,183,884 and 5,218,090; and Ullrich et al., Nature 309:4113-425, 1984), which are incorporated herein by reference).
  • EGF receptor proteins which are single chain polypeptides with molecular weights 170 kD, constitute a family of structurally related EGF receptors.
  • Cells known to express the EGF receptors include, for example, smooth muscle cells, fibroblasts, keratinocytes, and numerous human cancer cell lines, such as the: A431 (epidermoid); KB3-1 (epidermoid); COLO 205 (colon); CRL 1739 (gastric); HEP G2 (hepatoma); LNCAP (prostate); MCF-7 (breast); MDA-MB-468 (breast); NCI 417D (lung); MG63 (osteosarcoma); U-251 (glioblastoma); D-54MB (glioma); and SW-13 (adrenal).
  • A431 epidermoid
  • KB3-1 epidermoid
  • COLO 205 colon
  • CRL 1739 gastric
  • HEP G2 hepatoma
  • LNCAP prostate
  • MCF-7 breast
  • MDA-MB-468 breast
  • NCI 417D lung
  • MG63
  • HBEGF need only bind a specific HBEGF receptor and be internalized. Any member of the HBEGF family, whether or not it binds heparin, is useful within the context of this invention as long as it meets the requirements set forth above. Members of the HBEGF family are those that have sufficient nucleotide identity to hybridize under normal stringency conditions (typically greater than 75% nucleotide identity). Subfragments or subportions of a full-length HBEGF may also be desirable. One skilled in the art may find from the teachings provided within that certain biological activities are more or less desirable, depending upon the application. Thus, HBEGF may be customized for the particular application. Means for modifying proteins is provided in detail below. Briefly, additions, substitutions and deletions of amino acids may be produced by any commonly employed recombinant DNA method.
  • Any polypeptide or peptidomimetic that is reactive with an FGF receptor, a VEGF receptor, or an HBEGF receptor may be used in the methods herein. These include members of the families and fragments thereof, as well as constrained analogs of such peptides that bind to one of the receptor and internalize a linked targeted agent. Members of the FGF peptide family, including FGF-1 - FGF-9, are particularly preferred. Modified peptides, including FGF polypeptides that have the nuclear translocating sequence (NTS) removed (see, 2b(3) and Table 2, below) and chimeric peptides, which retain the specific binding and internalizing activities are also contemplated for use herein. FGF polypeptides that have been modified by removal of the NTS are particularly suited for use herein. Such polypeptides will not be transported to the nucleus and, as such, administration of conjugates containing the modified FGF should not exhibit mitogenic activity.
  • NTS nuclear translocating sequence
  • Modification of the polypeptide may be effected by any means known to those of skill in this art.
  • the preferred methods herein rely on modification of DNA encoding the polypeptide and expression of the modified DNA.
  • DNA encoding the FGF polypeptide may be isolated, synthesized or obtained from commercial sources (the amino acid sequences of FGF-1 - FGF-9 are set forth in SEQ ID NOS. 24-32; DNA sequences may be based on these amino acid sequences or may be those that are known to those of skill in this art (see, e.g., Genbank, release 86); see, also, U.S. Patent No. 4,956,455, U.S. Patent No. 5,126,323, U.S. Patent No. 5,155,217, U.S. Patent No. 4,868,113, published International Application WO 90/08771 (and the corresponding U.S. patent, upon its issuance), which is based on U.S. Application Serial No.
  • DNA encoding VEGF or HBEGF may also be isolated, synthesized or obtained from commercial sources.
  • DNA sequences are available in public databases, such as Genbank and in SEQ ID NOS 78-95. Based on these sequences, oligonucleotide primers may be designed and used to amplify the gene from cDNA or mRNA by polymerase chain reaction technique.
  • Mutation may be effected by any method known to those of skill in the art, including site-specific or site-directed mutagenesis of DNA encoding the protein and the use of DNA amplification methods using primers to introduce and amplify alterations in the DNA template, such as PCR splicing by overlap extension (SOE).
  • Site-specific mutagenesis is typically effected using a phage vector that has single- and double-stranded forms, such as M13 phage vectors, which are well-known and commercially available.
  • Other suitable vectors that contain a single-stranded phage origin of replication may be used (see, e.g., Veira et al., Meth. Enzymol. 75:3, 1987).
  • site-directed mutagenesis is performed by preparing a single-stranded vector that encodes the protein of interest (i.e., a member of the FGF family or a cytotoxic molecule, such as a saporin).
  • An oligonucleotide primer that contains the desired mutation within a region of homology to the DNA in the single-stranded vector is annealed to the vector followed by addition of a DNA polymerase, such as E. coli DNA polymerase I (Klenow fragment), which uses the double stranded region as a primer to produce a heteroduplex in which one strand encodes the altered sequence and the other the original sequence.
  • the heteroduplex is introduced into appropriate bacterial cells and clones that include the desired mutation are selected.
  • the resulting altered DNA molecules may be expressed recombinantly in appropriate host cells to produce the modified protein.
  • Suitable conservative substitutions of amino acids are known to those of skill in this art may be made generally without altering the biological activity of the resulting molecule. For example, such substitutions may be made in accordance with those set forth in TABLE 1 as follows:
  • the targeted agents include any agent intended for intracellular delivery, such as cytotoxins, therapeutic drugs, drugs for imaging (see, e.g., U.S. Patent No. 5,256,399) and nucleic acids.
  • the targeted agent is a cytotoxic agent or, if DNA, encodes a therapeutic compound that inhibits or prevents cell proliferation.
  • Cytotoxic agents Any agent that, upon internalization by a cell, inhibits cell growth or proliferation or results in cell death, is suitable for use herein. Cytotoxic agents include ribosome inactivating proteins, small metabolic inhibitors, antisense nucleic acids, toxic drugs, such as anticancer agents, and small molecules, such as porphyrins.
  • Ribosome-inactivating-proteins which include ricin, abrin and saporin, are plant proteins that catalytically inactivate eukaryotic ribosomes.
  • Some RIPs such as the toxins abrin and ricin, contain two constituent chains: a cell-binding chain that mediates binding to cell surface receptors and internalizing the molecule; and a chain responsible for toxicity.
  • Single chain RIPs (type I RIPS), such as the saporins, do not have a cell-binding chain. As a result, unless internalized, they are substantially less toxic to whole cells than the RIPs that have two chains. RIPS inactivate ribosomes by interfering with the protein elongation step of protein synthesis.
  • the RIP saporin (hereinafter also referred to as SAP) has been shown to inactivate 60S ribosomes by cleavage of the n-glycosidic bond of the adenine at position 4324 in the rat 28S ribosomal RNA (rRNA).
  • rRNA ribosomal RNA
  • the particular region in which A 4324 is located in the rRNA is highly conserved among prokaryotes and eukaryotes.
  • a 4324 in 28S rRNA corresponds to A 2660 in Escherichia coli (E. coli) 23 S rRNA.
  • E. coli Escherichia coli
  • Several RIPs also appear to interfere with protein synthesis in prokaryotes, such as E. coli.
  • Saporin and other ribosome inactivating proteins are the preferred cytotoxic agent for use herein. Any cytotoxic agent that, when internalized inhibits or destroys cell growth, cell proliferation or other essential cell functions may be used herein. Such cytotoxic agents are considered to be functionally equivalent to the RIPs described herein, and include, but are not limited to, saporin, the ricins, abrin and other RIPs, Pseudomonas exotoxin, inhibitors of DNA, RNA or protein synthesis or other metabolic inhibitors that are known to those of skill in this art.
  • Saporin is preferred, but other suitable RIPs include, but are not limited to, ricin, ricin A chain, maize RIP, gelonin, diphtheria toxin, diphtheria toxin A chain, trichosanthin, tritin, pokeweed antiviral protein (PAP), mirabilis antiviral protein (MAP), Dianthins 32 and 30, abrin, monordin, bryodin, shiga and others known to those of skill in this art (see, e.g., Barbieri et al., Cancer Surveys 7:489-520, 1982, and European published patent application No. 0466 222, incorporated herein by reference, which provide lists of numerous RIPs and their sources; see, also, U.S. Patent No. 5,248,608 to Walsh et al., which provides a RIP from maize).
  • Saporin is the most active and abundant, representing 7% of total seed proteins.
  • Saporin is very stable, has a high isoelectric point, does not contain carbohydrates, and is resistant to denaturing agents, such as sodium dodecyl sulfate (SDS), and a variety of proteases.
  • SDS sodium dodecyl sulfate
  • the amino acid sequences of several saporin-6 isoforms from seeds are known and there appear to be families of saporin RIPs differing in few amino acid residues. Because saporin is a type I RIP, it does not possess a cell-binding chain. Consequently, its toxicity to whole cells is much lower than other toxins, such as ricin and abrin. When internalized by eukaryotic cells, however, its cytotoxicity is 100- to 1000-fold more potent than ricin A chain.
  • the selected cytotoxic agent is derivatized to produce a group reactive with a cysteine on the selected FGF. If derivatization results in a mixture of reactive species, a mono-derivatized form of the cytotoxic agent is isolated and is then conjugated to the mutated FGF.
  • the saporin polypeptides include any of the isoforms of saporin that may be isolated from Saponaria officinalis or related species or modified form that retain cytotoxic activity.
  • modified saporin may be produced by modifying the DNA encoding the protein (see, e.g., International PCT Application Serial No. PCT/US93/05702, filed on June 14, 1993, which is a continuation-in-part of United States Application Serial No. 07/901,718; see, also, copending U.S. Patent Application No. 07/885,242 filed May 20, 1992, and Italian Patent No.
  • the SAP used herein includes any protein that is isolated from natural sources or that is produced by recombinant expression (see, e.g., copending International PCT Application Serial No. PCT/US93/05702, filed on June 14, 1993, which is a continuation-in-part of United States Application Serial No. 07/901,718, filed June 16, 1992; see, also, Example 1, below).
  • DNA encoding SAP or any cytotoxic agent may be used in the recombinant methods provided herein.
  • the DNA may be modified to include cysteine codon.
  • the codon may be inserted into any locus that does not reduce or reduces by less than about one order of magnitude the cytotoxicity of the resulting protein may be selected. Such locus may be determined empirically by modifying the protein and testing it for cytotoxicity in an assay, such as a cell-free protein synthesis assay.
  • the preferred loci in SAP for insertion of the cysteine residue is at or near the N-terminus (within about 10 residues of the N- terminus).
  • Host organisms include those organisms in which recombinant production of heterologous proteins have been carried out and in which the cytotoxic agent, such as saporin is not toxic or of sufficiently low toxicity to permit expression before cell death.
  • cytotoxic agent such as saporin
  • Presently preferred host organisms are strains of bacteria.
  • Most preferred host organisms are strains of E. coli, particularly, BL21(DE3) cells (NOVAGEN, Madison, WI).
  • the DNA encoding the cytotoxic agent such as saporin protein, is introduced into a plasmid in operative linkage to an appropriate promoter for expression of polypeptides in a selected host organism.
  • the presently preferred saporin proteins are saporin proteins that have been modified by addition of a Cys residue or replacement of a non-essential residue at or near the amino- or carboxyl terminus of the saporin with
  • Cys. Saporin such as that of SEQ ID NO. 7 has been modified by insertion of Met-Cys residue at the N-terminus and has also been modified by replacement of the Asn or He residue at positions 4 and 10, respectively (see Example 4).
  • the DNA fragment encoding the saporin may also include a protein secretion signal that functions in the selected host to direct the mature polypeptide into the periplasm or culture medium.
  • the resulting saporin protein can be purified by methods routinely used in the art, • including, methods described hereinafter in the Examples.
  • Methods of transforming suitable host cells, preferably bacterial cells, and more preferably E. coli cells, as well as methods applicable for culturing said cells containing a gene encoding a heterologous protein are generally known in the art. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
  • the DNA construct encoding the saporin protein is introduced into the host cell by any suitable means, including, but not limited to transformation employing plasmids, viral, or bacterial phage vectors, transfection, electroporation, lipofection, and the like.
  • the heterologous DNA can optionally include sequences, such as origins of replication that allow for the extrachromosomal maintenance of the saporin-containing plasmid, or can be designed to integrate into the genome of the host (as an alternative means to ensure stable maintenance in the host).
  • Positive transformants can be characterized by Southern blot analysis (Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) for the site of DNA integration; Northern blots for inducible-promoter-responsive saporin gene expression; and product analysis for the presence of saporin-containing proteins in either the cytoplasm, periplasm, or the growth media.
  • the desired saporin-containing protein is produced by subjecting the host cell to conditions under which the promoter is induced, whereby the operatively linked DNA is transcribed.
  • such conditions are those that induce expression from the E. coli lac operon.
  • the plasmid containing the DNA encoding the saporin-containing protein also includes the lac operator (O) region within the promoter and may also include the lac I gene encoding the lac repressor protein (see, e.g., Muller-Hill et al., Proc. Natl. Acad. Sci. USA 59:1259-12649, 1968).
  • the lac repressor represses the expression from the lac promoter until induced by the addition of IPTG in an amount sufficient to induce transcription of the DNA encoding the saporin- containing protein.
  • the expression of saporin in E. coli is, thus accomplished in a two-stage process. In the first stage, a culture of transformed E. coli cells is grown under conditions in which the expression of the saporin-containing protein within the transforming plasmid, preferably a encoding a saporin, such as described in Example 4, is repressed by virtue of the lac repressor. In this stage cell density increases. When an optimum density is reached, the second stage commences by addition of IPTG, which prevents binding of repressor to the operator thereby inducing the lac promoter and transcription of the saporin-encoding DNA.
  • the promoter is the T7 RNA polymerase promoter, which may be linked to the lac operator and the E. coli host strain includes DNA encoding T7 RNA polymerase operably linked to the lac operator and a promoter, preferably the lacUV5 promoter.
  • the presently preferred plasmid is pET 11a (NOVAGEN, Madison, WI), which contains the T71ac promoter, T7 terminator, the inducible E. coli lac operator, and the lac repressor gene.
  • the plasmid pET 15b (NOVAGEN, Madison, WI), which contains a His-TagTM leader sequence (Seq. ID No.
  • T7 RNA polymerase for use in purification with a His column and a thrombin cleavage site that permits cleavage following purification over the column, the T7-lac promoter region and the T7 terminator, has been used herein for expression of saporin.
  • Addition of IPTG induces expression of the T7 RNA polymerase and the T7 promoter, which is recognized by the T7 RNA polymerase.
  • Transformed strains which are of the desired phenotype and genotype, are grown in fermentors by suitable methods well known in the art. In the first, or growth stage, expression hosts are cultured in defined minimal medium lacking the inducing condition, preferably IPTG.
  • the inducer preferably IPTG
  • IPTG-responsive promoter a promoter region that contains lac operator
  • the resulting saporin-containing protein can be suitably isolated from the other fermentation products by methods routinely used in the art, e.g., using a suitable affinity column as described in Example 1.E-F and 2.D; precipitation with ammonium sulfate; gel filtration; chromatography, preparative flat-bed iso-electric focusing; gel electrophoresis, high performance liquid chromatography (HPLC); and the like.
  • a method for isolating saporin is provided in EXAMPLE 1 (see, also, Lappi et al., Biochem. Biophys. Res. Commun. 729:934-942, 1985).
  • the expressed saporin protein is isolated from either the cytoplasm, periplasm, or the cell culture medium (see, discussion below B.l.b below and see, e.g., EXAMPLE 4 for preferred methods and saporin proteins).
  • Porphyrins are well-known light activatable toxins that can be readily cross- linked to proteins (see, e.g., U.S. Patent No. 5,257,970; U.S. Patent No. 5,252,720; U.S. Patent No. 5,238,940; U.S. Patent No. 5,192,788; U.S. Patent No. 5,171,749; U.S. Patent No. 5,149,708; U.S. Patent No. 5,202,317; U.S. Patent No. 5,217,966; U.S. Patent No. 5,053,423; U.S. Patent No. 5,109,016; U.S. Patent No. 5,087,636; U.S. Patent No.
  • nucleic acids for targeted delivery The conjugates provided herein are also designed to deliver nucleic acids to targeted cells.
  • the nucleic acids include those intended to deliver a cytotoxic signal to a cell or to modify expression of genes in a cell and thereby effect genetic therapy.
  • Examples of nucleic acids include antisense RNA, DNA, ribozymes and other oligonucleotides that bind proteins.
  • the nucleic acids can also include RNA trafficking signals, such as viral packaging sequences (see, e.g., Sullenger et al., Science 262:1566-1569, 1994).
  • the nucleic acids also include DNA molecules that encode intact genes or that encode proteins useful for gene therapy or for cell cytotoxicity. Especially of interest are DNA molecules that encode an enzyme that results in cell death or renders a cell susceptible to cell death upon the addition of another product.
  • saporin is an enzyme that cleaves rRNA and inhibits protein synthesis.
  • Other enzymes that inhibit protein synthesis are especially well suited for the present invention.
  • Other enzymes may be used where the enzyme activates a compound with little or no cytotoxicity into a toxic product.
  • DNA (or RNA) that may be delivered to a cell to effect genetic therapy also includes DNA that encodes tumor-specific cytotoxic molecules, such as tumor necrosis factor, viral antigens and other proteins to render a cell susceptible to anti-cancer agents, and DNA encoding genes, such as the such as the defective gene (CFTR) associated with cystic fibrosis (see, e.g., International Application WO 93/03709, which is based on U.S. Application Serial No. 07/745,900; and Riordan et al., Science 245:1066-1073, 1989), to replace defective genes.
  • CFTR defective gene
  • Nucleic acids and oligonucleotides for use as described herein can be synthesized by any method known to those of skill in this art (see, e.g., Wo 93/01286, which is based on U.S. Application Serial No. 07/723,454; U.S.. Patent No. 5,218,088; U.S. Patent No. 5,175,269; U.S. Patent No. 5,109,124). Identification of oligonucleotides and ribozymes for use as antisense agents is well within the skill in this art. Selection of DNA encoding genes for targeted delivery for genetic therapy is also well within the level of skill of those in this art.
  • Antisense oligonuclotides are designed to resist degradation by endogenous nucleolytic enzymes and include, but are not limited to: phosphorothioate, methylphosphonate, sulfone, sulfate, ketyl, phosphorodithioate, phosphoramidate, phosphate esters, and other such linkages (see, e.g., Agrwal et al., Tetrehedron Lett. 25:3539-3542, 1987; Miller et al., J. Am. Chem. Soc.
  • Antisense oligonucleotides triplex molecules; dumbbell oligonucleotides; DNA; extracellular protein binding oligonucleotides; and small nucleotide molecules
  • Antisense nucleotides are oligonucleotides that specifically bind to mRNA that has complementary sequences, thereby preventing translation of the mRNA (see, e.g., U.S. Patent No. 5,168,053 to Altman et al., U.S. Patent No. 5,190,931 to Inouye, U.S. Patent No. 5,135,917 to Burch; U.S. Patent No. 5,087,617 to Smith and C isel et al., Nucl. Acids Res. 27:3405-3411, 1993, which describes dumbbell antisense oligonucleotides).
  • Triplex molecules refer to single DNA strands that target duplex DNA and thereby prevent transcription (see, e.g., U.S. Patent No. 5,176,996 to Hogan et al., which describes methods for making synthetic oligonucleotides that bind to target sites on duplex DNA).
  • Particularly useful antisense nucleotides and triplex molecules are molecules that are complementary or bind to the sense strand of DNA or mRNA that encodes an oncogene, such as bFGF, int-2, hst-1/K-FGF, FGF-5, hst-2/FGF-6, FGF-8 or protein that promotes unwanted cell proliferation or differentiation. Linkage of such antisense or triplex molecules to the corresponding FGF actor should specifically target tumor cells that express the oncogene.
  • an oncogene such as bFGF, int-2, hst-1/K-FGF, FGF-5, hst-2/FGF-6, FGF-8 or protein that promotes unwanted cell proliferation or differentiation.
  • FGF receptors since many tumors express FGF receptors, other oncogenes, such as p53, c-myc and erb-2, may also be targeted using an FGF, particu ⁇ larly bFGF linked to an antisense oligonucleotide or triplex molecule.
  • FGF FGF, particu ⁇ larly bFGF linked to an antisense oligonucleotide or triplex molecule.
  • Other useful antisense oligonucleotides include those that are specific for IL-8
  • Ribozymes are RNA constructs that specifically cleave messenger RNA. There are at least five classes of ribozymes that are known that are involved in the cleavage and/or ligation of RNA chains. Ribozymes can be targeted to any RNA transcript and can catalytically cleave such transcript (see, e.g., U.S. Patent No. 5,272,262; U.S. Patent
  • the ribozymes may be delivered to the targeted cells, such tumor cells that express an FGF receptor, as DNA encoding the ribozyme linked to a eukaryotic promoter, such as a eukaryotic viral promoter, generally a later promoter, such that upon introduction into the nucleus, the ribozyme will be directly transcribed.
  • the construct will also include a nuclear translocation sequence (NTS; see Table 2, below), generally as part of the growth factor or as part of a linker between the growth factor and linked DNA.
  • NTS nuclear translocation sequence
  • the conjugate In order to deliver the nucleic acid to the nucleus, the conjugate should include an NTS. If the conjugate is designed such that the heparin-binding growth factor and linked DNA is cleaved or dissociated in the cytoplasm, then the NTS should be included in a portion of the linker that remains bound to the DNA, so that, upon internalization, the conjugate will be trafficked to the nucleus.
  • the nuclear translocation sequence may be a heterologous sequence or a may be derived from the selected growth factor. All presently identified members of the FGF family of peptides contain an NTS (see, e.g., International Application WO 91/15229 and Table 2).
  • the conjugate must include a NTS located such that the linked DNA is translocated to the nucleus.
  • a typical consensus NTS sequence contains an amino-terminal proline or glycine followed by at least three basic residues in a array of seven to nine amino acids (see, e.g. Dang et al., J. Biol. Chem. 264:18019-18023, 1989; Dang et al., Mol. Cell. Biol. 5:4049-4058, 1988, and Table 2, which sets forth examples of NTSs and regions of proteins that share homology with known NTSs).
  • Host organisms include those organisms in which recombinant production of heterologous proteins have been carried out, such as, but not limited to, bacteria (for example, E. coli), yeast (for example, Saccharomyces cerevisiae and Pichia pastoris), mammalian cells, insect cells.
  • bacteria for example, E. coli
  • yeast for example, Saccharomyces cerevisiae and Pichia pastoris
  • mammalian cells for example, insect cells.
  • Presently preferred host organisms are strains of bacteria.
  • the DNA construct is introduced into a plasmid for expression in a desired host.
  • the host is a bacterial host.
  • the sequences of nucleotides in the plasmids that are regulatory regions, such as promoters and operators, are operationally associated with one another for transcription.
  • the sequence of nucleotides encoding the growth factor or growth factor-chimera may also include DNA encoding a secretion signal, whereby the resulting peptide is a precursor protein.
  • the resulting processed protein may be recovered from the periplasmic space or the fermentation medium.
  • the DNA plasmids also include a transcription terminator sequence.
  • the promoter regions and transcription terminators are each independently selected from the same or different genes.
  • the plasmids used herein preferably include a promoter in operable association with the DNA encoding the protein or polypeptide of interest and are designed for expression of proteins in a bacterial host. It has been found that tightly regulatable promoters are preferred for expression of saporin. Suitable promoters for expression of proteins and polypeptides herein are widely available and are well known in the art. Inducible promoters or constitutive promoters that are linked to regulatory regions are preferred. Such promoters include, but are not limited to, the T7 phage promoter and other T7-like phage promoters, such as the T3, T5 and SP6 promoters, the tip, lpp, and lac promoters, such as the lacUV5, from E.
  • coli the PI 0 or polyhedron gene promoter of baculovirus/insect cell expression systems (see, e.g., U.S. Patent Nos. 5,243,041, 5,242,687, 5,266,317, 4,745,051, and 5,169,784) and inducible promoters from other eukaryotic expression systems.
  • promoters are inserted in a plasmid in operative linkage with a control region such as the lac operon.
  • Preferred promoter regions are those that are inducible and functional in E. coli.
  • suitable inducible promoters and promoter regions include, but are not limited to: the E. coli lac operator responsive to isopropyl ⁇ -D-thiogalactopyranoside (IPTG; see, et al. Nakamura et al., Cell 75:1109-1117, 1979); the metallothionein promoter metal-regulatory-elements responsive to heavy-metal (e.g., zinc) induction (see, e.g., U.S. Patent No. 4,870,009 to Evans et al.); the phage T71ac promoter responsive to IPTG (see, e.g., U.S. Patent No. 4,952,496; and Studier et al., Meth. Enzymol. 755:60-89, 1990) and the TAC promoter.
  • IPTG isopropyl ⁇ -D-thiogalactopyranoside
  • the plasmids also preferably include a selectable marker gene or genes that are functional in the host.
  • a selectable marker gene includes any gene that confers a phenotype on bacteria that allows transformed bacterial cells to be identified and selectively grown from among a vast majority of untransformed cells.
  • Suitable selectable marker genes for bacterial hosts include the ampicillin resistance gene (Amp r ), tetracycline resistance gene (Tc r ) and the kanamycin resistance gene (Kan r ). The kanamycin resistance gene is presently preferred.
  • the preferred plasmids also include DNA encoding a signal for secretion of the operably linked protein.
  • Secretion signals suitable for use are widely available and are well known in the art. Prokaryotic and eukaryotic secretion signals functional in E. coli may be employed. The presently preferred secretion signals include, but are not limited to, those encoded by the following E. coli genes: ompA, ompT, ompF, ompC, beta- lactamase, and alkaline phosphatase, and the like (von Heijne, J. Mol. Biol. 754:99-105, 1985).
  • the bacterial pelB gene secretion signal (Lei et al., J. Bacteriol.
  • the phoA secretion signal, and the cek2 functional in insect cell may be employed.
  • the most preferred secretion signal is the E. coli ompA secretion signal.
  • Other prokaryotic and eukaryotic secretion signals known to those of skill in the art may also be employed (see, e.g., von Heijne, J. Mol. Biol. 754:99-105, 1985). Using the methods described herein, one of skill in the art can substitute secretion signals that are functional in either yeast, insect or mammalian cells to secrete proteins from those cells.
  • Particularly preferred plasmids for transformation of E. coli cells include the pET expression vectors (see, U.S patent 4,952,496; available from NOVAGEN, Madison, WI; see, also, literature published by Novagen describing the system).
  • Such plasmids include pET 11a, which contains the T71ac promoter, T7 terminator, the inducible E. coli lac operator, and the lac repressor gene; pET 12a-c, which contains the T7 promoter, T7 terminator, and the E. coli ompT secretion signal; and pET 15b (NOVAGEN, Madison, WI), which contains a His-TagTM leader sequence (Seq. ID No. 36) for use in purification with a His column and a thrombin cleavage site that permits cleavage following purification over the column; the T7-lac promoter region and the T7 terminator.
  • pET 11a which contains the T71ac promoter, T7 terminator, the
  • plasmids include the pKK plasmids, particularly pKK 223-3, which contains the TAC promoter, (available from Pharmacia; see, also, Brosius et al., Proc. Natl. Acad. Sci. 57:6929, 1984; Ausubel et al., Current Protocols in Molecular Biology; U.S. Patent Nos. 5,122,463, 5,173,403, 5,187,153, 5,204,254, 5,212,058, 5,212,286, 5,215,907, 5,220,013, 5,223,483, and 5,229,279), which contain the TAC promoter.
  • Plasmid pKK has been modified by replacement of the ampicillin resistance marker gene, by digestion with EcoRI, with a kanamycin resistance cassette with EcoRI sticky ends (purchased from Pharmacia; obtained from pUC4K, see, e.g., Vieira et al. (Gene 79:259-268, 1982; and U.S. Patent No. 4,719,179).
  • Baculovirus vectors such as a pBlueBac (also called pJVETL and derivatives thereof) vector, particularly pBlueBac III, (see, e.g., U.S. Patent Nos.
  • the pBlueBacIII vector is a dual promoter vector and provides for the selection of recombinants by blue/white screening as this plasmid contains the ⁇ -galactosidase gene (lacZ) under the control of the insect recognizable ETL promoter and is inducible with IPTG.
  • a DNA construct iso a baculovirus vector pBluebac III (INVITROGEN, San Diego, CA) and then co- transfected with wild type virus into insect cells Spodoptera frugiperda (sf9 cells; see, e.g., Luckow et al., Bio/technology 6:47-55, 1988, and U.S. Patent No. 4,745,051).
  • plasmids include the pIN-IIIompA plasmids (see, U.S. Patent No. 4,575,013 to Inouye; see, also, Duf aud et al., Meth. Enz. 755:492-507, 1987), such as pIN-IIIompA2.
  • the pIN-IIIompA plasmids include an insertion site for heterologous DNA linked in transcriptional reading frame with four functional fragments derived from the lipoprotein gene of E. coli.
  • the plasmids also include a DNA fragment coding for the signal peptide of the ompA protein of E.
  • the plasmids further include DNA encoding a specific segment of the E. coli lac promoter-operator, which is positioned in the proper orientation for transcriptional expression of the desired polypeptide, as well as a separate functional E. coli lad gene encoding the associated repressor molecule that, in the absence of lac operon inducer, interacts with the lac promoter-operator to prevent transcription therefrom.
  • the DNA fragment is replicated in bacterial cells, preferably in E. coli.
  • the preferred DNA fragment also includes a bacterial origin of replication, to ensure the maintenance of the DNA fragment from generation to generation of the bacteria. In this way, large quantities of the DNA fragment can be produced by replication in bacteria.
  • Preferred bacterial origins of replication include, but are not limited to, the fl-ori and col El origins of replication.
  • Preferred hosts contain chromosomal copies of DNA encoding T7 RNA polymerase operably linked to an inducible promoter, such as the lacUV promoter (see, U.S. Patent No. 4,952,496).
  • Such hosts include, but are not limited to, lysogens E. coli strains HMS174(DE3)pLysS, BL21 (DE3)pLysS, HMS 174(DE3) and BL21 (DE3). Strain BL21 (DE3) is preferred.
  • the pLys strains provide low levels of T7 lysozyme, a natural inhibitor of T7 RNA polymerase.
  • the DNA fragments provided may also contain a gene coding for a repressor- protein.
  • the repressor-protein is capable of repressing the transcription of a promoter that contains sequences of nucleotides to which the repressor-protein binds.
  • the promoter can be derepressed by altering the physiological conditions of the cell. The alteration can be accomplished by the addition to the growth medium of a molecule that inhibits, for example, the ability to interact with the operator or with regulatory proteins or other regions of the DNA or by altering the temperature of the growth media.
  • Preferred repressor-proteins include, but are not limited to the E. coli. lad repressor responsive to IPTG induction, the temperature sensitive cI857 repressor, and the like. The E. coli lad repressor is preferred.
  • DNA encoding full-length bFGF or the bFGF muteins has been linked to DNA encoding the mature saporin protein and introduced into the pET vectors, including pET-1 la and pET-12a expression vectors (NOVAGEN, Madison, WI), for intracellular and periplasmic expression, respectively, of FGF-SAP fusion proteins.
  • the resulting fusion proteins exhibit cytotoxic activity and appear to be at least as potent as the chemically conjugated FGF-SAP preparations.
  • the resulting bFGF-fusion proteins are highly cytotoxic when internalized by targeted cells.
  • linkers In order to increase the serum stability, solubility and/or intracellular concentration of the targeted agent, one or more linkers (are) inserted between the FGF protein and the targeted moiety or the heparin-binding growth factor and the DNA binding domain.
  • linkers include peptide linkers, such as intracellular protease substrates, and chemical linkers, such as acid labile linkers, ribozyme substrate linkers and others.
  • Peptides linkers may be inserted using heterobifunctional reagents, described below, or, preferably, are linked to FGF and other heparin-binding growth factors by linking DNA encoding the substrate to the DNA encoding the protein and expressing the resulting chimera.
  • the DNA encoding the linker can be inserted between the DNA encoding the heparin-binding growth factor protein and the DNA encoding the targeted protein agent.
  • Chemical linkers may be inserted by covalently coupling the linker to the FGF or other growth factor protein and the targeted agent.
  • the heterobifunctional agents described below, may be used to effect such covalent coupling.
  • protease-specific substrates are introduced between the heparin-binding growth factor protein and the targeted moiety.
  • the peptides may be inserted using heterobiofunctional reagents, described below, or, preferably, are linked to heparin-binding growth factor by linking DNA encoding the substrate to the DNA encoding the FGF protein and expressing the resulting chimera.
  • the targeted agent is a protein, such as a RIP
  • the DNA encoding the linker can be inserted between the DNA encoding the heparin-binding growth factor protein and the DNA encoding the targeted protein agent.
  • DNA encoding substrates specific for intracellular proteases has been inserted between the DNA encoding the FGF protein and a targeted agent, such as saporin.
  • a targeted agent such as saporin.
  • Any protease specific substrate see, e.g., O'Hare et al., FEBS 275:200-204,
  • Preferred substrates include those that are specific for proteases that are expressed at higher levels in tumor cells or that are preferentially expressed in the endosome.
  • cathepsin B substrate cathepsin D substrate
  • trypsin substrate trypsin substrate
  • thrombin substrate recombinant subtilisin substrate
  • PheAlaHisTyr SEQ ID NO. 56
  • linkers and linkers that increase solubility of the conjugates are contemplated for use, either alone or with other linkers, such as the protease specific substrate linkers.
  • linkers include, but are not limited to, (Gly 4 Ser) n , (Ser 4 Gly) n and (AlaAlaProAla) n in which n is 1 to 6, preferably 1-4, such as: a. Gly 4 Ser SEQ ID NO:40 CCATGGGCGGCGGCGGCTCTGCCATGG b. (Gly 4 Ser) 2 SEQ ID NO.41
  • reagents include, but are not limited to: N-succinimidyl-3-(2- pyridyldithio)propionate (SPDP; disulfide linker); sulfosuccinimidyl 6-[3-(2- pyridyldithio)propionamido]hexanoate (sulfo-LC-SPDP); succinimidyloxycarbonyl- ⁇ - methyl benzyl thiosulfate (SMBT, hindered disulfate linker); succinimidyl 6-[3-(2- pyridyldithio) propionamidojhexanoate (LC-SPDP); sulfosuccinimidyl 4-(N- maleimidomethyl)cyclohexane-l-carboxylate (sulfo-SMCC); succinimidyl 3-(2- pyridyldithio)butyrate (SPDB; hindered disul
  • linkers should be particularly useful when used in combination with peptide linkers, such as those that increase flexibility.
  • Acid cleavable linkers include, but are not limited to, bismaleimideothoxy propane; and adipic acid dihydrazide linkers (see, e.g., Fattom et al., Infection & Immun. 60:584-589, 1992) and acid labile transferrin conjugates that contain a sufficient portion of transferrin to permit entry into the intracellular transferrin cycling pathway (see, e.g., Welh ⁇ ner et al., J. Biol. Chem. 266:4309-4314, 1991). Conjugates linked via acid cleavable linkers should be preferentially cleaved in acidic intracellular compartments, such as the endosome.
  • Photocleavable linkers are linkers that are cleaved upon exposure to light (see, e.g., Goldmacher et al., Bioconj. Chem. 5:104-107, 1992, which linkers are herein incorporated by reference), thereby releasing the targeted agent upon exposure to light.
  • Photocleavable linkers are linkers that are cleaved upon exposure to light are known (see, e.g., Hazum et al., Pept., Proc. Eur. Pept. Symp., 16th, Brunfeldt, K (Ed), pp.
  • Photobiol 42:231-237, 1985 which describes nitrobenzyloxycarbonyl chloride cross linking reagents that produce photocleavable linkages), thereby releasing the targeted agent upon exposure to light.
  • linkers would have particular use in treating dermatological or ophthalmic conditions and other tissues, such as blood vessels during angioplasty in the prevention or treatment of restenosis, that can be exposed to light using fiber optics.
  • the eye or skin or other body part can be exposed to light, resulting in release of the targeted moiety from the conjugate. This should permit administration of higher dosages of such conjugates compared to conjugates that release a cytotoxic agent upon internalization.
  • Heat sensitive linkers would also have similar applicability.
  • Cytotoxic conjugates with linked targeted agents can be prepared either by chemical conjugation, recombinant DNA technology, or combinations of recombinant expression and chemical conjugation.
  • the methods herein are described with particular reference to bFGF and saporin. It is understood, however, that the same methods may be used prepare and use conjugates of any member of the FGF family with SAP, modified SAP, a nucleic acid binding domain, a nucleic acid or any other targeted agent via linkers as described herein.
  • the FGF protein is linked via one ore more selected linkers or directly to the targeted agent.
  • Chemical conjugation must be used if the targeted agent is other than a peptide or protein, such a nucleic acid or a non- peptide drug.
  • the FGF protein is prepared by any suitable method, including recombinant
  • linker or linkers is (are) linked to the FGF protein by chemical combination, generally relying on an available thiol or amine group on the
  • Heterobifunctional linkers are particularly suited for chemical conjugation.
  • the linker is a peptide linker
  • the FGF and linker can be expressed recombinantly as a fusion protein.
  • the targeted agent is a protein or peptide and the linker is a peptide
  • the entire conjugate can be expressed as a fusion protein.
  • Any protein that is reactive with an FGF receptor may be used herein.
  • any member of the FGF family of peptides or portion thereof that binds to an FGF receptor may be used herein.
  • any member of the FGF family of peptides or portion thereof that binds to an FGF receptor may be used herein.
  • any member of the FGF family of peptides or portion thereof that binds to an FGF receptor may be used herein.
  • any member of the FGF family of peptides or portion thereof that binds to an FGF receptor may be used herein.
  • any member of the FGF family of peptides or portion thereof that binds to an FGF receptor may be used herein.
  • FGF receptor and internalizes a linked agent may be used herein.
  • the protein may be produced recombinantly, produced synthetically or obtained from commercial or other sources.
  • the DNA encoding the FGF may be obtained from any known source or synthesized according to its DNA or amino acid sequences (see, e.g., SEQ ID NOS. 12,
  • any of the proteins reactive with an FGF may be modified as described herein in order to reduce the heterogeneity the resulting preparations of cytotoxic conjugates.
  • the heterogeneity of preparations of FGF protein- containing chemical conjugates and fusion proteins can be reduced by modifying the FGF protein by deleting or replacing a site(s) on the FGF that cause the heterogeneity and or by modifying the targeted agent.
  • sites in FGF are typically cysteine residues that, upon folding of the protein, remain available for interaction with other cysteines or for interaction with more than one cytotoxic molecule per molecule of FGF peptide.
  • cysteine residues do not include any cysteine residue that are required for proper folding of the FGF peptide or for retention of the ability to bind to an FGF receptor and internalize.
  • one cysteine residue that, in physiological conditions, is available for interaction is not replaced because it is used as the site for linking the cytotoxic moiety.
  • the resulting modified FGF is conjugated with a single species of targeted agent.
  • modified FGF polypeptides The polypeptide reactive with an FGF receptor is modified by removing one or more reactive cysteines that are not required for receptor binding, but that are available for reaction with appropriately derivatized cytotoxic agent, so that the resulting FGF protein has only one cysteine residue available for conjugation with the cytotoxic agent. If necessary, the contribution of each cysteine to the ability to bind to FGF receptors may be determined empirically. Each cysteine residue may be systematically replaced with a conservative amino acid change (see Table 1, above) or deleted. The resulting mutein is tested for the requisite biological activity, the ability to bind to FGF receptors and internalize linked cytotoxic moieties.
  • the cysteine residue is not required. Additional cysteines are systematically deleted and replaced and the resulting muteins are tested for activity. In this manner the minimum number and identity of the cysteines needed to retain the ability to bind to an FGF receptor and internalize may be determined. The resulting mutant FGF is then tested for retention of the ability to target a cytotoxic agent to a cell that expresses an FGF receptor and to internalize the cytotoxic agent into such cells. Retention of proliferative activity is indicative, though not definitive, of the retention of such activities. Proliferative activity may be measured by any suitable proliferation assay, such as the assay, exemplified below, that measures the increase in cell number of adrenal capillary endothelial cells.
  • modified or mutant FGFs may exhibit reduced or no proliferative activity, but may be suitable for use herein, if they retain the ability to target a linked targeted agent to cells bearing receptors to which the unmodified FGF binds and result in internalization of the targeted moiety.
  • FGF-1 - FGF-9 may be any of FGF-1 - FGF-9 may be so modified.
  • the complete amino acid sequence of each of FGF-1 - FGF- 9 is known (see, e.g., SEQ ID NO. 24 (FGF-1) and SEQ ID NOS. 26-32 (FGF-3 - FGF-9, respectively). The sequence is examined and cysteine residues are identified. Comparison among the amino acid sequences of FGF-1 -FGF-9 reveals that one Cys is conserved among FGF family of peptides (see Table 3). These cysteine residues may be required for secondary structure and should not be altered.
  • Each of the remaining cysteine residues may be systematically deleted and/or replaced by a serine residue or other residue that would not be expected to alter the structure of the protein.
  • the resulting peptide is tested for biological activity. If the cysteine residue is necessary for retention of biological activity it is not deleted; if it not necessary, then it is preferably replaced with a serine or other residue that should not alter the secondary structure of the resulting protein.
  • cysteine residues from each of FGF-1 - FGF-9 that appear to be essential for retention of biological activity and that should not deleted or replaced are as follows:
  • FGF-1 has cysteines at positions 31, 98 and 132; FGF-2 has cysteines at positions 34, 78, 96 and 101; FGF-3 has cysteines at positions 50 and 115; FGF-4 has cysteines at positions 88 and 155; FGF-5 has cysteines at positions 19, 93, 160 and 202; FGF-6 has cysteines at positions 80 and 147; FGF-7 has cysteines at positions 18, 23, 32, 46, 71, 133 and 137; FGF-8 has cysteines at positions 10, 19, 109 and 127; and FGF-9 has cysteines at positions 68 and 134.
  • FGF-3, FGF-4 and FGF-6 have only two cysteines, for purposes of chemical conjugation, preferably neither cysteine is deleted or replaced, unless another residue, preferably one near either terminus, is replaced with a cysteine. With respect to the other FGF family members, at least one cysteine must remain available for conjugation with the cytotoxic conjugate and probably two cysteines, but at least the cysteine residues set forth in Table 3. A second cysteine may be required to form a disulfide bond. Thus, any FGF peptide that has more than three cysteines is be modified for chemical conjugation by deleting or replacing the other cysteine residues. FGF peptides that have three cysteine residues are modified by elimination of one cysteine, conjugated to a cytotoxic moiety and tested for the ability to bind to FGF receptors and internalize the cytotoxic moiety.
  • cysteine 78 of basic FGF to serine [C78SJTGF) or cysteine 96 to serine ([C96S]FGF) produced two mutants that retain virtually complete proliferative activity of native basic FGF as judged by the ability to stimulate endothelial cell proliferation in culture.
  • the activities of the two mutants and the native protein do not significantly differ as assessed by efficacy or maximal response. Sequence analysis of the modified DNA verified that each of the mutants has one codon for cysteine converted to that for serine.
  • the resulting mutein FGF or unmodified FGF is reacted with a single species of cytotoxic agent to produced.
  • the bFGF muteins have been reacted with a single species of derivatized saporin (mono-derivatized saporin) thereby resulting in monogenous preparations of FGF-SAP conjugates and homogeneous compositions of FGF-SAP chemical conjugates.
  • the resulting chemical conjugate does not aggregate and retains the requisite biological activities.
  • Saporin for chemical conjugation may be produced by isolating the protein from the leaves or seeds of Saponaria officinalis (see, e.g., Example 1) or using recombinant methods and the DNA provided herein or known to those of skill in the art or obtained by screening appropriate libraries (see Examples 1 and 4 below and the discussion in A.2.a(l)-(3) above).
  • the SAP may be derivatized or modified such that it includes a cysteine residue for conjugation to the FGF protein.
  • SAP is derivatized by reaction with SPDP. This results in a heterogeneous population.
  • SAP that is derivatized by SPDP to a level of 0.9 moles pyridine-disulfide per mole of SAP includes a population of non-derivatized, mono-derivatized and di- derivatized SAP.
  • Ribosome-inactivating proteins which are overly derivatized with SPDP, may lose activity because of reaction with sensitive lysines (Lambert et al., Cancer Treat. Res. 57:175-209, 1988).
  • the quantity of non-derivatized SAP in the preparation of the non-purified material can be difficult to judge and this may lead to errors in being able to estimate the correct proportion of derivatized SAP to add to the reaction mixture. Because of the removal of a negative charge by the reaction of SPDP with lysine, the three species, however, have a charge difference. The methods herein rely on this charge difference for purification of mon-derivatized SAP by Mon ⁇ -S cation exchange chromatography. The use of purified mono-derivatized SAP has distinct advantages over the non-purified material.
  • the amount of basic FGF that can react with SAP is limited to one molecule with the mono-derivatized material, and it is seen in the results presented herein that a more homogeneous conjugate is produced. There are still sources of heterogeneity with the mono-derivatized SAP used here.
  • Native SAP as purified from the seed itself is a mixture of four isoforms, as judged by protein sequencing (see, e.g., International PCT Application Serial No. PCT US93/05702 and copending United States Application Serial No. 07/901,718; see, also, Montecucchi et al., Int. J. Pept. Prot. Res. 55:263-267, 1989; Maras et al., Biochem. Internat.
  • DNA provided herein includes a sequence of nucleotides encoding a saporin polypeptide or a modified saporin polypeptide and may include an N-terminal extension sequence linked to the amino terminus of the saporin that encodes a linker so that, if desired, the SAP and linker can be expressed as a fusion protein.
  • Saporin for chemical conjugation may be produced by isolating the protein from the leaves or seeds of Saponaria officinalis (see, e.g., Example 1) or using recombinant methods and the DNA provided herein or known to those of skill in the art or obtained by screening appropriate libraries (see Examples 1 and 4 below and the discussion in A.2.a(l)-(3) above).
  • DNA provided herein includes a sequence of nucleotides encoding a saporin polypeptide and may include an N-terminal extension sequence linked to the amino terminus of the saporin that encodes a linker so that, if desired, the SAP and linker can be expressed as a fusion protein.
  • the DNA molecules provided herein encode saporin that has substantially the same amino acid sequence and ribosome-inactivating activity as that of saporin-6 (SO- 6), including any of four isoforms, which have heterogeneity at amino acid positions 48 and 91 (see, e.g., Maras et al., Biochem. Internat. 27:631-638, 1990, and Barra et al., Biotechnol. Appl. Biochem. 75:48-53, 1991 and SEQ ID NOS. 3-7).
  • Other suitable saporin polypeptides include other members of the multi-gene family coding for isoforms of saporin-type RIP's including SO-1 and SO-3 (Fordham-Skelton et al., Mol.
  • SO-4 which includes the N-terminal 40 amino acids set forth in SEQ ID NO. 33, is isolated from the leaves of Saponaria officinalis by extraction with 0.1 M phosphate buffer at pH 7, followed by dialysis of the supernatant against sodium borate buffer, pH 9, and selective elution from a negatively charged ion exchange resin, such as Mono S (Pharmacia Fine Chemicals, Sweden) using gradient of 1 to 0.3 M. NaCl and first eluting chromatographic fraction that has SAP activity. The second eluting fraction is SO-5.
  • the saporin polypeptides exemplified herein include those having substantially the same amino acid sequence as those listed in SEQ ID NOS. 3-7.
  • the isolation and expression of the DNA encoding these proteins is described in Example 1.
  • muteins of saporin that contain a Cys at or near the amino or carboxyl terminus can be prepared.
  • the saporin instead of derivatizing saporin to introduce a sulfhydryl, the saporin can be modified by the introduction of a cysteine residue into the SAP such that the resulting modified saporin protein reacts with the FGF protein to produce a monogenous cytotoxic conjugate and the conjugate binds to FGF receptors on eukaryotic cells is cytotoxic upon internalization by such cells.
  • Preferred loci for introduction of a cysteine residue include the N-terminus region, preferably within about one to twenty residues from the N-terminus of the cytotoxic agent, such as SAP.
  • DNA encoding SAP has been modified by inserting a DNA encoding Met-Cys (ATG TGT or ATG TGC) at the N-terminus immediately adjacent to the codon for first residue of the mature protein.
  • Muteins in which a cysteine residue has been added at the N-terminus and muteins in which the amino acid at position 4 or 10 has been replaced with cysteine have been prepared by modifying the DNA encoding saporin (see, EXAMPLE 4).
  • the modified DNA may be expressed and the resulting saporin protein purified, as described herein for expression and purification of the resulting SAP.
  • the modified saporin can then be reacted with the modified FGF to form disulfide linkages between the single exposed cysteine residue on the FGF and the cysteine residue on the modified SAP.
  • the resulting preparations of FGF-SAP chemical conjugates are monogenous; compositions containing the conjugates also appear to be free of aggregates.
  • cytotoxic conjugate as a fusion protein by expression of DNA encoding the modified FGF protein linked to DNA encoding the cytotoxic agent, as described below.
  • DNA encoding a fusion of an FGF protein linked to the targeted agent results in a monogenous preparation of cytotoxic conjugates and is suitable for use, when the selected targeting agent and linker are polpypeptides.
  • Preparations containing the fusion proteins may be rendered more homogeneous by modifying the FGF and/or the targeted agent to prevent interactions between each conjugate, such as via unreacted cysteines.
  • FGF peptide that are not required for biological activity are deleted or replaced; and for use in the chemical conjugation methods herein, all except for one of these cysteines, which will be used for chemical conjugation to the cytotoxic agent ,are deleted or replaced.
  • cysteines including each of the cysteine residues set forth in Table 3
  • cysteines set forth in Table 3 are required for retention of the requisite biological activity of the FGF peptide.
  • FGF peptides that have more than two cysteines are modified by replacing the remaining cysteines with serines. The resulting muteins may be tested for the requisite biological activity.
  • FGF peptides such as FGF-3, FGF-4 and FGF-6, that have two cysteines can be modified by replacing the second cysteine, which is not listed in Table 3, and the resulting mutein used as part of a construct containing DNA encoding the cytotoxic agent linked to the FGF-encoding DNA.
  • the construct is expressed in a suitable host cell and the resulting protein tested for the ability to bind to FGF receptors and internalize the cytotoxic agent.
  • conjugates containing bFGF muteins in which Cys 78 and Cys 96 have been replaced with serine residues have been prepared.
  • the resulting conjugates are at least as active as recombinant conjugates that have wild type FGF components and at least as active as chemical conjugates of FGF.
  • the recombinantly produced conjugates are less toxic, and thus, can, if necessary, be administered in higher dosages.
  • DNA encoding the FGF protein is modified so that, upon expression, the resulting FGF portion of the fusion protein does not include any cysteines available for reaction.
  • DNA encoding an FGF polypeptide is linked to DNA encoding a saporin polypeptide.
  • the DNA encoding the FGF polypeptide is modified in order to remove the translation stop codon and other transcriptional or translational stop signals that may be present and to remove or replace DNA encoding the available cysteines.
  • the DNA is then ligated to the DNA encoding the saporin polypeptide directly or via a linker region of one or more codons between the first codon of the saporin and the last codon of the FGF.
  • the size of the linker region is any length as long as the resulting conjugate exhibits cytotoxic activity upon internalization by a target cell.
  • spacer regions of from about one to about seventy-five to ninety codons are preferred.
  • DNA encoding FGF peptides and/or the amino acid sequences FGFs are known to those of skill in this art (see, e.g., SEQ ID NOS. 24-32).
  • DNA may be prepared synthetically based on the amino acid sequence or known DNA sequence of an FGF or may be isolated using methods known to those of skill in the art or obtained from commercial or other sources known to those of skill in this art. For example, DNA encoding virtually all of the FGF family of peptides is known.
  • human aFGF (Jaye et al., Science 255:541-545, 1986), bovine bFGF (Abraham et al., Science 255:545-548, 1986), human bFGF (Abraham et al., EMBO J. 5:2523-2528, 1986; and Abraham et al., Quant. Biol. 57:657-668, 1986) and rat bFGF (see Shimasaki et al., Biochem. Biophys. Res. Comm., 1988, and Kurokawa et al., Nucleic Acids Res. 76:5201, 1988), FGF-3, FGF-7 and FGF-9 are known (see, also, U.S. Patent No.
  • Such DNA may then be mutagenized using standard methodologies to delete or delete and replace any cysteine residues, as describe herein, that are responsible for aggregate formation. If necessary, the identity of cysteine residues that contribute to aggregate formation may be determined empirically, by deleting and/or deleting and replacing a cysteine residue and ascertaining whether the resulting FGF with the deleted cysteine form aggregates in solutions containing physiologically acceptable buffers and salts.
  • any FGF protein in addition to basic FGF (bFGF) and acidic FGF (aFGF), including HST, INT12, FGF-5, FGF-6, KGF(FGF-7), FGF-8, and FGF-9 (see, e.g., Baird et al., Brit. Med. Bull 45:438-452, 1989; Tanaka et al., Proc. Natl. Acad. Sci. USA 59:8928-8932, 1992; Miyamoto et al., Mol. Cell. Biol. 75:4251- 4259, 1993; see, also, the data base, DNA * (July, 1993 release from DNASTAR, Inc.
  • FGF-1 - FGF-9 DNA and amino acid sequences of the FGF family; see SEQ ID NOS. 24-32 for amino acid sequences of FGF-1 - FGF-9, respectively), may be modified and expressed in accord with the methods herein.
  • Ail of the FGF proteins induce mitogenic activity in a wide variety of normal diploid mesoderm-derived and neural crest-derived cells and this activity is mediated by binding to an FGF cell surface receptor followed by internalization. Binding to an FGF receptor followed by internalization are the activities required for an FGF protein to be suitable for use herein.
  • FGF mitogenic activity which reflects the ability to bind to FGF receptors and to be internalized, is the ability to stimulate proliferation of cultured bovine aortic endothelial cells (see, e.g., Gospodarowicz et al., J. Biol. Chem. 257:12266-12278, 1982; Gospodarowicz et al., Proc. Natl. Acad. Sci. USA 75:4120-4124, 1976).
  • the DNA encoding the resulting modified FGF-SAP can be inserted into a plasmid and expressed in a selected host, as described above, to produce monogenous preparations of FGF-SAP and homogeneous compositions containing monogenous FGF-SAP.
  • modified FGF-SAP chimera or modified FGF-cytotoxic agent chimera can be inserted into a single plasmid in operative linkage with one promoter. When expressed, the resulting protein will be an FGF-SAP multimer. Typically two to six copies of the chimera are inserted, preferably in a head to tail fashion, into one plasmid.
  • DNA encoding human bFGF-SAP having SEQ ID NO. 12 has been mutagenized as described in the Examples using splicing by overlap extension (SOE). Another preferred coding region is set forth in SEQ ID NO. 13, nucleotides 1 - 465. In both instances, in preferred embodiments, the DNA is modified by replacing the cysteines at positions 78 and 96 with serine. The codons encoding cysteine residues at positions 78 and 96 of FGF in the FGF-SAP encoding DNA (SEQ ID NO. 12) were converted to serine codons by SOE.
  • Each application of the SOE method uses two amplified oligonucleotide products, which have complementary ends as primers and which include an altered codon at the locus at which the mutation is desired, to produce a hybrid product.
  • a second amplification reaction that uses two primers that anneal at the non-overlapping ends amplify the hybrid to produce DNA that has the desired alteration.
  • Retroviral vectors can only hold a limited length of nucleic acid and can activate oncogenes depending upon the insertion site in the target chromosome. Conditions for electroporation and CaPO4-mediated transfection are harsh and cause much cell death.
  • receptor mediated gene delivery as described herein is a more desirable method of selectively targeting toxic genes into cells that have "more active" receptors or that overexpress the specific receptor on the cell surface.
  • a receptor may be more active because it has a higher rate of internalization or higher cycling rate through the endosome to the cell surface.
  • Advantages of this method over other gene delivery methods include increased specificity of delivery, the absence of nucleic acid length limitations, reduced toxicity, and reduced immunogenicity of the conjugate. These characteristics allow for repeated administration of the material with minimal harm to cells and may allow increased level of expression of the toxic protein.
  • primary cultures can also be treated using this method.
  • Receptor mediated gene delivery is also useful for delivering other types of nucleic acids. Antisense and ribozymes will interfere with specific gene expression in a cell. With these nucleic acids, an inhibitory signal is delivered which may result in cytotoxicity or decreased gene expression without concomitant cytotoxicity.
  • gene delivery can be used to increase gene expression of specific genes.
  • genetic defects may be corrected, or novel proteins expressed to effect a "foreign" biological function on a cell, such as drug sensitivity, capability to bind to a substrate, enzymatic activity, and the like.
  • Specificity of delivery is achieved by coupling a nucleic acid binding domain to a growth factor, either by chemical conjugation or by generating a fusion protein.
  • the growth factor part of the conjugate or fusion confers specificity thus generating a cell- specific nucleic acid delivery conjugate.
  • the choice of the growth factor to use will depend upon the receptor expressed by the target cells.
  • the receptor type of the target cell population may be determined by conventional techniques like antibody staining, PCR of cDNA using receptor-specific primers, and biochemical or functional receptor binding assays. It is preferable that the receptor be cell type specific or have increased expression or activity within the target cell population.
  • the nucleic acid binding domain can be non-specific in its ability to bind nucleic acid or it can be highly specific so that the amino acid residues bind only the desired nucleic acid sequence.
  • Nonspecific binding proteins, polypeptides, or compounds are generally polycations or highly basic. Lys and Arg are basic residues and proteins enriched for these residues are candidate nucleic acid binding domains. Examples of basic proteins include histones, protamines, and repeating units of lysine and arginine.
  • Poly-L-lysine is a well-used nucleic acid binding domain. Polycations, such as spermine and spermidine, are also widely used to bind nucleic acids. Examples of sequence-specific proteins include Sp-1, AP-1, and the rev protein from HIV.
  • nucleic acid binding domains such as AP-1 and Sp-1 can be cloned in tandem, individually, in tandem, or in multiple repeats into a desired region of the growth factor of interest.
  • the domains can be chemically conjugated to the growth factor.
  • the corresponding response elements that bind the domain are incorporated into the nucleic acid molecule to be delivered. Condensation of the nucleic acid and protein will result in specific binding of response element to the nucleic acid binding domain. Even greater specificity of binding may be achieved by identifying and using the minimal amino acid sequence that binds to the nucleic acid of interest. For example, phage display methods can be used to identify amino acids residues of varying length that will bind to specific nucleic acid sequences with high affinity. (See U.S. Patent No. 5,223,409.) The peptide sequence can then be cloned into the ligand as a single copy or multiple copies. Alternatively, the peptide may be chemically conjugated to the ligand.
  • nucleic acid with the conjugated protein will result in a specific binding between the two.
  • conjugated protein may be used to deliver nucleic acids that encode saporin or other toxic proteins into cells that have FGF, VEGF, HBEGF, or other heparin-binding growth factor receptors that are more active in internalization upon binding or over expressed on the cell surfaces.
  • the cDNA encoding the gene is cloned downstream of a mammalian promoter such as SV40, CMV, TK or Adenovirus promoter.
  • promoters of interest may be active in any cell type, active only in a tissue-specific manner, such as ⁇ -crystalline or tyrosinase, or inducible, such as the MMTV LTR.
  • nucleic acid construct containing the therapeutic gene, antisense, ribozyme, or the like is bound onto a nucleic acid binding domain such as Sp-2, AP-1, poly-L- lysine or the like, as described below, which has been chemically conjugated or fused by recombinant means to a heparin-binding growth factor acting as a cell-specific ligand.
  • a nucleic acid binding domain such as Sp-2, AP-1, poly-L- lysine or the like, as described below, which has been chemically conjugated or fused by recombinant means to a heparin-binding growth factor acting as a cell-specific ligand.
  • nucleic acid binding domains interact with the target nucleic acid either in a sequence-specific manner or a nonspecific manner.
  • the NABD binds nucleic acid regardless of the sequence.
  • poly-L-lysine is a basic polypeptide that binds to oppositely charged DNA.
  • Other highly basic proteins or polycationic compounds such as histones, protamines, and spermidine, also bind to nucleic acids in a nonspecific manner.
  • Many proteins have been identified that bind specific sequences of DNA. These proteins are responsible for genome replication, transcription and repair of damaged DNA. The transcription factors regulate gene expression and are a diverse group of proteins.
  • Transcription factors are grouped into one of seven well-established classes based upon the structural motif used for recognition. Other classes or subclasses may eventually be delineated as more factors are discovered and defined. Proteins from those classes or proteins that do not fit within one of these classes, such as SV40 T antigen and p53 may also be used.
  • the major families include helix-turn-helix (HTH) proteins, homeodomains, zinc finger proteins, steroid receptors, leucine zipper proteins, the helix-loop-helix proteins, and ⁇ -sheets.
  • DNA-binding domain delineated for some of them.
  • a gene encoding it may be synthesized if the region is short.
  • the genes may be cloned from the genome or from cDNA libraries using oligonucleotides as probes or primers for polymerase chain reaction methods. Such methods may be found in (Sambrook et al., supra).
  • Helix-turn-helix proteins include the well studied ⁇ Cro protein, ⁇ cl, and E. coli CAP proteins (see, Steitz et al., Proc. Natl. Acad. Sci. USA 79:3097-3100, 1982; Ohlendorf et al., J. Mol. Biol. 169:757-769, 1983).
  • the Lac repressor Kerin et al., J. Mol. Biol. 752:179-182, 1985
  • Trp repressor Scheritz et al., Nature 577:782-786, 1985
  • Members of the homeodomain family include the Drosophila protein Antennapaedia (Qian et al., Cell.
  • Zinc finger proteins include TFIIIA (Miller et al., EMBOJ 4:1609-1614, 1985), Sp-1, zif268 and many others (see, generally Krizek et al., J. Am. Chem. Soc. 775:4518-4523, 1991).
  • Steroid receptor proteins include receptros for steroid hormones, retinoids, vitamin D, thyroid hormones, as well as other compounds. Specific examples include retenoic acid, knirps, progesterone, androgen, glucocosteroid and estrogen receptor proteins.
  • the leucine zipper family was defined by a heptad repeat of leucines over a region of 30 to 40 residues. Specific members of this family include C/EBP, C-fos, c-jun. GCN4, sis-A, and CREB (see, generally O'Shea et al., Science 254:539-544, 1991).
  • the helix- look-helix (HLH) family of proteins appears to have some similarities to the leucine zipper family.
  • Well-known members of this family myoD (Weintraub et al., Science 257:761-766, 1991); c-myg; and AP-2 (Williams and Tijan, Science 257:1067-1071, 1991).
  • the ⁇ -sheet family uses an antiparallel ⁇ -sheet for DNA binding, rather than the more common ⁇ -helix.
  • the family contains the MetT (Phillips, Curr. Opin. Struc. Biol. 7:89-98, 1991), Arc (Breg et al., Nature 546:586-589, 1990) and Mnt repressors.
  • MetT Phillips, Curr. Opin. Struc. Biol. 7:89-98, 1991
  • Arc Breg et al., Nature 546:586-589, 1990
  • Mnt repressors Mnt repressors
  • other motifs are used for DNA binding, such as the cysteine-rich motif in yeast GAL4 repressor, and the GATA factor.
  • viruses contain genes that bind specific sequences.
  • RRE rev responsive element
  • DNA sequences are inserted into the gene III or gene VIII gene of filamentous phage, such as Ml 3.
  • the DNA sequences may be randomly generated or variants of a known DNA- binding domain. Generally, the inserts encode from 6 to 20 amino acids.
  • the target molecule is preferably double-stranded, but single-stranded molecules may also be used.
  • the entire coding region of the DNA molecule is used as the target.
  • elements necessary for transcription that are included for in vivo or in vitro delivery may be present in the target DNA molecule.
  • Recovered bacteriophage are propagated and subsequent rounds of selection may be performed.
  • the final selected phage are propagated and the DNA sequence of the insert is determined.
  • sufficient peptide for use herein may be made either by recombinant means or synthetically, depending on the method of coupling.
  • the peptide may be generated as a tandem array of 2 or more peptides, in order to maximize affinity or binding of multiple DNA molecules to a single polypeptide.
  • DNA-binding domain/peptide that recognizes DNA encoding saporin is isolated.
  • DNA fragments encoding saporin may be isolated from a plasmid containing these sequences.
  • the plasmid FPFS1 contains the entire coding region of saporin. Digestion of the plasmid with Ncol and EcoRI restriction enzymes liberates the saporin specific sequence as a single fragment of approximately 780 bp. This fragment may be purified by any one of a number of methods, such as agarose gel electrophoresis and subsequent elution from the gel.
  • the saporin fragment is fixed to a solid support, such as in the wells of a 96- well plate.
  • a coating a positively charged molecule, may be used to promote D ⁇ A adherence.
  • the phage library is added to the * wells and an incubation period allows for binding of the phage to the D ⁇ A. Unbound phage are removed by a wash, typically containing lOmM Tris, ImM ⁇ DTA, and not containing any salt or low salt concentration. Bound phage are eluted starting at a 0.1 M ⁇ aCl containing buffer. The ⁇ aCl concentration is increased in a step-wise fashion until all the phage are eluted. Typically, phage binding with higher affinity will only be released by higher salt concentrations.
  • Eluted phage are propagated in the bacteria host. Further rounds of selection may be performed to select for a few phage binding with high affinity. The D ⁇ A sequence of the insert in the binding phage is then determined. In addition, peptides having a higher affinity may be isolated by making variants of the insert sequence and subjecting these variants to further rounds of selection.
  • FGF may be conjugated essentially as described in Section C.l above with the substitution of the nucleic acid binding domain for saporin. Unkers, as described in B above, may be incorporated into the chemical conjugates or fusion proteins. a. Preparation of proteins for chemical conjugation
  • FGF, VEGF or HBEGF may be isolated from a suitable source or may be produced using recombinant DNA methodology, discussed below.
  • the heparin-binding growth factor protein is conjugated generally via a reactive amine group or thiol group to the targeted agent or to a linker, which has been or is subsequently linked to the targeted agent.
  • the heparin-binding growth factor protein is conjugated either via its N-terminus, C-terminus, or elsewhere in the polypeptide.
  • the heparin-binding growth factor protein is conjugated via a reactive cysteine residue to the linker or to the targeted agent.
  • the heparin-binding growth factor can also be modified by addition of a cysteine residue, either by replacing a residue or by inserting the cysteine, at or near the amino or carboxyl terminus, within about 20, preferably 10 residues from either end, and preferably at or near the amino terminus.
  • the heparin-binding growth factor protein is modified by mutagenesis to replace reactive cysteines, leaving, preferably, only one available cysteine for reaction.
  • the heparin- binding growth factor protein is modified by deleting or replacing a site(s) on the heparin-binding growth factor that causes the heterogeneity.
  • sites are typically cysteine residues that, upon folding of the protein, remain available for interaction with other cysteines or for interaction with more than one cytotoxic molecule per molecule of heparin-binding growth factor peptide.
  • cysteine residues do not include any cysteine residue that are required for proper folding of the growth factor or for retention of the ability to bind to a heparin-binding growth factor receptor and internalize.
  • cysteine residues For chemical conjugation, one cysteine residue that, in physiological conditions, is available for interaction, is not replaced because it is used as the site for linking the cytotoxic moiety.
  • the resulting modified heparin-binding growth factor is conjugated with a single species of cytotoxic conjugate.
  • the contribution of each cysteine to the ability to bind to heparin- binding growth factor receptors may be determined empirically.
  • Each cysteine residue may be systematically replaced with a conservative amino acid change (see Table 1, above) or deleted.
  • the resulting mutein is tested for the requisite biological activity: the ability to bind to heparin-binding growth factor receptors and internalize linked cytotoxic moieties. If the mutein retains this activity, then the cysteine residue is not required. Additional cysteines are systematically deleted and replaced and the resulting muteins are tested for activity. Each of the remaining cysteine residues may be systematically deleted and/or replaced by a serine residue or other residue that would not be expected to alter the structure of the protein. The resulting peptide is tested for biological activity. If the cysteine residue is necessary for retention of biological activity it is not deleted; if it not necessary, then it is preferably replaced with a serine or other residue that should not alter the secondary structure of the resulting protein.
  • heparin-binding growth factor receptor binds to a heparin-binding growth factor receptor and internalize.
  • modified or mutant heparin-binding growth factors may exhibit reduced or no proliferative activity, but may be suitable for use herein, if they retain the ability to target a linked cytotoxic agent to cells bearing receptors to which the unmodified heparin-binding growth factor binds and result in internalization of the cytotoxic moiety.
  • VEGF 121 contains 9 cysteines and each of VEGF 165, VEGF 189 and VEGF206 contain 7 additional residues in the region not present in VEGF121.
  • the VEGF monomers are preferably linked via non-essential cysteine residues to the linkers or to the targeted agent.
  • VEGF that has been modified by introduction of a cys residue at or near one terminus, preferably the N-terminus is preferred for use in chemical conjugation (see Examples for preparation of such modified VEGF).
  • the VEGF is dimerized prior to linkage to the linker and/or targeted agent.
  • cysteines in the HBEGF polypeptide that are not required for biological activity can be deleted or replaced.
  • all except one of these cysteines which will be used for chemical conjugation to the cytotoxic agent, can be deleted or replaced.
  • Each of the HBEGF polypeptides described herein have six cysteine residues.
  • Each of the six cysteines may independently be replaced and the resulting mutein tested for the ability to bind to HBEGF receptors and to be internalized.
  • the resulting mutein-encoding DNA is used as part of a construct containing DNA encoding the NABD linked to the HBEGF-encoding DNA. The construct is expressed in a suitable host cell and the resulting protein tested for the ability to bind to HBEGF receptors and internalize. As long as this ability is retained the mutein is suitable for use herein.
  • the HBEGF polypeptide is linked via one or more selected linkers or directly to the targeted agent.
  • Chemical conjugation must be used if the targeted agent is other than a peptide or protein, such a nucleic acid or a non-peptide drug.
  • a nucleic acid binding domain is prepared for chemical conjugation essentially as described in C(l)(b) above. Briefly, a protein binding domain may be derivatized with SPDP of other chemical. If the binding domain does not have a Cys residue available for reaction, one can be either inserted or substituted for another amino acid.
  • Mono-derivatized species may be isolated, essentially as described above.
  • DNA encoding a fusion of a heparin-binding growth factor polypeptide linked to the targeted agent results in a more homogeneous preparation of cytotoxic conjugates and is suitable for use, when the selected targeting agent and linker are polypeptides. Aggregate formation can be reduced in preparations containing the fusion proteins by modifying the growth factor, such as by removal of nonessential cysteines in the heparin-binding domain and/or the nucleic acid domain to prevent interactions between each conjugate, such as via unreacted cysteines.
  • DNA encoding the polypeptides may be isolated, synthesized or obtained from commercial sources or prepared as described herein. Expression of recombinant heparin-binding growth factor polypeptides may be performed as described herein; and
  • DNA encoding these polypeptides may be used as the starting materials for the methods herein.
  • DNA encoding FGF, VEGF, and HBEGF polypeptides and or the amino acid sequences of these factors are known to those of skill in this art (see, e.g., SEQ ID NOS. 24-32, 78-95).
  • DNA may be prepared synthetically based on the amino acid sequence or known DNA sequence or may be isolated using methods known to those of skill in the art or obtained from commercial or other sources known to those of skill in this art. For example, suitable methods are described in Examples 3 and 5 for amplifying FGF encoding cDNA from plasmids containing FGF encoding cDNA.
  • cysteine residues may be mutagenized using standard methodologies to delete or replace any cysteine residues that are responsible for aggregate formation.
  • identity of cysteine residues that contribute to aggregate formation may be determined empirically, by deleting and/or deleting and replacing a cysteine residue and ascertaining whether the resulting growth factor with the deleted cysteine forms aggregates in solutions containing physiologically acceptable buffers and salts.
  • Loci for insertion of cysteine residues may also be determined empirically. Generally, regions at or near (within 20, preferably 10 amino acids) the C- or, preferably, the N-terminus are preferred.
  • the DNA construct encoding the conjugate can be inserted into a plasmid and expressed in a selected host, as described above, to produce a recombinant heparin- binding growth factor-NABD conjugate. Multiple copies of the chimera can be inserted into a single plasmid in operative linkage with one promoter. When expressed, the resulting protein will then be a multimer. Typically, two to six copies of the chimera are inserted, preferably in a head to tail fashion, into one plasmid.
  • the nucleic acids suitable for delivery include those described above. Briefly, these include antisense, ribozymes, single-strands that will form triplexes, protein- binding oligonucleotides, and therapeutic genes. Generally, antisense, ribozymes and the like, will be delivered without requiring further propagation or transcription translation, while therapeutic genes will need to be transcribed and translated for effectiveness. However, any of these molecules may be contained on self- replicating vectors for amplification of the nucleic acid. In the case of cytotoxic agents such as the ribosome-inactivating proteins, very few molecules need be present for cell killing. Indeed, only a single molecule of diphtheria toxoid is necessary to kill a cell. In other cases, it may be that propagation or stable maintenance of the construct is necessary to attain sufficient numbers or concentrations of the gene product for effective gene therapy. Examples of replicating and stable eukaryotic plasmids are found in the scientific literature.
  • nucleic acid constructs containing therapeutic genes will also contain elements necessary for transcription and translation.
  • the choice of the promoter will depend upon the cell type to be transformed and the control desired. Promoters can be constitutive or active in any cell type, tissue specific, cell specific or inducible. Examples of contitutive or nonspecific promoters include the SV40 early promoter, the SV40 late promoter, CMV early gene promoter, HIV LTR, and adenovirus promoter.
  • cellular promoters are also amenable within the context of this invention. In particular, cellular promoters for the so-called housekeeping genes are useful. Viral promoters are preferred, because generally they are stronger promoters than cellular promoters.
  • Tissue specific promoters are particularly useful when a particular tissue type is to be targeted for transformation. By using one of this class of promoters, an extra margin of specificity can be attained. For example, when the indication to be treated is ophthalmological, either the alpha-crystalline promoter or gamma-crystalline promoter is preferred. When a tumor is the subject of gene delivery, cellular promoters for specific tumor markers or promoters more active in tumor cells should be chosen. Thus, to transform prostate tumor cells the prostate-specific antigen promoter is especially useful. Similarly, the tyrosinase promoter or tyrosinase-related protein promoter is a preferred promoter for melanoma treatment.
  • the immunoglobulin variable region gene promoter for T lymphocytes, the TCR receptor variable region promoter, for helper T lymphocytes, the CD4 promoter, for liver, the albumin promoter, are but a few examples of tissue specific promoters. Many other examples of tissue specific promoters are readily available to one skilled in the art.
  • Inducible promoters may also be used. These promoters include the MMTV LTR, which is inducible by dexamethasone, metallothionein, which is inducible by heavy metals, and promoters with cAMP response elements, which are inducible by cAMP.
  • the nucleic acid may be delivered to a cell and will remain quiescent until the addition of the inducer. This allows further control on the timing of production of the therapeutic gene.
  • Therapeutic gene products may be noncytotoxic but activate a compound, which is endogenously produced or exogenously applied, from a nontoxic form to a toxic product.
  • HSVTK Gene products that activate compounds to be cytotoxic include HSVTK, which selectively monophosphorylates certain purine arabinosides and substituted pyrimidine compounds. More specifically, exposure of the drugs ganiclovir, acyclovir, or any of their analogues (e.g., FIAU, FIAC, DHPG) to HSVTK, phosphorylates the drug into its corresponding active nucleotide triphosphate form.
  • E. coli guanine phosphoribosyl transferase which converts thioxanthine into toxic thioxanthine monophosphate (Besnard et al., Mol. Cell. Biol.
  • alkaline phosphatase which converts inactive phosphorylated compounds such as mitomycin phosphate and doxorubicin-phosphate to toxic dephosphorylated compounds
  • fungal e.g., Fusarium oxysporum
  • bacterial cytosine deamihase which converts 5-fluorocytosine to the toxic compound 5-fluorouracil
  • carboxypeptidase G2 which cleaves glutamic acid from para-N-bis (2-chloroethyl) aminobenzoyl glutamic acid, creating a toxic benzoic acid mustard
  • Penicillin-V amidase which converts phenoxyacetabide derivatives of doxorubicin and melphalan to toxic compounds
  • promoters that are coordinately regulated with a particular cellular gene may be used.
  • promoters of genes that are coordinately expressed when a particular FGF receptor gene is expressed may be used. Then, the nucleic acid will be transcribed when the FGF receptor, such as FGFR1, is expressed, and not when FGFR2 is expressed.
  • This type of promoter is especially useful when one knows the pattern of FGF receptor expression in a particular tissue, so that specific cells within that tissue may be killed upon transcription of a cytotoxic agent gene without affecting the surrounding tissues.
  • the growth factor/NABD is incubated with the nucleic acid to be delivered under conditions that allow binding of the NABD to nucleic acid. Conditions will vary somewhat depending on the nature of the NABD, but will typically occur in 0.1 M NaCl and 20 mM H ⁇ P ⁇ S or other similar buffer.
  • nucleic acid delivery is the delivery of cytotoxic agents, such as saporin, in a non-toxic form.
  • cytotoxic agents such as saporin
  • the constructs that may be used to effect this strategy, test constructs have been made and assayed.
  • the first construct is a chemical conjugate of FGF and poly-L-lysine.
  • the FGF molecule is a variant in which the cys residue at position 96 has been changed to a serine; only the cys at position 78 is available for conjugation.
  • the poly-L-lysine was derivatized with SPDP and coupled to FGF2-3. This conjugate was used to condense a plasmid able to express the ⁇ -galactosidase gene.
  • the ability of a construct to bind nucleic acid molecules may be assessed by agarose gel electrophoresis.
  • a convenient test is to digest a plasmid, such as pSV ⁇ , with restriction enzymes to yield a variety of fragment sizes.
  • the fragments may be labeled with 32p either by filling in of the ends with DNA polymerase I or phosphorylation of the 5 '-end with polynucleotide kinase following a dephosphorylation using alkaline phosphatase.
  • the plasmid fragments are then incubated with the heparin-binding growth factor/nucleic acid binding domain in a buffered saline solution, such as 20mM HEPES, pH 7.3, 0.1M NaCl.
  • a buffered saline solution such as 20mM HEPES, pH 7.3, 0.1M NaCl.
  • the reaction mixture is electrophoresed on an agarose gel along side similarly digested, but nonreacted fragments. If a radioactive label was incorporated, the gel may be dried and autoradiographed. If no radioactive label is present, the gel may be stained with ethidium bromide and the DNA visualized by excitation with UV. Binding has occurred if the mobility of the fragments is retarded compared to the control. In the example case, the mobility of the fragments was retarded after binding with the FGF2-3/poly-L-lysine conjugate.
  • the conjugate binds to the cell surface receptor and is internalized into the cell. It is not necessary that the heparin- binding growth factor as part of the conjugate retain complete biological activity. For example, FGF is mitogenic on certain cell types. As discussed above, this activity may be desirable or not, depending upon the intended purpose of the nucleic acid delivery. If this activity is desirable or necessary, a proliferation assay is performed. Likewise, for each desirable activity, an appropriate assay is performed. However, for application of the subject invention, the only criteria that need be met are receptor binding and internalization. Receptor binding and internalization may be measured by the following three assays. A competitive inhibition assay of the complex to cells expressing the appropriate receptor is used to demonstrate receptor binding.
  • Receptor binding and internalization may be assayed by measuring ⁇ -gal expression (e.g., enzymatic activity) in cells that have been transformed with a complex of a ⁇ -gal containing plasmid condensed with a heparin-binding growth factor/NABD.
  • This assay is particularly useful for optimizing conditions to give maximal transformation.
  • the optimum ratio of growth factor/NABD to nucleic acid and the amount of DNA per cell may readily be determined by assaying and comparing the enzymatic activity of ⁇ -gal.
  • these first two assays are useful for preliminary analysis and failure to show receptor binding or ⁇ -gal activity does not eliminate a candidate heparin-binding growth factor/NABD conjugate or fusion protein from further analysis.
  • a third, preferred, assay is a cytotoxicity assay performed on cells transformed with a nucleic acid encoding a cytotoxic agent condensed with heparin-binding growth factor/NABD. While, in general, any cytotoxic agent may be used, ribosome-inactivating proteins are preferred and saporin, or another type I RIP, is particularly preferred.
  • a statistically significant reduction in cell number demonstrates the ability of the growth factor/NABD conjugate or fusion to deliver nucleic acids into a cell.
  • FGF-poly-L-lysine was used to condense pSV ⁇ and introduced into COS cells and ABAE, an endothelial cell line. Both of these cell lines express FGF receptors. Maximal ⁇ -galactosidase activity was achieved when 30 ⁇ g of pSV ⁇ per 100 ⁇ g of FGF2-3 -poly-L-lysine was used. Approximately 30% of the cells showed demonstrable staining with X-gal.
  • the transformation was dependent upon the presence of FGF receptors; ⁇ -gal activity was not significantly above background when cells were incubated with pSV ⁇ alone, poly-L-lysine plus pSV ⁇ , or unconjugated FGF2-3, poly-L-lysine, plus pSV ⁇ .
  • the heparin-binding growth factor protein is linked to the nucleic acid either directly or via one or more linkers.
  • Methods for conjugating nucleic acids, at the 5' ends, 3' ends and elsewhere, to the amino and carboxyl termini and other sites in proteins are known to those of skill in the art (for a review see, e.g., Goodchild, (1993) In: Perspectives in Bioconjugate Chemistry, Mears, Ed., American Chemical Society, Washington, D.C. pp. 77-99).
  • proteins have been linked to nucleic acids using ultraviolet irradiation (Sperling et al., Nucleic Acids Res.
  • the reagents N-acetyl-N'-(p-glyoxylylbenzolyl)cystamine and 2- iminothiolane have been used to couple DNA to proteins, such as ⁇ 2macroglobulin ( ⁇ 2M) via mixed disulfide formation (see, Cheng et al., Nucleic Acids Res. 77:659-669, 1983).
  • N-acetyl-N'-(p-glyoxylylbenzolyl)cystamine reacts specifically with nonpaired guaninine residues and, upon reduction, generates a free sulfhydryl group.
  • 2- Iminothiolane reacts with proteins to generate sulfhydryl groups that are then conjugated to the derivatized DNA by an intermolecular disulfide interchange reaction.
  • Any linkage may be used provided that, upon internalization of the conjugate the targeted nucleic acid is active. Thus, it is expected that cleavage of the linkage may be necessary, although it is contemplated that for some reagents, such as DNA encoding ribozymes linked to promoters or DNA encoding therapeutic agents for delivery to the nucleus, such cleavage may not be necessary.
  • Thiol linkages can be readily formed using heterbiofunctional reagents.
  • Amines have also been attached to the terminal 5' phosphate of unprotected oligonucleotides or nucleic acids in aqueous solutions by reacting the nucleic acid with a water-soluble carbodiimide, such as l-ethyl-3'[3-dimethylaminopropyl]carbodiimide (EDC) or N- ethyl-N'(3-dimethylaminopropylcarbodiimidehydrochloride (EDO), in imidazole buffer at pH 6 to produce the 5'phosphorimidazolide.
  • a water-soluble carbodiimide such as l-ethyl-3'[3-dimethylaminopropyl]carbodiimide (EDC) or N- ethyl-N'(3-dimethylaminopropylcarbodiimidehydrochloride (EDO)
  • the resulting solution is then buffered to pH 8.5 by adding, for example about 3 volutes of 100 mM citrate buffer, and adding about 5 ⁇ g - about 20 ⁇ g of an FGF, and agitating the resulting mixture at 40°C for about 48 hours.
  • the unreacted protein may be removed from the mixture by column chromatography using, for example, SEPHADEX G75 (Pharmacia) using 0.1 M ammonium carbonate solution, pH 7.0 as an eluting buffer.
  • the isolated conjugate may be lyopbilized and stored until used.
  • U.S. Patent No. 5,237,016 provides methods for preparing nucleotides that are bromacetylated at their 5' termini and reacting the resulting oligonucleotides with thiol groups. Oligonucleotides derivatized at their 5'-termini bromoacetyl groups can be prepared by reacting 5'-aminohexyl-phosphoramidate oligonucleotides with bromoacetic acid-N-hydroxysuccinimide ester as described in U.S. Patent No. 5,237,016. U.S. Patent No.
  • 5,237,016 also describes methods for preparing thiol- derivatized nucleotides, which can then be reacted with thiol groups on the selected growth factor.
  • thiol-derivatized nucleotides are prepared using a 5'-phosphory- lated nucleotide in two steps: (1) reaction of the phosphate group with imidazole in the presence of a diimide and displacement of the imidazole leaving group with cystamine in one reaction step; and reduction of the disulfide bond of the cystamine linker with dithiothreitol (see, also, Orgel et al., Nucl. Acids Res. 74:651, 1986, which describes a similar procedure).
  • the 5'-phosphorylated starting oligonucleotides can be prepared by methods known to those of skill in the art (see, e.g. , Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, p. 122, 1982).
  • the antisense oligomer or nucleic acid such as a methylphosphonate oligonucleotide (MP-oligomer) may be derivatized by reaction with SPDP or SMPB.
  • the resulting MP-oligomer may be purified by HPLC and then coupled to an FGF, such as an FGF or FGF mutein, modified by replacement of one or more cysteine residues, as described above.
  • the MP-oligomer (about 0.1 ⁇ M) is dissolved in about 40-50 ⁇ l of 1:1 acetonitrile/water to which phosphate buffer (pH 7.5, final concentration 0.1 M) and a 1 mg MP-oligomer in about 1 ml phosphate buffered saline is added.
  • the reaction is allowed to proceed for about 5-10 hours at room temperature and is then quenched with about 15 ⁇ L 0.1 iodoacetamide.
  • the FGF-oligonucleotide conjugates can be purified on heparin sepharose Hi Trap columns (1 ml, Pharmacia) and eluted with a linear or step gradient. The conjugate should elute in 0.6 M NaCl.
  • the resulting plasmids have been and can be transformed into bacterial hosts including BL21, BL231(DE3)+pLYS S, HMS175(DE3), HMS175(DE3)+pLYS S (NOVAGEN, Madison, WI) and N4830(cI857) (see, Gottesman et al., J. Mol. Biol. 740:57-75, 1980, commercially available from PL Biochemicals, Inc., also, see, e.g., U.S. Patent Nos.
  • N4830 harbors a heavily deleted phage lambda prophage carrying the mutant cl857 temperature sensitive repressor and an active N gene.
  • the chemical conjugates exhibit comparable biological activities to the fusion proteins.
  • the FGF conjugates appear to exhibit potent anti-tumor activity.
  • Weekly intravenous injections of bFGF-SAP conjugates (total dose 125 ⁇ g/kg) over four weeks in mice, with established SK-Mel-5 xenografts, resulted in a mean tumor volume that was 49% of the control volume.
  • Modification oi the weekly regiment to include cis-platin (5 mg/kg intraperitoneally once per week on the day following FGF- SAP treatment) resulted in a mean tumor volume at sixty days that was that was 23% of the controls.
  • the combined treatment resulted in complete tumor remission in 10% of the treated mice.
  • bFGF-SAP administration of bFGF-SAP to mice with established PA-1 tumors (human ovarian teratocarcinoma), HT-1197 (human bladder carcinoma), and DU-145 (human prostate carcinoma) resulted in prolonged survival and statistically significant dose-related suppression in tumor growth.
  • Conjugates produced herein have been injected into rats and appear to have low toxicity.
  • the fusions proteins FPFSl, FPFS4, and FPFS5 were injected at a dosage of 75 ⁇ g/kg into groups of 4 rats on 3 successive days (r animals survived at day 4 as compared to 3 and 2 animals).
  • CCFS-SMPB containing a non-cleavable linker
  • CCFS-LC a long chain SPOP linker
  • FPFSl containing a trypsin sensitive linker or CCFS1.
  • CCFS6 containing a trypsin sensitive linker or CCFS1.
  • bFGF-SAP demonstrated an anti-proliferative effect on smooth muscle cells in rabbit balloon injury models of restenosis (see, also, U.S. Patent No. 5,308,622) and on cultured fibroblasts for pterygii.
  • Incubation of subconfluent cultures of pterygial fibroblasts with FGF-SAP yielded a dose and time dependent inhibition of cell growth as assayed by cell number, with a ID5 0 of 50 and 5nM for 0.5 hr and 6 days exposure, respectively.
  • bFGF-SAP was more cytotoxic than 5-fluorouricol and mitomycin C as compared by the ID5 0 values. Therefore, these results suggest that intraoperative application of bFGF-SAP may be an effective adjunct for preventing and minimizing reoccurrence of pterygium after excision.
  • FGF-SAP was also applied to the episcleral surface in eyes of rabbits having posterior lip sclerectomy.
  • the conjunctival blebs in the treated eyes appeared significantly more avascular, although marked surrounding conjunctival hyperemia and chemoses were noted in all treated eyes.
  • conjugates and fusion proteins containing linkers demonstrate activity at least comparable to FPFSl and CCFSl.
  • the fusion protein FPFS4, containing a trypsin sensitive linker and FPFSl or CCFSl were tested for cytotoxicity on BHK-21 cells and SK-Mel-28 cells. In all experiments FPFS4 demonstrated similar cytotoxic activity.
  • FPFS4 In a much larger test FPFS4, FPFS5 (cathepsin B linker), FPFS6 (gly 4 ser linker), FPFS7 ((gly 4 ser) 2 linker), FPFS8 (ser 4 gly linker) and FPFSl 2 (mutein C965 with trypsin linker), CCFS3 and CCFS4 were assayed against FPFSl and CCFSl as standards on SK-MEL 28 and BHK-21 cells.
  • FPFS4, 6, and 12 had ID 5 o values equivalent to FPFSl.
  • FPFS5, 7, and 8 had somewhat higher ID 50 values, generally 2-3 fold higher.
  • the chemical conjugate CCFS4 performed as well or better than CCFSl, while CCFS3 performed equivalently. Taken together, these data suggest that conjugates and fusions containing linkers are at least as efficacious as conjugates without linkers.
  • compositions suitable for topical, local, intravenous and systemic application may be formulated into pharmaceutical compositions suitable for topical, local, intravenous and systemic application.
  • local administration either by topical administration or by injection is preferred.
  • Time release formulations are also desirable.
  • Effective concentrations of one or more of the conjugates are mixed with a suitable pharmaceutical carrier or vehicle.
  • concentrations or amounts of the conjugates that are effective requires delivery of an amount, upon administration, that ameliorates the symptoms or treats the disease.
  • the compositions are formulated for single dosage administration. Therapeutically effective concentrations and amounts may be determined empirically by testing the conjugates in known in vitro and in vivo systems, such as those described here; dosages for humans or other animals may then be extrapolated therefrom.
  • the conjugates herein are formulated into ophthamologically acceptable compositions and are applied to the affected area of the eye during or immediately after surgery.
  • the composition is applied to the cornea; following trabeculectomy the composition is applied to the fistula; and following removal of pterygii the composition is applied to the cornea.
  • the compositions may also be used to treat pterygii.
  • the conjugates are applied during and immediately following surgery and may, if possible be applied post-operatively, until healing is complete.
  • the compositions are applied as drops for topical and subconjunctival application or are injected into the eye for intraocular application.
  • the compositions may also be absorbed to a biocompatible support, such as a cellulosic sponge or other polymer delivery device, and contacted with the affected area.
  • the resulting mixture may be a solution, suspension, emulsion or the like.
  • the form of the resulting mixture depends upon a number of factors, including the intended mode of administration and the solubility of the conjugate in the selected carrier or vehicle.
  • the effective concentration is sufficient for ameliorating the symptoms of the disease, disorder or condition treated and may be empirically determined based upon in vitro and/or in vivo data, such as the data from the mouse xenograft model for tumors or rabbit ophthalmic model. If necessary, pharmaceutically acceptable salts or other derivatives of the conjugates may be prepared.
  • Pharmaceutical carriers or vehicles suitable for administration of the conjugates provided herein include any such carriers known to those skilled in the art to be suitable for the particular mode of administration.
  • the conjugates may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients.
  • the conjugates can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid, semi-liquid or solid form and are formulated in a manner suitable for each route of administration. Preferred modes of administration depend upon the indication treated. Dermatological and ophthalmologic indications will typically be treated locally; whereas, tumors and restenosis, will typically be treated by systemic, intradermal or intramuscular, modes of administration.
  • therapeutically i.e., ophthamologically, effective concentrations and amounts may be determined for each application herein empirically by testing the conjugates in known in vitro and in vivo systems (rabbit and baboon models), such as those described herein; dosages for humans or other animals may then be extrapolated therefrom.
  • Demonstration that the conjugates prevent or inhibit proliferation of serum stimulated corneal keratocytes or fibroblasts explanted from eyes, as shown herein, and demonstration of any inhibition of proliferation of such tissues in rabbits should establish human efficacy.
  • the rabbit eye model is a recognized model for studying the effects of topically and locally applied drugs (see, e.g., U.S. Patent Nos. 5,288,735, 5,263,992, 5,262,178, 5,256,408, 5,252,319, 5,238,925, 5,165,952; see, also, Mirate et al., Curr. Eye Res. 7:491-493, 1981).
  • the conjugate is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. It is understood that number and degree of side effects depends upon the condition for which the conjugates are administered. For example, certain toxic and undesirable side effects are tolerated when treating life- threatening illnesses, such as tumors, that would not be tolerated when treating disorders of lesser consequence.
  • concentration of conjugate in the composition will depend on absorption, inactivation and excretion rates thereof, the dosage schedule, and amount administered as well as other factors known to those of skill in the art.
  • a therapeutically effective dosage should produce a serum concentration of active ingredient of from about 0.1 ng/ml to about 50-100 ⁇ g/ml.
  • the pharmaceutical compositions typically should provide a dosage of from about 0.01 mg to about 100 - 2000 mg of conjugate, depending upon the conjugate selected, per kilogram of body weight per day. For example, for treatment of restenosis a daily dosage of about between 0.05 and 0.5 mg/kg (based on FGF-SAP chemical conjugate or an amount of conjugate provided herein equivalent on a molar basis thereto) should be sufficient.
  • Local application for ophthalmic disorders and dermatological disorders should provide about 1 ng up to 100 ⁇ g, preferably about 1 ng to about 10 ⁇ g, per single dosage administration. It is understood that the amount to administer will be a function of the conjugate selected, the indication treated, and possibly the side effects that will be tolerated.
  • the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data. It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.
  • Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include any of the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent; antimicrobial agents, such as benzyl alcohol and methyl parabens; antioxidants, such as ascorbic acid and sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates and phosphates; and agents for the adjustment of toxicity such as sodium chloride or dextrose.
  • a sterile diluent such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerine, propylene glycol or other synthetic solvent
  • antimicrobial agents such as benzyl alcohol and methyl parabens
  • antioxidants such as ascorbic acid and sodium bisulfit
  • suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • PBS physiological saline or phosphate buffered saline
  • suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • PBS physiological saline or phosphate buffered saline
  • solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.
  • Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art.
  • the conjugates may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application.
  • solutions particularly those intended for ophthalmic use, may be formulated as 0.01% -10% isotonic solutions, pH about 5-7, with appropriate salts.
  • the ophthalmic compositions may also include additional components, such as hyaluronic acid.
  • the conjugates may be formulated as aerosols for topical application (see, e.g., U.S. Patent Nos. 4,044,126, 4,414,209, and 4,364,923).
  • the conjugates may be prepared with carriers that protect them against rapid elimination from the body, such as time release formulations or coatings.
  • Such carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others.
  • the composition may be applied during surgery using a sponge, such as a commercially available surgical sponges (see, e.g., U.S. Patent Nos. 3,956,044 and 4,045,238; available from Week, Alcon, and Mentor), that has been soaked in the composition and that releases the composition upon contact with the eye.
  • compositions may also be applied in pellets (such as Elvax pellets(ethylene-vinyl acetate copolymer resin); about 1- 5 ⁇ g of conjugate per 1 mg resin) that can be implanted in the eye during surgery.
  • the conjugate should be provided in a composition that protects it from the acidic environment of the stomach.
  • the composition can be formulated in an enteric coating that maintains its integrity in the stomach and releases the active compound in the intestine.
  • the composition may also be formulated in combination with an antacid or other such ingredient.
  • Oral compositions will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules.
  • the active compound or compounds can be incorporated with excipients and used in the form of tablets, capsules or troches.
  • Pharmaceutically compatible binding agents and adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder, such as microcrystalline cellulose, gum tragacanth and gelatin; an excipient such as starch and lactose, a disintegrating agent such as, but not limited to, alginic acid and corn starch; a lubricant such as, but not limited to, magnesium stearate; a glidant, such as, but not limited to, colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; and a flavoring agent such as peppermint, methyl salicylate, and fruit flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth and gelatin
  • an excipient such as starch and lactose, a disintegrating agent such as, but not limited to, alginic acid and corn starch
  • a lubricant such as, but not limited to, magnesium stearate
  • the dosage unit form When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil.
  • dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents.
  • the conjugates can also be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like.
  • a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
  • the conjugates may be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye.
  • Such solutions particularly those intended for ophthalmic use, may be formulated as 0.01%-10% isotonic solutions, pH about 5-7, with appropriate salts.
  • Suitable ophthalmic solutions are known (see, e.g., U.S. Patent No. 5,116,868, which describes typical compositions of ophthalmic irrigation solutions and solutions for topical application).
  • Such solutions which have a pH adjusted to about 7.4, contain, for example, 90-100 mM sodium chloride, 4-6 mM dibasic potassium phosphate, 4-6 mM dibasic sodium phosphate, 8-12 mM sodium citrate, 0.5-1.5 mM magnesium chloride, 1.5-2.5 mM calcium chloride, 15-25 mM sodium acetate, 10-20 mM D.L.-sodium ⁇ -hydroxybutyrate and 5-5.5 mM glucose.
  • the active materials can also be mixed with other active materials, that do not impair the desired action, or with materials that supplement the desired action, including viscoelastic materials, such as hyaluronic acid, which is sold under the trademark HEALON (solution of a high molecular weight (MW of about 3 millions) fraction of sodium hyaluronate; manufactured by Pharmacia, Inc. see, e.g., U.S. Patent Nos.
  • HEALON solution of a high molecular weight (MW of about 3 millions) fraction of sodium hyaluronate
  • VISCOAT fluorine-containing (meth)acrylates, such as, lH,lH,2H,2H-hepta- decafluorodecylmethacrylate; see, e.g., U.S. Patent Nos. 5,278,126, 5,273,751 and 5,214,080; commercially available from Alcon Surgical, Inc.), ORCOLON (see, e.g., U.S. Patent Nos.
  • the viscoelastic materials are present generally in amounts ranging from about 0.5 to 5.0%, preferably 1 to 3% by weight of the conjugate material and serve to coat and protect the treated tissues.
  • the compositions may also include a dye, such as methylene blue or other inert dye, so that the composition can be seen when injected into the eye or contacted with the surgical site during surgery.
  • Ophthamologically effective concentrations or amounts of one or more of the conjugates are mixed with a suitable pharmaceutical carrier or vehicle.
  • concentrations or amounts of the conjugates that are effective requires delivery of an amount, upon administration, that prevents or substantially reduces corneal clouding, trabeculectomy closure, or pterygii recurrence.
  • the ophthalmologic indications herein are typically be treated locally either by the application of drops to the affected tissue(s), contacting with a biocompatible sponge that has absorbed a solution of the conjugates or by injection of a composition.
  • the composition will be applied during or immediately after surgery in order to prevent closure of the trabeculectomy, prevent a proliferation of keratocytes following excimer laser surgery, or to prevent a recurrence of pterygii.
  • the composition may also be injected into the affected tissue following surgery and applied in drops following surgery until healing is completed. For example, to administer the formulations to the eye, it can be slowly injected into the bulbar conjunctiva of the eye.
  • Conjugates with photocleavable linkers are among those preferred for use in the methods herein.
  • the eye Upon administration of such composition to the affected area of the eye, the eye is exposed to light of a wavelength, typically visible or UV that cleaves the linker, thereby releasing the cytotoxic agent.
  • the active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as cis-platin for treatment of tumors.
  • the compounds may be packaged as articles of manufacture containing packaging material, one or more conjugates or compositions as provided herein within the packaging material, and a label that indicates the indication for which the conjugate is provided.
  • packaging material one or more conjugates or compositions as provided herein within the packaging material, and a label that indicates the indication for which the conjugate is provided.
  • E. coli strain JA221 (lpp- hdsM+ trpE5 leuB6 lacY recAl F'flacli lac + pro + ]) is publicly available from the American Type Culture Collection (ATCC), Rockville, MD 20852, under the accession number ATCC 33875. (JA221 is also available from the Northern Regional Research Center (NRRL), Agricultural Research Service, U.S. Department of Agriculture, Peoria, IL 61604, under the accession number NRRL B-15211; see, also, U.S. Patent No. 4,757,013 to Inouye; and Nakamura et al., Cell 75:1109-1117, 1979). Strain INVl ⁇ is commercially available from Invitrogen, San Diego, CA. 2. DNA Manipulations
  • restriction and modification enzymes employed herein are commercially available in the U.S. Native saporin and rabbit polyclonal antiserum to saporin were obtained as previously described in Lappi et al., Biochem. Biophys. Res. Comm. 729:934-942. Ricin A chain is commercially available from SIGMA, Milwaukee, WI. Antiserum was linked to Affi-gel 10 (BIO-RAD, Emeryville, CA) according to the manufacturer's instructions. Sequencing was performed using the Sequenase kit of United States Biochemical Corporation (version 2.0) according to the manufacturer's instructions.
  • Saponaria officinalis leaf genomic DNA was prepared as described in Bianchi et al., Plant Mol. Biol. 77:203-214, 1988. Primers for genomic DNA amplifications were synthesized in a 380B automatic DNA synthesizer.
  • the primer corresponding to the "sense" strand of saporin includes an EcoR I restriction site adapter immediately upstream of the DNA codon for amino acid -15 of the native saporin N-terminal leader sequence (S ⁇ Q ID NO. 1): 5'-CTGCAGAATTCGCATGGATCCTGCTTCAAT-3 * .
  • the primer 5'-CTGCAGAATTCGCCTCGTTTGACTACTTTG-3' corresponds to the "antisense" strand of saporin and complements the coding sequence of saporin starting from the last 5 nucleotides of the DNA encoding the carboxyl end of the mature peptide.
  • Use of this primer introduced a translation stop codon and an EcoRI restriction site after the sequence encoding mature saporin.
  • Unfractionated Saponaria officinalis leaf genomic DNA (1 ⁇ l) was mixed in a final volume of 100 ⁇ l containing 10 mM Tris-HCl (pH 8.3), 50 mM KC1, 0.01% gelatin, 2 mM MgCl 2 , 0.2 mM dNTPs, 0.8 ⁇ g of each primer.
  • 2.5 U TaqI DNA polymerase Perkin Elmer Cetus was added and the mixture was overlaid with 30 ⁇ l of mineral oil (Sigma). Incubations were done in a DNA Thermal Cycler (Ericomp).
  • One cycle included a denaturation step (94 OC for 1 min.), an annealing step (60 OC for 2 min.), and an elongation step (72 ⁇ C for 3 min.). After 30 cycles, a 10 ⁇ l aliquot of each reaction was run on a 1.5% agarose gel to verify the correct structure of the amplified product.
  • the amplified DNA was digested with EcoRI and subcloned into EcoR I- restricted M13mpl8 (NEW ENGLAND BIOLABS, Beverly, MA; see, also, Yanisch- Perron et al. (1985), "Improved Ml 3 phage cloning vectors and host strains: Nucleotide sequences of the M13mpl8 and pUC19 vectors", Gene 33:103).
  • Single- stranded DNA from recombinant phages was sequenced using oligonucleotides based on internal points in the coding sequence of saporin (see, Bennati et al., Eur. J. Biochem. 753:465-470, 1989).
  • M13mpl8 derivatives Nine of the M13mpl8 derivatives were sequenced and compared. Of the nine sequenced clones, five had unique sequences, set forth as SEQ ID NOS. 3-7, respectively. The clones were designated M13mpl8-G4, -Gl, -G2, -G7, and -G9. Each of these clones contains all of the saporin coding sequence and 45 nucleotides of DNA encoding the native saporin N-terminal leader peptide.
  • M13 mpl8-G4 containing the SEQ ID NO. 3 clone from Example I.B.2.
  • the ligation was accomplished such that the DNA encoding saporin, including the N- terminal extension, was fused to the leader peptide segment of the bacterial ompA gene.
  • the resulting plasmid pOMPAG4 contains the lpp promoter (Nakamura et al., Cell 75:1109-1117, 1987), the E. coli lac promoter operator sequence (lac O) and the E. coli ompA gene secretion signal in operative association with each other and with the saporin and native N-terminal leader-encoding DNA listed in SEQ ID NO. 3.
  • the plasmid also includes the E. coli lac repressor gene (lac I).
  • the M13 mpl8-Gl, -G2, -G7, and -G9 clones obtained from Example 1.B.2, containing SEQ ID NOS. 4-7 respectively, are digested with EcoR I and ligated into EcoR I digested pIN-IIIompA2 as described for Ml 3 mpl8-G4 above in this example.
  • the resulting plasmids, labeled pOMPAGl, pOMPAG2, pOMPAG7, pOMPA9, are screened, expressed, purified, and characterized as described for the plasmid pOMPAG4.
  • INVl ⁇ competent cells were transformed with pOMPAG4 and cultures containing the desired plasmid structure were grown further in order to obtain a large preparation of isolated pOMPAG4 plasmid using methods described in Example l.A.2.
  • the pOMPAG4 transformed E. coli cells were grown under conditions in which the expression of the saporin-containing protein is repressed by the lac repressor to an O.D. in or at the end of the log phase of growth after which IPTG was added to induce expression of the saporin-encoding DNA.
  • E. coli which corresponds to the supernatant, from the intracellular fraction corresponding to the pellet.
  • the periplasmic fraction from Example l.D. was dialyzed against borate-buffered saline (BBS: 5 mM boric acid, 1.25 mM borax, 145 mM sodium chloride, pH 8.5).
  • BBS borate-buffered saline
  • the dialysate was loaded onto an immunoaffinity column (0.5 x 2 cm) of anti-saporin antibodies, obtained as described in Lappi et al., Biochem. Biophys. Res. Comm., 729:934-942, 1985, bound to Affi-gel 10 and equilibrated in BBS at a flow rate of about 0.5 ml/min.
  • the column was washed with BBS until the absorbance at 280 nm of the flow-through was reduced to baseline.
  • the column containing the antibody bound saporin was eluted with 1.0 M acetic acid and 0.5 ml fractions were collected in tubes containing 0.3 ml of 2 M ammonium hydroxide, pH 10.
  • the fractions were analyzed by ELISA (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
  • the peak fraction of the ELISA was analyzed by Western blotting as described in Example 1.A.2 and showed a single band with a slightly higher molecular weight than native saporin.
  • the fractions that contained saporin protein, as dete ⁇ -nined by the ELISA were then pooled for further purification.
  • the recombinantly produced saporin can be separated by size and one of the five polypeptides used to produce the conjugates.
  • the suspension was left at room temperature for one hour, then frozen in liquid nitrogen and thawed in a 370C bath three times, and then sonicated for two minutes.
  • the lysate was centrifiiged at 11,500 x g for 30 min.
  • the supernatant was removed and stored.
  • the pellet was resuspended in an equal volume of lysis buffer, centrifiiged as before, and this second supernatant was combined with the first.
  • the pooled supernatants were dialyzed versus BBS and chromatographed over the immunoaffinity column as described in Example l.E.l. This material also retained cytotoxic activity.
  • the RIP activity of recombinant saporin was compared to the RIP activity of native SAP in an in vitro assay measuring cell-free protein synthesis in a nuclease-treated rabbit reticulocyte lysate (Promega).
  • Samples of immunoaffinity- purified saporin, obtained in Example l.E.l. were diluted in PBS and 5 ⁇ l of sample was added on ice to 35 ⁇ l of rabbit reticulocyte lysate and 10 ⁇ l of a reaction mixture containing 0.5 ⁇ l of Brome Mosaic Virus RNA, 1 mM amino acid mixture minus leucine, 5 ⁇ Ci of tritiated leucine and 3 ⁇ l of water.
  • Assay tubes were incubated 1 hour in a 30OC water bath. The reaction was stopped by transferring the tubes to ice and adding 5 ⁇ l of the assay mixture, in triplicate, to 75 ⁇ l of 1 N sodium hydroxide, 2.5% hydrogen peroxide in the wells of a Millititer HA 96-well filtration plate (Millipore). When the red color had bleached from the samples, 300 ⁇ l of ice cold 25% trichloroacetic acid (TCA) were added to each well and the plate left on ice for another 30 min. Vacuum filtration was performed with a Millipore vacuum holder. The wells were washed three times with 300 ⁇ l of ice cold 8% TCA. After drying, the filter paper circles were punched out of the 96-well plate and counted by liquid scintillation techniques.
  • TCA trichloroacetic acid
  • the IC 50 for the recombinant and native saporin were approximately 20 pM. Therefore, recombinant saporin-containing protein has full protein synthesis inhibition activity when compared to native saporin.
  • Restriction and modification enzymes were purchased from BRL (Gaithersburg, MD), Stratagene (La Jolla, CA) and New England Biolabs (Beverly, MA). Native SAP was obtained from Saponaria officinalis (see, e.g., Stirpe et al., Biochem. J. 216:617- 625, 1983).
  • the seeds were extracted by grinding in 5 mM sodium phosphate buffer, pH 7.2 containing 0.14 M NaCl, straining the extracts through cheesecloth, followed by centrifugation at 28,00 g for 30 min to produce a crude extract, which was dialyzed against 5 mM sodium phosphate buffer, pH 6.5, centrifiiged and applied to CM-cellulose (CM 52, Whatman, Maidstone, Kent, U.K.).
  • CM-cellulose CM 52, Whatman, Maidstone, Kent, U.K.
  • the CM column was washed and SO-6 was eluted with a 0-0.3 M NaCl gradient in the phosphate buffer. Plasmid isolation, production of competent cells, transformation and Ml 3 manipulations were carried out according to published procedures (Sambrook et al.
  • Cytotoxicity experiments were performed with the Promega (Madison, WI) CellTiter 96 Cell Proliferation/Cytotoxicity Assay.
  • Cell types used were SK-Mel-28, human melanoma Swiss 3T3 mouse fibroblasts (from Dr. Pamela Maher, La Jolla, CA), B16F10, mouse melanoma, PA-1, human ovarian carcinoma (from Dr. Julie Beitz, Roger Williams Hospital, Buffalo RI), and baby hamster kidney (BHK) (obtained from the American Type Culture Collection (ATCC)). 2500 cells were plated per well.
  • Saporin (49 mg) at a concentration of 4.1 mg/ml was dialyzed against 0.1 M sodium phosphate, 0.1 M sodium chloride, pH 7.5. A 1.1 molar excess (563 ⁇ g in 156 ⁇ l of anhydrous ethanol) of SPDP (Pharmacia, Uppsala, Sweden) was added and the reaction mixture immediately agitated and put on a rocker platform for 30 minutes. The solution was then dialyzed against the same buffer. An aliquot of the dialyzed solution was examined for extent of derivatization according to the Pharmacia instruction sheet. The extent of derivatization was 0.86 moles of SPDP per mole of SAP. During these experiments, another batch of SAP was derivatized using an equimolar quantity of SPDP in the reaction mixture with a resulting 0.79 molar ratio of SPDP to SAP.
  • Derivatized SAP (32.3 mg) was dialyzed in 0.1 M sodium borate, pH 9.0 and applied to a Mono S 16/10 column equilibrated with 25 mM sodium chloride in dialysis buffer. A gradient of 25 mM to 125 mM sodium chloride in dialysis buffer was run to elute SAP and derivatized SAP. The flow rate was 4.0 ml min. and 4 ml fractions were collected. Aliquots of fractions were assayed for protein concentration (BCA Protein Assay, Pierce Chemical, Chicago, IL) and for pyridylthione released by reducing agent. Individual fractions (25 to 37) were analyzed for protein concentration and pyridyl- disulfide concentration.
  • the initial eluting peak was composed of SAP that is approximate!) di-derivatized; the second peak is mono-derivatized and the third peak shows no derivatization.
  • the di-derivatized material accounts for 20% of the three peaks; the second accounts for 48% and the third peak contains 32%.
  • Material from the second peak was pooled and gave an average ratio of pyridyl-disulfide to SAP of 0.95. Fraction 33, which showed a divergent ratio of pyridine-2-thione to protein, was excluded from the pool.
  • E. coli strains BL21(DE3), BL21(DE3)pLysS, HMS174(DE3) and HMS 174(DE3)pLysS were purchased from NOVAGEN, Madison, WI.
  • Plasmid pFC80, described below, has been described in the WIPO International Patent Application No. WO 90/02800, except that the bFGF coding sequence in the plasmid designated pFC80 herein has the sequence set forth as SEQ ID NO. 12, nucleotides 1-465.
  • the plasmids described herein may be prepared using pFC80 as a starting material or, alternatively, by starting with a fragment containing the CII ribosome binding site (SEQ ID NO. 15) linked to the FGF-encoding DNA (SEQ ID NO. 12).
  • E. coli strain JA221 (lpp- hdsM+ trpE5 leuB6 lacY recAl F'[lacl ⁇ lac + pro + ]) is publicly available from the American Type Culture Collection (ATCC), Rockville, MD 20852, under the accession number ATCC 33875. (JA221 is also available from the Northern Regional Research Center (NRRL), Agricultural Research Service, U.S. Department of Agriculture, Peoria, IL 61604, under the accession number NRRL B-15211; see, also, U.S. Patent No. 4,757,013 to Inouye; and Nakamura et al., Cell 75:1109-1117, 1979). Strain INVl ⁇ is commercially available from Invitrogen, San Diego, CA. 2. DNA Manipulations
  • the restriction and modification enzymes employed here are commercially available in the U.S. Native SAP, chemically conjugated bFGF-SAP and rabbit polyclonal antiserum to SAP and FGF were obtained as described in Lappi et al., Biochem. Biophys. Res. Comm. 729:934-942, 1985, and Lappi et al., Biochem. Biophys., Res. Comm. 160:917-923, 1989.
  • the pET System Induction Control was purchased from NOVAGEN, Madison, WI.
  • the sequencing of the different constructions was done using the Sequenase kit of United States Biochemical Corporation (version 2.0).
  • a Nco I restriction site was introduced into the SAP-encoding DNA the M13mpl8-G4 clone, prepared as described in Example l.B.2. by site-directed mutagenesis method using the Amersham In v/tro-mutagenesis system 2.1.
  • the oligonucleotide employed to create the Nco I restriction site was synthesized using a
  • Plasmid pFC80 is a derivative of pDS20 (see, e.g., Duester et al., Cell 30:855-864, 1982; see, also, U.S. Patent Nos. 4,914,027, 5,037,744, 5,100,784, and 5,187,261; see, also, PCT International Application No. WO 90/02800; and European Patent Application No.
  • Plasmid pKG1800 includes the 2880 bp EcoR I-Pvw II of pBR322 that contains the contains the ampiciUin resistance gene and an origin of replication.
  • Plasmid pFC80 was prepared from pDS20 by replacing the entire galK gene with the FGF-encoding DNA of S ⁇ Q ID NO. 12, inserting the trp promoter (S ⁇ Q ID NO. 14) and the bacteriophage lambda CII ribosome binding site (S ⁇ Q. ID No. 15; see, e.g., Schwarz et al., Nature 272:410, 1978) upstream of and operatively linked to the FGF-encoding DNA.
  • the Trp promoter can be obtained from plasmid pDR720 (Pharmacia PL Biochemicals) or synthesized according to S ⁇ Q ID NO. 14.
  • Plasmid pFC80 contains the 2880 bp EcoR 1-Bam ⁇ I fragment of plasmid pSD20, a synthetic Sal l-Nde I fragment that encodes the Trp promoter region (S ⁇ Q ID NO. 14): EcoR I
  • the FGF-encoding DNA was removed from pFC80 by treating it as follows.
  • the pFC80 plasmid was digested by Hga l and Sai l, which produces a fragment containing the CII ribosome binding site linked to the FGF-encoding DNA.
  • the resulting fragment was blunt ended with Klenow's reagent and inserted into M13mpl8 that had been opened by Sma l and treated with alkaline phosphatase for blunt-end ligation.
  • an insert in the ORI minus direction was mutagenized using the Amersham kit, as described above, using the following oligonucleotide (SEQ ID NO. 9): GCTAAGAGCGCCATGGAGA.
  • SEQ ID NO. 9 contains one nucleotide between the FGF carboxy terminal serine codon and a Nco I restriction site; it replaced the following wild type FGF encoding DNA having SEQ ID NO. 10:
  • FGFM13 The resulting mutant derivative of M13mpl8, lacking a native stop codon after the carboxy terminal serine codon of bFGF, was designated FGFM13.
  • the mutagenized region of FGFM13 contained the correct sequence (SEQ ID NO. 11).
  • Plasmid pFS92 (also designated PZ1A)
  • Plasmid FGFM13 was cut with Nco I and Sac I to yield a fragment containing the CII ribosome binding site linked to the bFGF coding sequence with the stop codon replaced.
  • the M13mpl8 derivative mpNG4 containing the saporin coding sequence was also cut with restriction endonucleases Nco I and Sac I, and the bFGF coding fragment from FGFM13 was inserted by ligation to DNA encoding the fusion protein bFGF-SAP into the M13mpl 8 derivative to produce mpFGF-SAP, which contains the CII ribosome binding site linked to the FGF-SAP fusion gene.
  • the sequence of the fusion gene is set forth in SEQ ID NO. 12 and indicates that the FGF protein carboxy terminus and the saporin protein amino terminus are separated by 6 nucleotides (SEQ ID NOS. 12 and 13, nts 466-471) that encode two amino acids Ala Met.
  • Plasmid mpFGF-SAP was digested with Ma I and EcoR I and the resulting fragment containing the bFGF-SAP coding sequence was isolated and ligated into plasmid p ⁇ T-l la (available from NOVAGEN, Madison, WI; for a description of the plasmids see U.S. Patent No. 4,952,496; see, also, Studier et al., Meth. Enz. 755:60-89, 1990; Studier et al., J. Mol. Biol. 759:113-130, 1986; Rosenberg et al., Gene 56:125- 135, 1987) that had also been treated with EcoR I and Xba I. The resulting plasmid was designated pFS92. It was renamed PZ1 A.
  • Plasmid pFS92 (or PZ1A) contains DNA the entire basic FGF protein (S ⁇ Q ID NO. 12), a 2-amino acid long connecting peptide, and amino acids 1 to 253 of the mature SAP protein. Plasmid pFS92 also includes the CII ribosome binding site linked to the FGF-SAP fusion protein and the T7 promoter region from p ⁇ T-1 la. E. coli strain BL21(D ⁇ 3)pLysS (NOVAGEN, Madison WI) was transformed with pFS92 according to manufacturer's instructions and the methods described in Example 2.A.2. b.
  • Plasmid PZlB Plasmid pFS92 was digested with EcoR I, the ends repaired by adding nucleoside triphosphates and Klenow DNA polymerase, and then digested with Nde I to release the FGF-encoding DNA without the CII ribosome binding site. This fragment was ligated into p ⁇ T 11a, which had been BamH I digested, treated to repair the ends, and digested with Nde I. The resulting plasmid was designated PZlB. PZlB includes the T7 transcription terminator and the p ⁇ T- 11 a ribosome binding site.
  • E. coli strain BL21(D ⁇ 3) (NOVAGEN, Madison WI) was transformed with PZlB according to manufacturer's instructions and the methods described in Example 2.A.2.
  • Plasmid PZ1C Plasmid PZ1C was prepared from PZlB by replacing the ampiciUin resistance gene with a kanamycin resistance gene. d. Plasmid PZID
  • Plasmid pFS92 was digested with EcoR I and Nde I to release the FGF-encoding DNA without the CII ribosome binding site and the and the ends were repaired. This fragment was ligated into p ⁇ T 12a, which had been BamH I digested and treated to repair the ends. The resulting plasmid was designated PZID.
  • PZID includes DNA encoding the OMP T secretion signal operatively linked to DNA encoding the fusion protein.
  • K coli strains BL21(D ⁇ 3), BL21(DE3)pLysS, HMS174(DE3) and HMS174(DE3)pLysS were transformed with PZID according to manufacturer's instructions and the methods described in Example 2.A.2.
  • bFGF-SAP fusion protein recombinant bFGF- SAP protein
  • BL21(DE3)pLysS from an overnight culture (1 :100 dilution) that were obtained according to Example 2.B.
  • Cells were grown at 37°C in an incubator shaker to an OD 600 of 0.7.
  • IPTG Sigma Chemical, St. Louis, MO
  • IPTG Sigma Chemical, St. Louis, MO
  • the pellet was resuspended in lysis solution (45-60 ml per 16 g of pellet; 20 mM TRIS, pH 7.4, 5 mM EDTA, 10% sucrose, 150 mM NaCl, lysozyme, 100 ⁇ g/ml, aprotinin, 10 ⁇ g/ml, leupeptin, 10 ⁇ g/ml, pepstatin A, 10 ⁇ g/ml and 1 mM PMSF) and incubated with stirring for 1 hour at room temperature. The solution was frozen and thawed three times and sonicated for 2.5 minutes.
  • the suspension was centrifiiged at 12,000 X g for 1 hour; the resulting first-supernatant was saved and the pellet was resuspended in another volume of lysis solution without lysozyme.
  • the resuspended material was centrifiiged again to produce a second-supernatant, and the two supernatants were pooled and dialyzed against borate buffered saline, pH 8.3.
  • LB medium containing ampiciUin 100 ⁇ g/ml were inoculated with a fresh glycerol stock of PZID.
  • Cells were grown at 30°C in an incubator shaker to an OD 600 of 0.7 and stored overnight at 4°C. The following day the cells were pelleted and resuspended in fresh LB medium (no ampiciUin). The cells were divided into 5 1 -liter batches and grown at 30°C in an incubator shaker to an OD ⁇ of 1.5.
  • IPTG SIGMA CHEMICAL, St. Louis, MO
  • the cells are grown in medium containing kanamycin (50 ⁇ g/ml) in place of ampiciUin.
  • LB medium containing ampiciUin 100 ⁇ g/ml; LB AMP 100 medium
  • LB AMP 100 medium Two hundred and fifty mis of LB medium containing ampiciUin (100 ⁇ g/ml; LB AMP 100 medium) were inoculated with a fresh glycerol stock of PZlB. Cells were grown at 30°C in an incubator shaker to an OD ⁇ o of 0.7 and stored overnight at 4°C. The following day the cells were pelleted and resuspended in fresh LB medium (no ampiciUin). The cells were used to inoculate a 1 liter batch of LB medium and grown at 30°C in an incubator shaker to an OD 600 of 1.5. IPTG (SIGMA CHEMICAL, St.
  • Example 2.C. was applied to HiTrap heparin-Sepharose column (Pharmacia, Uppsala, Sweden) equilibrated with 0.15 M NaCl in lO mM TRIS, pH 7.4 (buffer A). The column was washed: first with equilibration buffer; second with 0.6 M NaCl in buffer A; third with 1.0 M NaCl in buffer A; and finally eluted with 2 M NaCl in buffer A into 1.0 ml fractions. Samples were assayed by the ELISA method.
  • the anti-SAP and anti-FGF antisera bound to a protein with an approximate molecular weight of 48,000 kd, which corresponds to the sum of the independent molecular weights of SAP (30,000) and bFGF (18,000).
  • Cytotoxicity experiments were performed with the Promega (Madison, WI) CellTiter 96 Cell Proliferation/Cytotoxicity Assay. About 1,500 SK-Mel-28 cells (available from ATCC), a human melanoma cell line, were plated per well in a 96 well plate in 90 ⁇ l HDMEM plus 10% FCS and incubated overnight at 37°C, 5% CO 2 . The following morning 10 ⁇ l of media alone or 10 ⁇ l of media containing various concentrations of the rbFGF-SAP fusion protein, basic FGF or saporin were added to the wells. The plate was incubated for 72 hours at 37°C.
  • the number of living cells was determined by measuring the incorporation and conversion of the commonly available dye MTT supplied as a part of the Promega kit. Fifteen ⁇ l of the MTT solution was added to each well, and incubation was continued for 4 hours. Next, 100 ⁇ l of the standard solubilization solution supplied as a part of the Promega kit was added to each well. The plate was allowed to stand overnight at room temperature and the absorbance at 560 nm was read on an ELISA plate reader (Titertek Multiskan PLUS, ICN, Flow, Costa Mesa, CA).
  • the chemical FGF-SAP conjugate has an ID 50 of 0.3 nM
  • the bFGF-SAP fusion protein has a similar ID J0 of 0.6 nM
  • unconjugated SAP which is unable to bind to the cell surface, has an ID 50 of 200 nM. Therefore, when internalized, the bFGF-SAP fusion protein appears to have approximately the same cytotoxic activity as the chemically conjugated FGF-SAP.
  • SAP is modified by addition of a cysteine residue by at the N-terminus-encoding portion of the DNA or the addition of a cysteine at position 4 or 10.
  • the resulting saporin can then reacted with an available cysteine on an
  • FGF FGF or reacted with a linker or a linker attached to an FGF to produce conjugates that are linked via the added Cys or Met-Cys on saporin.
  • Modified SAP has prepared by modifying DNA encoding the saporin by inserting DNA encoding Met-Cys or Cys at position -1 or by replacing the He or the Asp codon within 10 or fewer residues of the N-terminus.
  • the resulting DNA has been inserting into pETl la and pET15b and expressed in BL21 cells.
  • the resulting saporin proteins are designated FPSl (saporin with Cys at -1), FPS2 (saporin with Cys at position 4) and FPS3 (saporin with Cys at position 10).
  • a plasmid that encodes FPSl and that has been for expression of FPSl has been designated PZ50B.
  • Plasmids that encode FPS2 and that have been used for expression of FPS2 have been designated PZ51B (pETl la-based plasmid) and PZ51E (petl5b-based plasmid). Plasmids that encode FPS3 and that have been used for expression of FPS3 have been designated PZ52B (pETl la-based plasmid) and PZ52E (petl5b-based plasmid).
  • Plasmid PZlB (designated PZ1B1) described in Example 2 was used as the DNA template.
  • Primer #2 - Antisense primer complements the coding sequence of saporin spanning nucleotides 547-567 of SEQ ID NO. 12 and contains a BamHl site
  • PZIBI DNA was amplified by PCR as follows using the above primers.
  • PZlB DNA (1 ⁇ l) was mixed in a final volume of 100 ⁇ l containing lO mM Tris-HCl (pH 8.3), 50 mM KC1, 0.01% gelatin, 2 mM MgCl 2 , 0.2 mM dNTPs, 0.8 ⁇ g of each primer.
  • 2.5 U TaqI DNA polymerase (Boehringer Mannheim) was added and the mixture was overlaid with 30 ⁇ l of mineral oil (Sigma). Incubations were done in a DNA Thermal Cycler (Ericomp).
  • One cycle included a denaturation step (94°C for 1 min.), an annealing step (60°C for 2 min.), and an elongation step (72°C for 3 min.). After 35 cycles, a 10 ⁇ l aliquot of each reaction was run on a 1.5% agarose gel to verify the correct structure of the amplified product.
  • the amplified DNA was gel purified and digested with Ndel and BamHl and subcloned into Ndel and - ⁇ HI-digested pZlBl. This digestion and subcloning step removed the FGF-encoding DNA and 5' portion of SAP up to the BamHl site at nucleotides 555-560 (SEQ ID NO. 12) and replaced this portion with DNA encoding a saporin molecule that contains a cysteine residue at position -1 relative to the start site of the native mature SAP protein. The resulting plasmid is designated pZ50Bl.
  • constructs were designed to introduce a cysteine residue at position 4 or 10 of the native protein by replacing the isoleucine residue at position 4 or the asparagine residue at position 10 with cysteine.
  • the bacterial strains were Novablue and BL21(DE3) (NOVAGEN, Madison, WI).
  • SAP was amplified by polymerase chain reaction (PCR) from the parental plasmid pZlB 1 encoding the FGF-SAP fusion protein.
  • Primer #2 - Antisense primer complements the coding sequence of saporin spanning nucleotides 547-567 of SEQ ID NO. 12 and contains a BamHl site (SEQ ID NO. 35): CAGGTTTGGATCCTTTACGTT.
  • the PCR conditions was performed as described above, using the following cycles: denaturation step 94°C for 1 minute, annealing for 2 minutes at 60°C, and extension for 2 minutes at 72°C for 35 cycles.
  • the amplified DNA was gel purified, digested with Ndel and BamHl, and subcloned into Ndel and BamHl digested pZlBl. This digestion removed the FGF and 5' portion of SAP (up to the newly added BamHl) from the parental FGF-SAP vector (pZlBl) and replaced this portion with a SAP molecule containing a CYS at position 4 or 10 relative to the start site of the native mature SAP protein.
  • the resulting plasmids are designated pZ51Bl and pZ52Bl, respectively.
  • the initial step in this construction was the mutagenesis of the internal BamHl site at nucleotides 555-560 (SEQ ID NO. 12) in pZlBl by PCR using a sense primer corresponding to nucleotides 543-570 (SEQ ID NO. 12) but changing the G at nucleotide 555 (the third position in the Lys codon) to an A.
  • the complement of the sense primer was used as the antisense primer.
  • the PCR reactions were conducted as in B above.
  • One ⁇ l of the resulting PCR product was used in a second PCR reaction using the same sense oligonucleotide as in B., above, in order to introduce a Ndel site and a Cys codon onto the 5' end of the saporin-encoding DNA.
  • the antisense primer was complementary to the 3' end of the saporin protein and encoded a BamHl site for cloning and a stop codon (SEQ ID NO. 37):
  • the resulting plasmid was digested with Ndel/BamHl and inserted into pET15b (NOVAGEN, Madison, WI), which has a His-TagTM leader sequence (SEQ ID NO. 36), that had also been digested Ndel/BamHl.
  • SAP-Cys-4 and Sap-Cys-10 mutants were similarly inserted into pET15b using SEQ ID NOS. 76 and 77, respectively, as the sense primers and SEQ ID NO. 37 as the antisense primer.
  • DNA encoding unmodified SAP (Example 1) can be similarly inserted into a petl5b or petl lA and expressed as described below for the modified SAP-encoding DNA.
  • BL21(DE3) cells were transformed with the resulting plasmids and cultured as described in Example 2, except that all incubations were conducted at 30°C instead of
  • Lysis buffer (20 mM NaPO 4 , pH 7.0, 5 mM EDTA, 5 mM EGTA, 1 mM DTT, 0.5 ⁇ g/ml leupeptin, 1 ⁇ g/ml aprotinin, 0.7 ⁇ g/ml pepstatin) was added to the rSAP cell paste (produced from pZ50Bl in BL21 cells, as described above) in a ratio of 1.5 ml buffer/g cells. This mixture was evenly suspended via a Polytron homogenizer and passed through a microfluidizer twice.
  • the resulting lysate was centrifiiged 50,000 rpm for 45 min.
  • the supernatant was diluted with SP Buffer A (20 mM NaPO 4 , 1 mM EDTA, pH 7.0) so that the conductivity was below 2.5 mS/cm.
  • the diluted lysate supernatant was then loaded onto a SP-Sepharose column, and a linear gradient of 0 to 30% SP Buffer B (1 M NaCl, 20 mM NaPO 4 , 1 mM EDTA, pH 7.0) in SP Buffer A with a total of 6 column volumes was applied. Fractions containing rSAP were combined and the resulting rSAP had a purity of greater than 90%.
  • a buffer exchange step was used here to get the SP eluate into a buffer containing 50 mM NaBO 3 , 1 mM EDTA, pH 8.5 (S Buffer A). This sample was then applied to a Resource S column (Pharmacia, Sweden) pre-equilibrated with S Buffer A. Pure rSAP was eluted off the column by 10 column volumes of a linear gradient of 0 to 300 mM NaCl in SP Buffer A. The final rSAP was approximately 98% pure and the overall yield of rSAP was about 50% (the amount of rSAP in crude lysate was determined by ELISA).
  • the seeds were extracted by grinding in 5 mM sodium phosphate buffer, pH 7.2 containing 0.14 M NaCl, straining the extracts through cheesecloth, followed by centrifugation at 28,00 g for 30 min to produce a crude extract, which was dialyzed against 5 mM sodium phosphate buffer, pH 6.5, centrifiiged and applied to CM-cellulose (CM 52, Whatman, Maidstone, Kent, U.K.).
  • CM-cellulose CM 52, Whatman, Maidstone, Kent, U.K.
  • the CM column was washed and SO-6 was eluted with a 0-0.3 M NaCl gradient in the phosphate buffer.
  • Plasmid pFC80 containing the basic FGF coding sequence, was a gift of
  • Plasmid pFC80 has been described in the WIPO International Patent Application No. WO 90/02800 and co-pending International PCT Application Serial No. PCT/US93/05702, which are herein incorporated in their entirety by reference.
  • the sequence of DNA encoding bFGF in pFC80 is that set forth in copending International PCT Application Serial No. PCT/US93/05702 and in SEQ ID NO. 12.
  • the construction of pFC80 is set forth above in Example 2.
  • Horseradish peroxidase labeled anti-IgG was used as the second antibody as described (Davis, L., Dibner et al. (1986) Basic Methods in Molecular Biology, p. 1, Elsevier Science Publishing Co., New York).
  • Cysteine to serine substitutions were made by oligonucleotide-directed mutagenesis using the Amersham (Arlington Heights, IL) in vz ' tro-mutagenesis system 2.1. Oligonucleotides encoding the new amino acid were synthesized using a 380B automatic DNA synthesizer (Applied Biosystems, Foster City, CA).
  • the oligonucleotide used for in vitro mutagenesis of cysteine 78 was AGGAGTGTCTGCTAACC (SEQ ID NO. 16), which spans nucleotides 225-241 of
  • E. coli strain JM109 and single plaques were picked and sequenced for verification of the mutation.
  • the FGF mutated gene was then cut out of Ml 3, ligated into the expression vector pFC80, which had the non-mutated form of the gene removed, and transformed into E. coli strain JM109.
  • Single colonies were picked and the plasmids sequenced to verify the mutation was present. Plasmids with correct mutation were then transformed into the E. coli strain FICE 2 and single colonies from these transformations were used to obtain the mutant basic FGFs.
  • An excellent level of expression approximately 20 mg per liter of fermentation broth, was achieved.
  • Cells were grown overnight in 20 ml of LB broth containing 100 ⁇ g/ml ampiciUin. The next morning the cells were pelleted and transferred to 500 ml of M9 medium with 100 ⁇ g/ml ampiciUin and grown for 7 hours.
  • the cells were pelleted and resuspended in lysis solution (10 mM TRIS, pH 7.4, 150 mM NaCl, lysozyme, 10 ⁇ g/mL, aprotinin, 10 ⁇ g/mL, leupeptin, lO ⁇ g/mL, pepstatin A, lO ⁇ g/mL and 1 mM PMSF; 45-60 ml per 16 g of pellet) and incubated while stirring for 1 hour at room temperature. The solution was frozen and thawed three times and sonicated for 2.5 minutes.
  • lysis solution 10 mM TRIS, pH 7.4, 150 mM NaCl, lysozyme, 10 ⁇ g/mL, aprotinin, 10 ⁇ g/mL, leupeptin, lO ⁇ g/mL, pepstatin A, lO ⁇ g/mL and 1 mM PMSF; 45-60 ml per 16 g of pellet
  • Extract volumes 40 ml were diluted to 50 ml with lO mM TRIS, pH 7.4 (buffer A). Pools were loaded onto a 5 ml Hi-Trap heparin- Sepharose column (Pharmacia, Uppsala, Sweden) equilibrated in 150 mM sodium chloride in buffer A. The column was washed with 0.6 M sodium chloride and 1 M sodium chloride in buffer A and then eluted with 2 M sodium chloride in buffer A.
  • Cytotoxicity experiments were performed with the Promega (Madison, WI) CellTiter 96 Cell Proliferation/Cytotoxicity Assay.
  • Cell types used were SK-Mel-28, human melanoma Swiss 3T3 mouse fibroblasts (from Dr. Pamela Maher, La Jolla, CA), B16F10, mouse melanoma, PA-1, human ovarian carcinoma (from Dr. Julie Beitz, Roger Williams Hospital, Buffalo RI), and baby hamster kidney (BHK) [obtained from the American Type Culture Collection (ATCC)]. 2500 cells were plated per well.
  • [C78S]FGF or [C96S]FGF (1 mg; 56 nmol) that had been dialyzed against phosphate-buffered saline was added to 2.5 mg mono-derivatized SAP (a 1.5 molar excess over the basic FGF mutants) and left on a rocker platform overnight. The next morning the ultraviolet-visible wavelength spectrum was taken to determine the extent of reaction by the release of pyridylthione, which adsorbs at 343 nm with a known extinction coefficient. The ratio of pyridylthione to basic FGF mutant for [C78SJFGF was 1.05 and for [C96S]FGF was 0.92.
  • reaction mixtures were treated identically for purification in the following manner: reaction mixture was passed over a HiTrap heparin-Sepharose column (1 ml) equilibrated with 0.15 M sodium chloride in buffer A at a flow rate of 0.5 ml/min. The column was washed with 0.6 M NaCl and 1.0 M NaCl in buffer A and the product eluted with 2.0 M NaCl in buffer A. Fractions (0.5 ml) were analyzed by gel electrophoresis and absorbance at 280 nm. Peak tubes were pooled and dialyzed versus 10 mM sodium phosphate, pH 7.5 and applied to a Mono.-S 5/5 column equilibrated with the same buffer.
  • Coomassie staining and Western blotting of the purified proteins showed a prominent band at a molecular weight of about 48,000, corresponding to the combined molecular weights of SAP and bFGF.
  • a much lighter band at a slightly lower molecular weight was detected and attributed to the described mobility of an artifact produced by the high isoelectric point (10.5) (Gelfi et al., J. Biochem. Biophys. Meth. 75:41-48, 1987) of SAP that causes a smearing in SDS gel electrophoresis (see, e.g., Lappi et al., Biochem. Biophys. Res. Commun. 729:934-942, 1985).
  • the rSAP and [C96S]FGF were each treated with 10 mM dithiothreitol (DTT), incubated for 1 h at room temperature, and the DTT was removed by gel filtration in conjugation buffer (0.1 M NaPO 4 , 100 NaCl and 1 mM EDTA, pH 7.5). A 100-fold molar excess of DTNB was added to the rSAP, incubated for 1 h at room temperature. Unreacted DTNB was removed by gel filtration. The [C96S]FGF was added to DTNB-treated SAP (3:1 molar ratio of [C96S]FGF:SAP) and incubated at room temperature for about 1 hr or for 16 hrs at 4°C.
  • DTT dithiothreitol
  • the mixture was loaded on heparin sepharose in 10 mM NaPO 4 , 1 mM EDTA, pH 6 and the conjugate and free [C96S]FGF were eluted with 2 M NaCl in 10 mM NaPO 4 , 1 mM EDTA, pH 6.
  • the free [C96S]FGF was removed by gel filtration on Sephacryl SI 00 (Pharmacia). The resulting conjugate was designated CCFS4.
  • Heterogeneous FGF-SAP (CCFSl) is very cytotoxic to SK-MEL-28 cells, human melanoma cells, with an ED J0 of approximately 8 ng/ml.
  • the mutant FGF-SAPs are also potently cytotoxic to these cells.
  • [C78S]FGF-SAP and [C96S]FGF-SAP each have an ED 50 comparable to the heterogeneous chemically conjugates, indicting that mutant FGFs are able to internalize SAP to virtually the same extent as the heterogeneous FGF-SAP.
  • CCFS4 was tested in the in vitro cytotoxicity assay and its activity is at least as good to the wild-type chemical conjugate (CCFSl). .
  • Plasmid PZlB (designated PZIBI) described in Example 2 was used as the DNA template.
  • the primers were prepared as follows: (2) Primers
  • Primer #4 - Antisense primer to spanning the Ncol site of FGF in pZIB (corresponding to nucleotides 456-485 of SEQ ID NO. 12) GTGATTGATGTGACCATGGCGCTCTTAGCA (SEQ ID NO. 21).
  • PZIBI DNA 100 ng was mixed (final volume of 100 ⁇ l upon addition of the Taq polymerase) with primer #1 (50 ⁇ M); primer #2 (50 ⁇ M), lO mM Tri-HCl (pH 8.3), 50 mM KC1, 0.01% gelatin, 2 mM MgCl 2 , 0.2 mM dNTPs.
  • primer #3 50 ⁇ M
  • primer #4 50 ⁇ M
  • Each reaction mixture was heated to 95°C for 5 min, 0.5 U TaqI DNA polymerase (1 ⁇ l; Boehringer Mannheim) was added and the mixture was overlaid with 100 ⁇ l of mineral oil (Perkin Elmer Cetus). Incubations were done in a DNA Thermal Cycler (Ericomp). Each cycle included a denaturation step (95°C for 1 min.), an annealing step (60°C for 1.5 min.), and an elongation step (75°C for 3 min.). After 20 cycles, the reaction mixture was incubated at 75°C for 10 minutes for a final elongation. The products were resolved on a 2% agarose gel and DNA of the correct size (247 bp and 250 bp) was purified. The ends were repaired by adding nucleoside triphosphates and Klenow DNA polymerase.
  • the resulting reaction mixture was heated to 95°C for 5 min, 0.5 U TaqI DNA polymerase (1 ⁇ l; Boehringer Mannheim) was added and the mixture was overlaid with 100 ⁇ l of mineral oil (Perkin Elmer Cetus). Incubations were done in a DNA Thermal Cycler (Erricomp). Each cycle included a denaturation step (95°C for 1 min.), an annealing step (60°C for 1.5 min.), and an elongation step (75°C for 3 min.), followed, after 20 cycles, by a final elongation step at 75°C for 10 minutes. The amplified product was resolved on a 1.5% agarose gel and the correct size fragment (460 bp), designated FGFC78S-SAP was purified.
  • Erricomp DNA Thermal Cycler
  • FGFC78S-SAP-encoding DNA 100 ng was mixed (final volume of 100 ⁇ l upon addition of the Taq polymerase) with primer #1 (50 ⁇ M); primer #5 (50 ⁇ M), lO mM Tri-HCl (pH 8.3), 50 mM KC1, 0.01% gelatin, 2 mM MgCl 2 and 0.2 mM dNTPs.
  • primers #4 and #6 50 ⁇ M final concentration of each were used instead of primers #1 and #5.
  • Each reaction mixture was heated to 95°C for 5 min, 0.5 U TaqI DNA polymerase (1 ⁇ l; Boehringer Mannheim) was added and the mixture was overlaid with 100 ⁇ l of mineral oil (Perkin Elmer Cetus).
  • Incubations were done in a DNA Thermal Cycler (Ericomp). Each cycle included a denaturation step (95 °C for 1 min.), an annealing step (60°C for 1.5 min.), and an elongation step (75°C for 3 min.) for 20 cycles, followed by a final elongation step at 75 °C for 10 minutes.
  • the products were resolved on a 2% agarose gel and DNA of the correct size (297 bp and 190 bp) was purified. The ends were repaired by adding nucleoside triphosphates and Klenow DNA polymerase.
  • FPFS4 recombinant FGFC78/96S-SAP fusion proteins
  • the cells were divided into 5 1-liter batches and grown at 30°C in an incubator shaker to an OD 600 of 1.5.
  • IPTG SIGMA CHEMICAL, St. Louis, MO
  • kanamycin 50 ⁇ g/ml
  • the cytotoxicity of the mutein FGF-SAP produced from PZ2B1 was assessed on SK MEL 28 cells and was at least equivalent to the activity of the wild type FGF-SAP chemical conjugate, and recombinant FGF-SAP produced from PZ 1 B 1.
  • oligos in which the sense strand encodes a protease substrate have been synthesized either using a cyclone machine (Millipore, MA) according the instructions provided by the manufacturer, or were made by Midland Certified Reagent Co. (MIDLAND, TX)or by National Biosciences, INC. (MN). The following oligos have been synthesized and introduced into constructs encoding bFGF- SAP.
  • Cathepsin B substrate linker 5'- CCATGGCCCTGGCCCTGGCCCTGGCCCTGGCCCTGGCCATGG SEQ ID NO:38
  • ATC GAA GGT CGT SEQ ID NO. 54 He Glu gly Arg
  • the complementary oligos were annealed by heating at 95°C for 15 min., cooled to room temperature, and then incubated at 4°C for a minute to about an hour.
  • the oligos were digested with Ncol and ligated overnight, at a
  • Bacteria ( ⁇ ovablue ( ⁇ OVAGE ⁇ , Madison, WI) were transformed with ligation mixture (1 ⁇ l) and plated on LB-amp or LB-Kan, depending upon the plasmid).
  • Colonies were selected, clones isolated and sequenced to determine orientation of the insert. Clones with correct orientation were used to transform strain expression strain
  • BL21(DE3) ( ⁇ OVAGE ⁇ , Madison WI). Glycerol stocks were generated from single transformed colonies. The transformed strains were cultured as described in Example 2 and fusion proteins with linkers were expressed.
  • exemplary fusion proteins containing cathepsin B substrate (FPFS9), cathepsin D substrate (FPFS5), Gly 4 Ser (FPFS7), (Gly 4 Ser) 2 (FPFS8), trypsin substrate (FPFS6), (Ser 4 Gly) 4 (FPFS12) and (Ser 4 Gly) 2 (FPFSl 1) linkers, respectively, are set forth in SEQ ID ⁇ OS. 45-51 (see, also, Table 4).
  • DNA encoding the conjugates set forth above and summarized in Table 4 have been expressed in BL21 cells as described above for PZIBI using plasmids prepared as described above and summarized in TABLE 5.
  • EXAMPLE 8 ANTIPROLIFERATIVE ACTIVITY OF BASIC FIBROBLAST GROWTH FACTOR-SAPORIN MITOTOXIN IN CULTURED KERATOCYTES
  • PRK excimer laser photorefractive keratectomy
  • bFGF-SAP basic fibroblast growth factor- saporing
  • saporin a conjugate of bFGF and the ribosome-inactivation protein, saporin
  • Rabbit keratocytes cell lines were established by primary explant culture from
  • Keratocyte proliferation was inhibited by 3 hours exposure to bFGF-SAP in a dose-dependent manner. The indicated that short-term application of bFGF-SAP may be useful in limiting keratocyte proliferation following excimer laser surgery.
  • keratocytes cell lines were established by primary explant culture from New Zealand white rabbits. Keratocytes were incubated with 11 different concentrations (5 x 10- 12 M- 1 x 10- 6 M) of bFGF-SAP (FPFSl), bFGF-SAP (CCFSl), FGF, SAP and FGF SAP for 48 hours and analyzed for their effects on keratocyte proliferation.
  • FPFSl bFGF-SAP
  • CCFSl bFGF-SAP
  • FGF bFGF-SAP
  • SAP and FGF SAP FGF had little effect.
  • This experiment was repeated with a 3 hour exposure time to the conjugates. The results were qualitatively similar. Higher concentrations of conjugate were required to achieve inhibition of proliferation.
  • Keratocytes were serum starved and then serum stimulated in order to ascertain the effects of the conjugates on proliferating keratocytes.
  • the serum stimulated kertocytes were incubated with varying (1 x 10- 8 M - 1 x 10- 4 M) of bFGF-SAP (FPFSl), bFGF-SAP (CCFSl), FGF, and SAP for 3 hours.
  • FPFSl bFGF-SAP
  • CCFSl bFGF-SAP
  • FGF and SAP for 3 hours.
  • CCFSl inhibited cell proliferation in a dose dependent manner with an ID 50 of between about 1 and 10 nM
  • FPFSl inhibited cell proliferation in a dose dependent manner with an ID 50 of between about 1 and 10 nM
  • FGF appeared to stimulate cell proliferation, and SAP slightly inhibited cell proliferation.
  • a sample size of 15 rabbits, male and female, divided into 3 groups according to the surgical technique used, is sufficient to detect a statistically significant difference among the groups at p ⁇ 0.05, if there is a treatment benefit.
  • Wild-type chemical conjugate bFGF-SAP was supplied in Dulbecco's phosphate buffered saline (PBS) at a concentration of 1.0 mg/ml.
  • Fusion protein bFGF-SAP in E. coli was supplied in Dulbecco's PBS at a concentration of 9.0 mg/ml.
  • Basic FGF was supplied in Dulbecco's PBS at a concentration of 1.0 mg/ml.
  • Saporin was supplied in Dulbecco's PBS (0.01 M Phosphate, 0.14 M NaCl, pH 7.4) at a concentration of 1.0 mg/ml. All dilutions were made in Dulbecco's PBS with 0.1% bovine serum albumin (NB 1005-18).
  • mice Female Balb/c nu/nu athymic mice (Roger Williams Hospital Animal Facility, Buffalo, RI), 8-12 weeks old, were maintained in an aseptic environment. Sixty- three animals were selected for the study, and body weights ranged from 25-30 grams the day prior to dosing.
  • PA-1 human ovarian teratocarcinoma cells were obtained from the American Type Culture Collection (Rockville, MD; ATCC accession no. CRL1572) were grown in modified Eagle's medium supplemented with 10% fetal calf serum. (6) Tumor Implantation
  • mice received a subcutaneous injection of tumor cells (approximately 2 x 10 6 PA-1 human ovarian teratocarcinoma cells/mouse) in the right rear flank.
  • tumor cells approximately 2 x 10 6 PA-1 human ovarian teratocarcinoma cells/mouse
  • Dosing material was prepared by mixing the test material with appropriate volumes of PBS/0.1% BSA to achieve the final doses. (9) Dosing Procedures
  • mice received four weekly IV injection (250-300 ul) into the tail vein on days 5, 12, 19 and 26 with day 1 designated as the day that the tumor cells were injected into the mice. Doses were individualized for differences in body weight.
  • tumors were measured prior to injection of the test material and at bi-weekly intervals for 61 days. Tumors from animals in all groups were approximately 55-60 mm 3 on day 5 when treatment began.
  • the vehicle-treated group (PBS with 0.1% BSA) showed a 50-fold increase in tumor volume over the 61 days of the study.
  • the other control groups demonstrated similar levels of tumor growth: the SAP control group showed a 30-fold increase, the bFGF control group showed a 50-fold increase, and the bFGF plus SAP group showed a 50-fold increase in tumor volume. In all the control groups, the rate of growth of the tumor was fairly consistent over the 61 -day period.
  • the 0.5 ⁇ g/kg/week fusion protein bFGF-SAP group showed significant suppression of tumor growth to day 26 when tumors were at 71% of controls. There was no statistical difference between tumor volumes in the 0.5 ⁇ g/kg/week wild-type chemical conjugate bFGF-SAP and fusion protein bFGF-SAP groups at 30 days. A statistical comparison of the two 50 ⁇ g/kg/week treatment groups was not done because there were only two surviving animals in the fusion protein bFGF-SAP group.
  • A. Summary Wild-type chemical conjugate bFGF-SAP and fusion protein bFGF-SAP were evaluated for anti-proliferative activity against smooth muscle cells in a rat balloon injury model of restenosis. Thirty-six male Sprague-Dawley rats (300 to 350 g) were randomized into six treatment groups (n 6/treatment); animals underwent balloon denudation of the left carotid artery and then received three doses of wild-type chemical conjugate bFGF-SAP (75 ug/kg/day), fusion protein bFGF-SAP (1.25, 5.0, 25, 75 ug/kg/day), or vehicle (PBS with 0.1% BSA) via tail vein injections at 5 min, 24 hr, and 48 hr. Animals were sacrificed six days postdenudation surgery, and carotid arteries were sectioned and analyzed for intimal smooth muscle cell number.
  • the six animals in the high dose fusion protein bFGF-SAP group either died or were sacrificed before the end of the study. Deaths also occurred in the 25 ug/kg/day fusion protein bFGF-SAP group; two of the six animals survived. Three of the animals in the wild-type chemical conjugate bFGF-SAP group (75 ug/kg/day) showed thrombosis at the balloon injury site upon necropsy and were not included in the calculated average. Anti-proliferative activity was seen with wild-type chemical conjugate bFGF-
  • SAP and fusion protein bFGF-SAP intimal smooth muscle cell number was decreased relative to controls with 75 ug/kg/day wild-type chemical conjugate bFGF-SAP and with 1.25 And 25 ug/kg/day fusion protein bFGF-SAP.
  • Wild-type chemical conjugate bFGF-SAP was supplied in Dulbecco's phosphate buffered saline (PBS) at a concentration of 1.0 mg/ml.
  • PBS Dulbecco's phosphate buffered saline
  • the left common carotid artery was denuded of endothelium by intraluminal passage of a 2F Fogarty balloon.
  • the animals were sacrificed with an overdose of sodium pentobarbital.
  • Evans blue 0.5 ml, 5% in saline
  • the animals were perfusion-fixed by placing a catheter in the abdominal aorta and infusing 4% paraformadehyde in phosphate buffer (0.1 M, pH 7.3) at physiological pressure and flow for 4 min.
  • Segments from the denuded carotid arteries were embedded in paraffin and counter-stained with hematoxylin, and the total number of intimal smooth muscle cells was determined by light microscopy. 4. Determination of intimal smooth muscle cell number
  • Dosing material was prepared by mixing the test material with appropriate volumes of PBS/0.1% BSA to achieve the final doses.
  • Poly- L- lysine was dissolved in 0.1 M NaPO4, 0.1 M NaCl, 1 mM EDTA, pH 7.5 (buffer A) at 3 mg/ml. Approximately 30 mg of poly-L-lysine solution was mixed with 0.187 ml of 3 mg/ml SPDP in anhydrous ethanol resulting in a molar ratio of SPDP/poly-L-lysine of 1.5. The derivitization reaction was carried out at room temperature for 30 minutes. The reaction mixture was then dialyzed against 4 liters of Buffer A for 4 hours at room temperature.
  • CCFL A sample of CCFL was electorphoresed on SDS/PAGE under reducing conditions. The protein migrated at the same molecular weight as FGF. Under non- reducing conditions the conjugate did not enter the gel because of its high charge density.
  • a proliferation assay was performed to determine if the conjugation procedure reduced the ability of FGF2-3 ability to stimulate mitogenesis. The results revealed that CCFL is equivalent to FGF2-3 in stimulating proliferation.
  • ⁇ -galactosidase encoding plasmid nucleic acid pSV ⁇ were mixed with 100 ⁇ g of CCFL in 20mM HEPES pH7.3, 0.1 M NaCl. The reaction was incubated for 1 hour at room temperature, nucleic acid binding to the FGF-lysine conjugate was confirmed by gel mobility shift assay using 32p_ ⁇ a b e led SV40- ⁇ -gal nucleic acid cut with PVHI restriction endonuclease.
  • SV40 ⁇ -gal nucleic acid was digested with Pvwl restriction endonucleases; ends were labeled by filling in 32pdNTPs with DNA polymerase I (Klenow fragment).
  • a proliferation assay was performed to determine if the condensed nucleic acid had an effect the ability of CCFL to stimulate mitogenesis.
  • the proliferation assay showed that only the highest dose of nucleic acid (200ug) had an inhibitory effect on proliferation as compared to FGF2-3 and CCFL.
  • the CCFL/nucleic acid mixture was introduced into COS cells and an endothelial cell line, ABAE, both of which express FGF receptors. The cells were subsequently assayed for b-galactosidase enzyme activity.
  • COS and ABEA cells were grown on coverslips and incubated with the different ratios of CCFL:DNA for 48 hours. The cells were then fixed and stained with X-gal. Maximal ⁇ -galactosidase enzyme activity was seen when 30 ug of pSV ⁇ per 100 ug of FGF2-3-polylysine conjugate was used.
  • Sensitivity of the receptor mediated gene delivery system was determined using the optimized CCFL/DNA ratio for complex formation. Increasing amounts of the CCFL/DNA complex was added to cells. 100 ⁇ g of CCFL was mixed with 30 ug of pSVB for 1 hour at room temperature. The COS and endothelial cells were incubated with increasing amounts of condensed material (0 ng, 1 ng, 10 ng, 100 ng, 1000 ng and 10,000 ng). The cells were incubated for 48 hours and then were assayed for ⁇ -galactosidase activity. In addition, cells grown on cover slips were treated with 1000 ng of CCFL-DNA for 48 hours, then fixed and stained using X-gal.
  • the ⁇ -gal enzyme assay revealed that with increasing amounts of material there is an increase in enzyme activity.
  • Cells incubated with X-gal showed blue staining throughout the cytoplasm in approximately 30% of the cells on the coverslip.
  • ⁇ -galactosidase activity was determined for cells treated with nucleic acid alone, with nucleic acid poly-L-lysine and with FGF2-3 + poly-L-lysine + nucleic acid, ⁇ -galactosidase gene expression was not significantly above background, indicating that a covalent linkage between FGF2-3 and poly-L-lysine is necessary for ⁇ -galactosidase expression to occur in the cells.
  • CCFL/nucleic acid is being taken up through the FGF receptors
  • an excess of free FGF2-3 is added to a constant amount of CCFL/nucleic acid to compete for binding to its cognate receptor. If CCFL- ⁇ -gal is being delivered to the cytoplasm by the FGF receptor, then increasing doses of free FGF should decrease or eliminate ⁇ -gal expression.
  • MOLECULE TYPE DNA (genomic)
  • MOLECULE TYPE DNA (genomic)
  • ANTI-SENSE YES

Abstract

L'invention concerne des préparation de conjugués d'un facteur de croissance des fibroplastes et d'un agent ciblé, ainsi que des composition contenant lesdites préparations. Lesdits conjugués contiennent un polypeptide réagissant avec un récepteur du facteur de croissance des fibroplastes FGF tel que le bFGF ou tout autre facteur FGF couplé à un agent ciblé au moyen d'un segment de liaison. Le segment de liaison est sélectionné pour augmenter la spécificité, la toxicité, la solubilité, la stabilité sérique, et/ou la disponibilité intracellulaire de la fraction ciblée. On peut utiliser plusieurs segments de liaison de manière à tirer profit des propriétés voulues de chacun d'eux. L'invention porte également sur des compositions pharmaceutiques contenant ces conjugués de FGF et un agent ciblé, ainsi que sur des méthodes de prévention de la récurrence de ptérigions, de la fermeture d'une trabéculectomie et de l'opacification de la cornée comme suite à une chirurgie au laser excimère. Lesdites méthodes consistent à mettre la zone de l'oeil ayant été traitée chirurgiquement en contact avec la composition pendant ou immédiatement après l'intervention chirurgicale. L'invention se rapporte aussi à des compositions de conjugués du facteur de croissance des fibroplastes et du domaine de liaison de l'acide nucléique. Lesdits conjugués fixent les molécules d'acide nucléique par l'intermédiaire du domaine de liaison de l'acide nucléique. Ces conjugués peuvent être utilisés pour libérer un acide nucléique codant une protéine cytotoxique ou un acide nucléique antisens et similaire dans des cellules exprimant les récepteurs du facteur de croissance des fibroplastes.
EP95916103A 1994-03-15 1995-03-15 Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil Withdrawn EP0776218A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01125266A EP1188448A3 (fr) 1994-03-15 1995-03-15 Facteurs de croissance de fibroplastes pour la thérapie génétique et le traitement de troubles du segment antérieur de l'oeil

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US213447 1980-12-05
US21344694A 1994-03-15 1994-03-15
US21344794A 1994-03-15 1994-03-15
US213446 1994-03-15
PCT/US1995/003448 WO1995024928A2 (fr) 1994-03-15 1995-03-15 Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP01125266A Division EP1188448A3 (fr) 1994-03-15 1995-03-15 Facteurs de croissance de fibroplastes pour la thérapie génétique et le traitement de troubles du segment antérieur de l'oeil

Publications (1)

Publication Number Publication Date
EP0776218A2 true EP0776218A2 (fr) 1997-06-04

Family

ID=26908098

Family Applications (2)

Application Number Title Priority Date Filing Date
EP95916103A Withdrawn EP0776218A2 (fr) 1994-03-15 1995-03-15 Facteurs de croissance des fibroplastes pour la therapie genique et le traitement de troubles du segment anterieur de l'oeil
EP01125266A Withdrawn EP1188448A3 (fr) 1994-03-15 1995-03-15 Facteurs de croissance de fibroplastes pour la thérapie génétique et le traitement de troubles du segment antérieur de l'oeil

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01125266A Withdrawn EP1188448A3 (fr) 1994-03-15 1995-03-15 Facteurs de croissance de fibroplastes pour la thérapie génétique et le traitement de troubles du segment antérieur de l'oeil

Country Status (5)

Country Link
EP (2) EP0776218A2 (fr)
JP (1) JPH09510352A (fr)
AU (1) AU702323B2 (fr)
CA (1) CA2185671A1 (fr)
WO (1) WO1995024928A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008293A1 (fr) * 1992-12-23 1996-03-21 Patrick Edison Kane Balle de golf moulee par injection et soluble dans l'eau
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
AU3374795A (en) * 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
WO1996008274A2 (fr) * 1994-09-13 1996-03-21 Prizm Pharmaceuticals, Inc. Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
CA2221269A1 (fr) * 1995-05-16 1996-11-21 Lois A. Chandler Compositions contenant des acides nucleiques et des ligands pour un traitement therapeutique
US5728546A (en) 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
AU5433798A (en) * 1996-11-27 1998-06-22 Human Genome Sciences, Inc. Fibroblast growth factor-13
SE513149C2 (sv) * 1997-12-05 2000-07-17 Katarina Edwards Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
CA2316015A1 (fr) 1997-12-22 1999-07-01 Human Genome Sciences, Inc. Formulations du facteur-2 de croissance des keratinocytes
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
KR20010040906A (ko) 1998-02-13 2001-05-15 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2의 치료학적 용도
DE69903612T2 (de) * 1998-03-12 2003-07-10 Genentech Inc Verwendung von fgf-5 polypetiden zur vorbeugung des absterbens retinaler neuronen und behandlung okularer krankheiten
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6656718B2 (en) 2000-07-07 2003-12-02 Cancer Research Technology Limited Modified carboxypeptidase enzymes and their use
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
EP1984397A2 (fr) * 2006-01-19 2008-10-29 Université de Liège Variantes du vegf
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
PT2043662E (pt) * 2006-07-26 2015-11-25 Intrexon Corp Métodos e composições para tratamento de doença

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5191067A (en) * 1989-04-27 1993-03-02 The Salk Institute For Biological Studies Fibroblast growth factor conjugates
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
JPH06501005A (ja) * 1990-09-19 1994-01-27 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ Ｆｇｆ−細胞毒素コンジュゲートによる腫瘍性病理生理学的状態の治療
EP0646174A1 (fr) * 1992-06-16 1995-04-05 The Whittier Institute For Diabetes And Endocrinology Production recombinee de proteines contenant de la saporine
WO1995003831A1 (fr) * 1993-08-02 1995-02-09 Prizm Pharmaceuticals, Inc. Preparations monogenes de conjugues cytotoxiques
CA2221269A1 (fr) * 1995-05-16 1996-11-21 Lois A. Chandler Compositions contenant des acides nucleiques et des ligands pour un traitement therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9524928A3 *

Also Published As

Publication number Publication date
EP1188448A2 (fr) 2002-03-20
EP1188448A3 (fr) 2002-04-17
WO1995024928A3 (fr) 1995-10-12
AU2272495A (en) 1995-10-03
JPH09510352A (ja) 1997-10-21
AU702323B2 (en) 1999-02-18
WO1995024928A2 (fr) 1995-09-21
CA2185671A1 (fr) 1995-09-21

Similar Documents

Publication Publication Date Title
AU702323B2 (en) Heparin-binding growth factors for gene therapy and anterior eye disorders
US6503886B1 (en) Compositions containing nucleic acids and ligands for therapeutic treatment
WO1996006641A1 (fr) Conjugues du facteur de croissance endothelial vasculaire avec des agents cibles
AU710309B2 (en) Compositions containing nucleic acids and ligands for therapeutic treatment
WO1996008274A2 (fr) Conjugues d'un facteur de croissance semblable au facteur de croissance epidermique de type hbgf, et d'agents a cible definie
JP4489353B2 (ja) 融合タンパク質
EP0382781B1 (fr) Composition pour le traitement des cancers caracterises par la surexpression du proto-oncogene c-fms
CA2168647A1 (fr) Preparations monogenes de conjugues cytotoxiques
AU2002252867A1 (en) Fusion proteins
JP4892132B2 (ja) ７０ｋＤ熱ショック蛋白による化合物の細胞内標的輸送
EP0923387B1 (fr) Instruments medicaux recouverts d' heparine a usage intraveineux contenant des conjugues de facteur de croissance des fibroblastes
US20030040496A1 (en) Methods for halting unwanted cell growth, such as using ligand-directed nucleic acid delivery vehicles
WO1997049434A9 (fr) Instruments medicaux heparines contenant des conjugues de facteur de croissance des fibroblastes
CA2342970A1 (fr) Proteines de fusion

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961009

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20011127